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Fanconi anemia (FA) is a rare disorder that is characterized by bonemarrow failure in the first decade of life, developmental abnormalities, and
predisposition to malignancies. The majority of patients have mutations in one of
the 22 known FA genes, while a small number of patients have not been assigned
to a complementation group. FA proteins are required for the proper repair of DNA
interstrand crosslinks (ICL), a deleterious type of DNA damage that covalently
binds DNA strands. We have used Whole Exome Sequencing (WES) in
conjunction with cell-based assays to determine disease-causing mutations in a
subset of patients enrolled in the International Fanconi Anemia Registry (IFAR)
who are not assigned to a known complementation group. In this thesis, we
present three cases that were the focus of study.

We describe a new FA complementation group identified in a patient
presenting with typical FA features and deficiency of the ubiquitin-conjugating
enzyme (E2), UBE2T. No pathogenic gene variants were identified by WES, but
RNA sequencing (RNA-seq) uncovered a significant decrease in UBE2T
transcript, and western blot confirmed deficiency of UBE2T protein. Sanger

sequencing of genomic DNA revealed a large paternal deletion and maternal
duplication resulting from Alu-mediated recombination. In the absence of UBE2T,
the patient cells are defective for FA pathway activation and are hypersensitive to
crosslinking agents. These cellular defects are complemented by expression of
wild type UBE2T demonstrating that deficiency of the protein UBE2T causes this
individual’s FA.

WES

of

a

sibling

pair

with

FA

revealed

biallelic

mutations

in FANCD1/BRCA2. Both siblings presented with multiple developmental
abnormalities at birth, but did not develop any early childhood malignancies or
hematological

abnormalities

typically

associated

with

the

FANCD1

complementation group. FANCD1/BRCA2 is best known for its role in homologous
recombination directed repair of DNA double strand breaks, a function also
required during the repair of ICLs. Each sibling inherited a LOF BRCA2 mutation
in trans to a missense mutation of the BRCA2 DNA binding domain. Evaluation of
BRCA2 DNA binding domain mutations revealed that this domain is important for
replication fork protection, and to a lesser extent canonical homologous
recombination.

FA is a very heterogeneous disorder and as a consequence of overlapping
clinical features, patients may be misdiagnosed with FA in lieu of another DNA
repair or replication deficiency. Besides identifying FA mutations, we have

identified non-FA patient enrolled in the IFAR. This individual has a defect in
resolving DNA replication stress that presented in childhood as tri-lineage bone
marrow failure, facial dysmorphia, and small stature. Our analysis demonstrated
that the patient cells lack the hallmarks of FA, but are defective for cellular
resistance to DNA replication stress.
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Chapter 1: Introduction

1

1.1 DNA replication and genome maintenance
1.1.1 Cell division and replication
For growth and development, cells must undergo cellular reproduction by
which the parental cell divides resulting in two genetically identical daughter cells.
This requires that the genetic material is precisely duplicated. High fidelity DNA
replication is important for cell viability and normal function, and it also prevents
mutations and tumorigenesis. The DNA replication machinery, a large multiprotein
complex termed the replisome, initiates replication from many places in the
eukaryotic genome called replication origins during the S-phase of the cell cycle.
At the very basic level, the eukaryotic replisome consists of the Cdc45, MCM2-7,
and Gins (CMG) helicase, DNA polymerases, PCNA sliding clamps, primase, and
single stranded binding protein RPA (O'Donnell et al., 2013). During replication,
the CMG helicase unwinds the DNA duplex and the DNA polymerases synthesize
nucleotides along the template parental strand.

During replication, the replisome may encounter many obstacles that pose
a risk to precisely copying the genetic material. Cellular responses have evolved
to manage replication stress imposed by these obstacles and work to ensure that
the genome is fully and accurately reproduced each cell cycle. Cells can also incur
damage that is repaired outside of S-phase that can result from normal cellular
metabolism or insults from exogenous sources. Repair of these DNA lesions
requires many dedicated pathways.
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1.1.2 DNA damage response
Damaged DNA must be repaired to ensure integrity of the genetic material
to ensure normal function and prevent tumorigenesis. The cellular DNA damage
response (DDR) primarily depends on the activation of three phosphoinositide 3kinase (PI3K) related kinases (PIKK), ATM, ATR, and DNA-PK (Blackford and
Jackson, 2017).

DNA-PKcs and ATM activation
The DNA-PKcs and ATM kinase are both involved in signaling and directing
repair of DNA double strand breaks (DSB). DNA-PKcs serves as a regulator of
DNA repair by non-homologous end joining (NHEJ) and is recruited to DSBs by
Ku proteins where it becomes activated and undergoes auto-phosphorylation
(Figure 1.1A) (Kienker et al., 2000; Kurimasa et al., 1999). DNA-PKcs binds and
stabilizes broken DNA ends to prohibit end-resection and promote NHEJ. NHEJ is
the primary repair pathway of DSBs outside of S/G2 phases (Ciccia and Elledge,
2010). DSB repair by NHEJ involves the ligation of the broken ends of DNA and is
generally efficient, but is an error-prone repair pathway when DNA ends are joined
irrespective of homology (Blackford and Jackson, 2017).

ATM has a more global role in the repair of DSB. ATM is recruited to DSBs
through interaction with NBS1, a part of the MRE11-RAD50-NBS1 (MRN) complex
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(Figure 1.1B). Activated ATM initiates a signaling cascade that promotes DNA
repair activation, chromatin signaling, apoptosis, senescence, and transcription
(Blackford and Jackson, 2017; Matsuoka et al., 2007). At DSBs, ATM promotes
end-resection to channel repair to the homologous recombination (HR) pathway.
Due to crosstalk in DSB repair, ATM activation can contribute to promoting a
minority of repair events by NHEJ (Blackford and Jackson, 2017; Ciccia and
Elledge, 2010). However, during S/G2 phase of the cell cycle the homologous
sister-chromatid is available as a repair template, and homology directed repair
predominates.

ATR activation
The ATR kinase is activated in response to DNA replication stress (Figure
1.2). Replication stress is defined as the slowing or stalling of the replication fork
(Zeman and Cimprich, 2014). The replisome may encounter many obstacles such
as damaged DNA template, difficult to replicate regions (repetitive DNA
sequences), active transcription machinery, RNA-DNA hybrids, DNA-protein
structures, and secondary DNA structures that all cause replication stress (Zeman
and Cimprich, 2014). Activation of oncogenes and rapid cell proliferation also
generate replication stress (Ahuja et al., 2016; Neelsen et al., 2013; Zeman and
Cimprich, 2014). These obstacles ultimately cause slowing of the DNA
polymerases and activation of the ATR kinase.

4

Figure 1.1 Activation of the DDR kinases DNA-PKcs and ATM.
(A) DNA-PKcs is recruited to DSBs by the Ku heterodimer and becomes activated.
DNA-PKcs stabilizes the DNA ends and undergoes auto-phosphorylation that
permits end processing by ARTEMIS. NHEJ repair factors LIG4/XRCC4 and XLF,
promote the ligation of the DNA ends. (B) ATM is recruited to DSBs by the MRN
complex. ATM is activated resulting in a signaling cascade that promotes DSB
repair by HR and activation of p53 and CHK2. Consequences of the ATM signaling
cascade include DDR activation, chromatin signaling, regulation of transcription,
senescence, and apoptosis.
5

The generation of single stranded DNA (ssDNA) at stressed replication
forks serves to recruit the ATR interacting protein (ATRIP) (Saldivar et al., 2017;
Zou and Elledge, 2003). ATRIP binding facilitates the association of ATR;
however, ATR activation requires the binding of an activator protein, either
TOPBP1 or ETAA1 (Kumagai et al., 2006). The RAD9-RAD1-HUS1 (9-1-1)
checkpoint complex binds at the ssDNA-dsDNA junction and recruits TOPBP1
which directly interact with ATRIP-ATR (Mordes et al., 2008; Zou and Elledge,
2003). ETAA1 binds RPA on ssDNA where it then can activate ATR by association
with the ATRIP-ATR complex (Bass et al., 2016; Haahr et al., 2016).

Once activated, ATR phosphorylates downstream targets including the
CHK1 kinase to promote the DNA damage response (Blackford and Jackson,
2017; Liu et al., 2006; Sorensen et al., 2004). The ATR kinase modulates the
response to replication stress by activating and recruiting DNA repair machinery
to DNA lesions, preventing new origin firing, and promoting replication fork stability
and processing so that replication may resume (Saldivar et al., 2017). In the
absence of ATR, replication stress leads to extensive ssDNA formation resulting
in RPA exhaustion and DNA breakage (Toledo et al., 2013). Improper response to
replication stress can result in replication fork collapse. In the absence of ATR
activity, the replisome components are stable; however, the proteome at the stalled
fork is altered reflecting the requirement of ATR activity for modulating effectors of
the replication stress response to prevent fork collapse (Dungrawala et al., 2015).
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Figure 1.2 Replication stress and ATR activation.
The generation of ssDNA at stressed replication forks serves to recruit ATRIP
through ssDNA bound RPA. ATRIP binding facilitates ATR association, but ATR
activation requires the binding of an ATR activating protein, TOPBP1 or ETAA1.
The 9-1-1 checkpoint complex binds at the ssDNA-dsDNA junction and recruits
TOPBP1. ETAA1 interacts with RPA where it interacts with the ATRIP-ATR
complex. Once activated, ATR phosphorylates downstream targets including the
CHK1 kinase to promote the DNA damage response.
7

1.2 Fanconi anemia/BRCA DNA repair pathway
The Fanconi anemia (FA) pathway is responsible for resolving interstrand
crosslinks (ICLs), deleterious DNA lesions that covalently link the two DNA strands
impeding transcription and replication. During DNA replication, ICLs cause
replication fork stalling resulting in checkpoint and FA pathway activation (Figure
1.3) (Garcia-Higuera et al., 2001; Knipscheer et al., 2009). FANCM function is
important for efficient checkpoint-signaling by ATR; an activity that extends to ICL
repair where FANCM is reported to promote ATR activation by regulating RPA
recruitment at ICLs (Collis et al., 2008; Huang et al., 2010; Schwab et al., 2010;
Singh et al., 2013). ATR activation results in phosphorylation of the FA factors
FANCA, FANCG, FANCD2, and FANCI (Ho et al., 2006; Ishiai et al., 2008; Wang,
2008; Wilson et al., 2008). Removal of ICLs is a multistep process requiring
activation of the FA core complex (composed of FANCA, FANCB, FANCC,
FANCE, FANCF, FANCG, FANCL, FANCM, and their interacting factors),
nucleolytic processing at the lesion, translesion synthesis (TLS) past the DNA
crosslink adduct, and homologous recombination.

A key step in ICL repair is the core complex-mediated monoubiquitination
of FANCD2 and FANCI at K561 and K523, respectively (Garcia-Higuera et al.,
2001; Smogorzewska et al., 2007a; Timmers et al., 2001; Walden and Deans,
2014). Ubiquitin transfer requires the activity of an E1 ubiquitin-activating enzyme,
an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligating enzyme (Hershko
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and Ciechanover, 1998). The FANCL subunit of the FA core complex is the E3
ubiquitin-ligase that monoubiquitinates FANCD2 and FANCI (Meetei et al., 2003a).
UBE2T is the E2 ubiquitin-conjugating enzyme and its interaction with FANCL is
required for monoubiquitination of FANCD2 and FANCI (Alpi et al., 2008; Hira et
al., 2015; Hodson et al., 2014; Longerich et al., 2009; Machida et al., 2006;
Rajendra et al., 2014; Rickman et al., 2015; Sato et al., 2012).

Monoubiquitinated FANCD2 and FANCI form a heterodimer (ID2 complex)
that is recruited to chromatin and is required for the downstream processing of the
ICL. Nucleolytic unhooking of the crosslink is dependent on FANCP/SLX4 and
FANCO/XPF (Kim et al., 2011; Kim et al., 2013; Klein Douwel et al., 2014;
Niedernhofer et al., 2004). Unhooking of the ICL enables translesion bypass on
one strand and double strand break (DSB) repair by homologous recombination
(HR) on the second strand (Howlett et al., 2002; Litman et al., 2005; Long et al.,
2011; Xia et al., 2007).

The current working model of interstrand crosslink repair has been
corroborated by studies in Xenopus egg extracts where replication intermediates
of plasmids carrying a site-specific ICL (pICL) can be analyzed synchronously
(Zhang and Walter, 2014). Repair in this system is replication dependent and
results in ATR activation and monoubiquitination of FANCI and FANCD2 (Raschle
et al., 2008). In this model of ICL repair, two replication forks converge on the pICL,
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one of the leading strands is extended to within one nucleotide of the lesion, and
dual incisions that require XPF are made on either side of the lesion generating a
double strand break (Klein Douwel et al., 2014; Raschle et al., 2008; Zhang et al.,
2015). In the absence of the I/D2 complex repair of the pICL is defective and no
incisions are made (Knipscheer et al., 2009). Translesion synthesis restores the
adduct containing strand while RAD51-mediated HR is required to repair the
incised DNA ends (Long et al., 2011; Raschle et al., 2015). Synthesis across from
the lesion and extension requires a replicative polymerase and a complex of Rev1
and POLx respectively (Budzowska et al., 2015; Raschle et al., 2008).

An alternative repair pathway of ICLs described from Xenopus egg extract
studies utilizes the NEIL3 DNA glycosylase. In this model, dual forks converge on
the pICL and NEIL3 cleaves a N-glycosyl bond of the psoralen crosslink to release
the ICL without incising the DNA (Semlow et al., 2016).

The dual fork model proposed from Xenopus egg extract studies is
performed on a 6-kb plasmid that guarantees that the replication forks, in this
limited space, will converge (Raschle et al., 2008; Zhang and Walter, 2014).
However, in mammalian cells distance between origins is much greater and single
fork collisions with ICLs may occur. How repair may be similar or different from
converging forks is unclear. One proposed mechanism of single fork collisions is
ICL traverse. Using DNA-fiber techniques to examine fluorescently labeled ICLs,
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Figure 1.3 Fanconi anemia pathway.
The FA pathway is responsible for resolving DNA interstrand crosslinks (ICLs)
that impede DNA replication. Stalling of replication machinery at ICLs results in
the activation of the FA pathway. The activated FA core complex composed of 8
FA proteins, FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and
FANCM, monoubiquitinates FANCI and FANCD2 via the E3 ubiquitin ligase
activity of FANCL and E2 ubiquitin-conjugating enzyme FANCT/UBE2T. The
ubiquitinated FANCI and FANCD2 complex orchestrates downstream processing
of the ICL, which entails unhooking by nucleolytic processing of the lesion,
translesion bypass, and homologous recombination.
11

it was discovered that in 60% of ICL containing species, lesion bypass occurred
without ICL unhooking. ICL traverse required the activity of FANCM (Huang et al.,
2013).
In both the ICL traverse and glycosylase studies, psoralen based ICLs were
used. NEIL3 mediated repair does not occur on cisplatin based ICLs largely used
in other Xenopus studies These data suggest that ICLs produced endogenously
or by exogenous chemicals may be repaired by many different pathways and
repair mechanisms identified using specific crosslinking agents may not apply to
all types of ICLs.

1.3 Disorders of interstrand crosslink repair
1.3.1 Fanconi anemia
Fanconi anemia (FA) is a rare disorder with an incidence of 1/100,000 that
results when genes important for resolving DNA interstrand crosslinks are mutated
(Kottemann and Smogorzewska, 2013). FA is a heterogeneous disorder
characterized by developmental abnormalities, bone marrow failure (BMF),
predisposition to solid tumors and leukemia, and cellular hypersensitivity to
crosslinking agents (Auerbach, 2009; Nalepa and Clapp, 2018). FA patient
mutations have been identified in 22 FANC genes, -A, -B, -C, -D1 (BRCA2), -D2,
-E, -F, -G, -I, -J (BRIP), -L, -M, -N (PALB2), -O (RAD51C), -P (SLX4), -Q (XPF), R (RAD51), -S (BRCA1), -T (UBE2T), -U (XRCC2), -V (REV7), and -W (RFWD3)
(Bagby, 2018; Wang and Smogorzewska, 2015). FA is largely inherited in an
autosomal recessive manner; however, there are exceptions, FANCB is X-linked
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and FANCR is autosomal dominant (Ameziane et al., 2015; Meetei et al., 2004;
Wang et al., 2015). A minority of FA patients still have unknown causative gene
mutations.

Patients with FA may present at birth with a spectrum of developmental
malformations that range in severity including short stature, renal dysplasia or
ectopia, craniofacial abnormalities, radial ray malformations, VATER association,
central nervous system defects (CNS), café-au-lait spots, cardiac defects, or
gastrointestinal or genitourinary malformations (Alter and Rosenberg, 2013;
Nalepa and Clapp, 2018; Stivaros et al., 2015). FA patients often present with BMF
in the first decade of life with a median age of seven years old. Some patients will
present with acute myeloid leukemia (AML) or myelodysplastic syndrome
(Auerbach, 2009). Endocrine dysfunction including growth hormone (GH)
deficiency,

abnormal

glucose

metabolism,

dyslipidemia,

hypothyroidism,

hypogonadism, and infertility are frequent in individuals with FA (Petryk et al.,
2015). FA patients also develop solid tumors at an increased incidence. Head and
neck squamous cell carcinoma (SCC) and anogenital SCC incidence are elevated
500-700 fold in individuals with FA (Kutler et al., 2003; Nalepa and Clapp, 2018).

Diagnosis of FA is based on chromosomal breakage tests of peripheral
blood (PB) samples or lymphocytes exposed to either the crosslinking agent
diepoxybutane (DEB) or mitomycin C (MMC) (Auerbach, 2009; Auerbach and
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Wolman, 1976). FA patient cells show increased chromosomal breakage levels
when treated with these genotoxic agents compared to normal cells. Somatic
mosaicism of the hematopoietic compartment can occur in FA resulting in partial
or full rescue of chromosomal breakage (Gregory et al., 2001; Lo Ten Foe et al.,
1997; Soulier et al., 2005; Waisfisz et al., 1999). Patient fibroblasts can be tested
in individuals with suspected mosaicism or those post hematopoietic stem cell
transplant to confirm diagnosis.

Exogenous compounds, many common chemotherapeutics, such as
mitomycin C (MMC), diepoxybutane (DEB), cisplatin, psoralen, and nitrogen
mustards can generate DNA ICLs. The endogenous source of DNA ICLs has been
an intense area of study and current models provide evidence that naturally
occurring biological metabolites such as aldehydes are suspected to generate
ICLs in vivo (Garaycoechea et al., 2012; Hira et al., 2013; Langevin et al., 2011;
Oberbeck et al., 2014; Ren et al., 2013; Ridpath et al., 2007).

Karyomegalic Interstitial Nephritis (KIN) is a second disorder of ICL repair.
Although patient cells are sensitive to ICLs the disease is distinct from FA. KIN is
an autosomal recessive disorder that results from mutations in Fanconi anemiaassociated nuclease 1 (FAN1). FAN1 was discovered as an interactor of the FA
pathway, is recruited to ICLs by the ID2 complex, and may have a specific role in
the nucleolytic processing of the DNA lesion (Kratz et al., 2010; Liu et al., 2010;
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MacKay et al., 2010; Smogorzewska et al., 2010). KIN is characterized by tubular
degeneration, fibrosis, and karyomegally in the kidney that results in end stage
kidney disease (Zhou et al., 2012). The discovery that FAN1 mutations do not
result in FA was surprising, but recent studies have demonstrated that FAN1 has
roles outside of the FA pathway and cells deficient for FAN1 have a milder
sensitivity to ICLs than FANC protein deficiency (Thongthip et al., 2016; Zhou et
al., 2012).

1.3.2 Homologous recombination deficient FA subtypes
The Fanconi anemia repair pathway requires HR factors for proper ICL
repair. A number of proteins mutated in FA, FANCD1/BRCA2, FANCN/PALB2,
FANCJ/BRIP1, FANCQ/RAD51C, FANCR/RAD51, and FANCS/BRCA1, are
known for their importance in facilitating HR (Howlett et al., 2002; Litman et al.,
2005; Rahman et al., 2007; Sawyer et al., 2015; Vaz et al., 2010; Xia et al., 2007).
In contrast to other FA subtypes, carriers of single allele mutations in many of these
genes (-D1, -N, -J, -Q, and –S) are predisposed to breast and/or ovarian cancers
(Bryant et al., 2005; Patel et al., 1998; Rahman et al., 2007; Ratajska et al., 2012;
Wong et al., 2011).

FA

patients

with

biallelic

mutations

in

complementation

groups

FANCD1/BRCA2 or FANCN/PALB2 present with a more severe clinical phenotype
than those in other complementation groups; developing embryonal malignancies
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and acute myeloid leukemia (AML) early in childhood (Alter et al., 2007;
Tischkowitz and Xia, 2010). Medulloblastoma and Wilms tumor are the
predominant solid tumors of the FANCD1/BRCA2 and FANCN/PALB2
complementation group (Alter et al., 2007; Tischkowitz and Xia, 2010).

Biallelic FANCS/BRCA1 mutations have only recently been described in a
limited number of patients. All individuals display a number of congenital
abnormalities typical of FA, but no bone marrow failure. Two female individuals
identified with biallelic FANCS/BRCA1 mutations each developed cancer, ovarian
and breast, in their 20s. Both of these BRCA1/FANCS individuals carried loss of
function (LOF) mutations in trans to a hypomorphic missense allele (Domchek et
al., 2013; Sawyer et al., 2015). In two other families, homozygous LOF mutations
have been identified and the children display congenital abnormalities
characteristic of FA and one child presented with neuroblastoma at the age of 2
(Freire et al., 2018; Mehmet Demirel, 2016).

FA patients with biallelic FANCO/RAD51C mutations present with an FAlike syndrome; characterized by developmental abnormalities and intermediate
chromosomal breakage, but no bone marrow failure (Vaz et al., 2010). Similarly,
monoallelic dominant negative FANCR/RAD51 mutations result in an FA-like
syndrome characterized by mild chromosomal breakage levels, defects in ICL
repair, but no bone marrow failure or cancer (Ameziane et al., 2015; Wang et al.,
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2015). Examination of FANCR/RAD51 patient cells revealed intact HR activity
likely accounting for the absence of early childhood malignancies associated with
FANCD1 and FANCN complementation groups.

1.4 BRCA2 in homologous recombination and cancer susceptibility
1.4.1 BRCA2 structure and function
The identification of the BRCA breast cancer susceptibility genes was
pursued on the observation that there was familial clustering of highly penetrant
and autosomal dominant breast cancer (King, 2014). Shortly after the discovery of
BRCA1 and BRCA2, the generation of mouse models for each, demonstrated that
homozygous inactivation of either gene is embryonic lethal and that these genes
are essential (Hakem et al., 1996; Liu et al., 1996; Sharan et al., 1997). BRCA1
and BRCA2 deficient cells display spontaneous chromosomal aberrations and
hypersensitivity to genotoxic agents including DSBs induced by ionizing radiation
(IR) (Chen et al., 1998; Connor et al., 1997; Deng and Scott, 2000; Patel et al.,
1998; Sharan et al., 1997; Shen et al., 1998). Both BRCA1 and BRCA2 were
identified as interactors of the RAD51 recombinase and found to be important for
the repair of DSBs by homology directed repair (Chen et al., 1998; Moynahan et
al., 1999; Moynahan et al., 2001; Scully et al., 1997; Sharan et al., 1997;
Snouwaert et al., 1999).
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BRCA2 is a large protein composed of 3418 amino acid (aa) residues and
a molecular weight of 390 kDa. At the N-terminus BRCA2 interacts with PALB2
through aa 21-39. BRCA2 has eight BRC repeats composed of aa 1009-2083 that
bind to RAD51 (Roy et al., 2012). The BRCA2 DNA binding domain (DBD) is
composed of five domains, a helical domain, three oligonucleotide/oligosaccharide
binding (OB) folds (OB1/OB2/OB3), and a Tower domain (Yang et al., 2002). The
Tower domain is composed of a 130 aa structure of anti-parallel helices that extend
out from the OB2 domain and are supporting a three-helix bundle (3HB) (Yang et
al., 2002). The BRCA2 DBD binds ssDNA and dsDNA, but the binding preference
is for ssDNA tails in the context of dsDNA. This DNA binding activity is dependent
on OB2, OB3, and the Tower domain. 3HB domains generally recognize dsDNA
so the Tower domain in conjunction with the OB folds may provide recognition of
dsDNA/ssDNA junctions (Jensen, 2013; Yang et al., 2002). The small peptide
protein DSS1 binds BRCA2 though interaction with the helical domain, OB1, and
OB2 (Yang et al., 2002). An NLS and additional RAD51 binding domain are located
at the C-terminus (Roy et al., 2012).

1.4.2 Canonical homologous recombination pathway
To initiate DSB repair by HR, BRCA1 localizes to breaks to promote endresection and the generation of 3’ ssDNA overhangs (Jasin and Rothstein, 2013).
End resection is modulated by the competing factors 53BP1-Rif1 and BRCA1CtIP. 53BP1-Rif1 favors end-protection and the NHEJ pathway of DSB repair while
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BRCA1-CtIP promotes end-resection and HR (Bunting et al., 2010; Di Virgilio et
al., 2013; Escribano-Diaz et al., 2013). Pathway choice by these factors is
modulated by chromatin modifications and cyclin dependent kinases to promote
HR during S/G2 phases (Nielsen et al., 2016; Tang et al., 2013). The deletion of
53BP1 in BRCA1 deficient cells rescues HR defects (Bunting et al., 2010).
Similarly, deletion of 53BP1 rescues the embryonic lethality of homozygous
BRCA1 mice and suppresses tumor formation (Cao et al., 2009). These data
suggest that the primary role of BRCA1 is pathway choice and to promote endresection for repair by HR.

The MRE11-RAD50-NBS1 (MRN) complex and the CtIP endonuclease
initiate symmetrical end-resection of the DSB in the 3’ to 5’ direction (Figure 1.4).
Longer 3’ ssDNA tails are generated by more extensive resection by either the
EXO1 exonuclease or the BLM-DNA2 helicase nuclease complex in the 5’ to 3’
direction (Gravel et al., 2008; Mimitou and Symington, 2008; Sartori et al., 2007;
Symington, 2014; Zhu et al., 2008). The ssDNA overhangs are coated by RPA,
which is replaced by RAD51 nucleofilaments prior to HR.

PALB2 is a BRCA1 and BRCA2 interacting partner required for proper
RAD51 filament formation (Xia et al., 2006). BRCA1 promotes BRCA2 localization
to DSBs through the mutual interaction of PALB2 (Sy et al., 2009; Zhang et al.,
2009a; Zhang et al., 2009b). While BRCA2-PALB2 interact irrespective of cell
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cycle, the BRCA1-PALB2 interaction is inhibited by ubiquitination outside of S/G2
phase. Deubiquitination of PALB2 results in the BRCA1-PALB2-BRCA2 interaction
and permits BRCA2 recruitment to DSBs (Orthwein et al., 2015).

BRCA2 is required for displacing the ssDNA binding protein RPA from the
3’ overhangs and loading RAD51 nucleofilaments (Jensen et al., 2010; Yang et
al., 2005). RAD51 nucleofilaments invade the sister chromatid to perform
homology search. The homologous DNA is then used as a template for precise
DNA repair (Jasin and Rothstein, 2013; Jensen et al., 2010). Following strand
invasion and DNA synthesis, double Holliday junctions (HJ), are dissolved by
either the BLM/TOPOIIIa/RMI1-RMI2 (BTR) complex or resolved by nucleolytic
processing by GEN1 or the SLX4-SLX1/MUS81-EME1 complex (Sarbajna and
West, 2014).

1.4.3 BRCA1 and BRCA2 in cancer susceptibility
Heterozygous germline BRCA1 or BRCA2 mutations predispose individuals
to hereditary breast and ovarian cancer (HBOC) and to a lesser extent pancreatic,
prostate, and other cancers (Prakash et al., 2015). Carriers of BRCA1 mutations
largely experience increased risk of female breast and ovarian cancer. BRCA2
mutation carriers are predisposed to female and male breast cancer, ovarian,
pancreas, and prostate cancers (Attard et al., 2016; Rustgi, 2014; Venkitaraman,
2014). The estimated life-time risk for ovarian cancer by the age of 70 for BRCA1
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Figure 1.4 Double strand break repair by homologous recombination.
Homologous recombination mediated repair of DSBs requires the formation of 3’
ssDNA overhangs. The MRE11-RAD50-NBS1 (MRN) complex senses DSB and
with the CtIP endonuclease initiates DNA end resection. The EXO1 exonuclease
or the BLM-DNA2 helicase nuclease complex are responsible for more extensive
resection. BRCA2 loads and stabilizes RAD51 nucleofilaments on the ssDNA
overhangs displacing the ssDNA binding protein RPA. RAD51 nucleofilaments
invade the sister chromatid to perform homology search. DNA synthesis can
proceed utilizing homologous DNA for precise repair.
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and BRCA2 carriers is 57-65% and 45-55% respectively (Nielsen et al., 2016).
BRCA1 carries have a higher lifetime risk of ovarian cancer at 39-44% by the age
of 70 compared to BRCA2 carriers’ lifetime risk of 11-18% (Nielsen et al., 2016).
PALB2 carriers also have an increased lifetime risk of breast cancer of 35% with
no significant increase in ovarian cancer (Nielsen et al., 2016; Rahman et al.,
2007). BRCA mutations account for approximately 25% of HBOCs, and the list of
associated candidate HBOC genes is growing, but for the majority, more
information is required to determine if they pose a significant risk.

Cells null for BRCA1 or BRCA2 are generally nonviable and deficiency of
either protein is embryonic lethal (Feng and Jasin, 2017; Gowen et al., 1996;
Hakem et al., 1996; Ludwig et al., 1997). However, in the context of malignancy,
BRCA1 and BRCA2 loss of function (LOF) tumors do arise when the wild type
(WT) allele becomes mutated. These cancer cells have acquired the ability to
handle high levels of replication stress despite BRCA1 or BRCA2 deficiency.
Current treatment regimens such as radiation therapy, cisplatin, and PARP
inhibitor (PARPi) take advantage of loss of HR in these malignancies.
Understanding the mechanism of how these factors work to suppress
tumorigenesis will be informative for hereditary tumors, but also sporadic tumors
that display what has been termed BRCAness. BRCAness describes tumors that
have characteristics of BRCA1 or BRCA2 LOF but do not result from germline
mutation. BRCAness can arise via somatic mutation or silencing of either gene,
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mutations in other genes in the HR network, or other undefined mechanisms (Lord
and Ashworth, 2016).

PARP inhibition in combination with BRCA1 or BRCA2 deficiency is
synthetically lethal making PARP inhibitor (PARPi) therapy an attractive treatment
option for hereditary BRCA cancers. PARPi has shown efficacy in treating BRCA1
or BRCA2 mutated tumors (Farmer et al., 2005, Bryant et al 2005., Lord et al 2015).
Like with most therapies, advanced cancers acquire chemo-resistance. A clinically
confirmed mechanism of chemotherapy resistance in BRCA1/2 tumors is
acquisition of secondary mutations that restore BRCA1/2 activity providing
resistance to platinum based and PARPi therapy (Barber et al., 2013; Edwards et
al., 2008; Norquist et al., 2011; Sakai et al., 2008; Swisher et al., 2008). Other
mechanisms of resistance have been investigated for BRCA1/2 cancers including
loss of 53BP1, REV7, or PARP1 activity, drug efflux transporters, and restoration
of replication fork protection (Jaspers et al., 2013; Patch et al., 2015; Pettitt et al.,
2013; Ray Chaudhuri et al., 2016; Rottenberg et al., 2008; Xu et al., 2015).

PARPi synthetic lethality has been attributed to a few proposed
mechanisms: (1) the persistence of single strand breaks (SSBs), that once
encountered during replication results in replication fork collapse and DSB
generation that would require canonical homology directed repair (HDR) and (2)
the “trapping” of PARP1 on DNA by inhibiting auto PARylation activity that would
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release the protein, generating a protein-DNA lesion during replication (Lord and
Ashworth, 2017). The role of PARP1 in promoting nascent strand degradation by
MRE11 in BRCA deficient cells adds further complexity to the mechanism of
PARPi lethality and acquired chemoresistance (Ding et al., 2016).

1.5 The role of BRCA2 in replication fork protection
1.5.1 Homologous recombination independent function of BRCA2 in
replication fork protection
Outside of its role in HR mediated DSB repair, BRCA2 function is required
to protect stalled replication forks (Figure 1.5). By studying DNA replication at the
single molecule level (DNA fibers), the Jasin laboratory discovered that BRCA2
protects stalled replication forks from nucleolytic processing by the MRE11
nuclease. Importantly, this activity appeared to be independent of the canonical
HR function of BRCA2. The study identified the BRCA2 S3291A mutant as a
separation of function mutant, which permitted the uncoupling of the two roles of
BRCA2 in HR and replication fork protection (Schlacher et al., 2011). BRCA2
Ser3291 is a cyclin-dependent kinase phosphorylation site that regulates the Cterminal interaction of BRCA2 and RAD51 (Esashi et al., 2005). The C-terminal
interacting domain of BRCA2 is hypothesized to stabilize RAD51 nucleofilaments
on ssDNA and upon phosphorylation of Ser3291 this interaction is lost (Davies and
Pellegrini, 2007). The S3291A BRCA2 mutant is proficient for HDR activity, but is
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unable to protect against nascent strand degradation by MRE11 (Feng and Jasin,
2017; Schlacher et al., 2011).

In the absence of BRCA2, newly synthesized ssDNA at stalled replication
forks is not protected and undergoes extensive degradation that is reported to
result in increased chromosomal aberrations (Schlacher et al., 2011). The BRCA2
C-terminal interaction and stabilization of RAD51 on the nascent ssDNA is required
for replication fork protection. In support of this conclusion, disruption of RAD51
nucleofilaments by expression of the BRC4 peptide results in nascent strand
degradation. Conversely, overexpression of a RAD51 mutant, K133R, that forms
stable nucleofilaments due to loss of ATPase activity required for dissociation from
DNA, renders replication forks resistant to degradation (Schlacher et al., 2011).

Furthermore, depletion or inhibition of RAD51 has been shown to also result
in nascent strand degradation at stalled replication forks and cause replication fork
restart defects (Hashimoto et al., 2010; Petermann et al., 2010; Taglialatela et al.,
2017). However, the role of RAD51 recombinase in replication fork protection has
been disputed due to conflicting results among studies. In other studies, RAD51
depletion does not result in nascent strand degradation at stalled replication forks
(Feng and Jasin, 2017; Lemacon et al., 2017; Mijic et al., 2017; Thangavel et al.,
2015). Different thresholds of RAD51 activity may account for these discrepancies,
which may be in part due to a newly described BRCA2 independent role of RAD51
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in replication fork reversal (discussed below) identified by electron microscopy
(EM) analysis of replication fork intermediates by (Lemacon et al., 2017; Mijic et
al., 2017).

Following the discovery that BRCA2 and RAD51 are required for the
protection of stalled replication forks, other proteins in the DNA damage response
pathway were also found to have a role including BRCA1, RAD51 paralogs, FA
proteins including FANCA and FANCD2, BOD1L, Abro1, RECQ1, and WRNIP1
(Higgs et al., 2015; Leuzzi et al., 2016; Schlacher et al., 2012; Somyajit et al., 2015;
Xu et al., 2017).

1.5.2 BRCA2 independent role of RAD51 in replication fork reversal
Replication forks that slow and stall can undergo remodeling into a reversed
replication fork structure. Reversed forks are formed when the parental DNA
strands reanneal and nascent DNA strands anneal forming a “regressed arm” and
a joint molecule resembling a Holliday junction. Replicating cells display a baseline
level of reversed replication forks that is increased upon exogenous genotoxic
stress to a wide array of agents including topoisomerase inhibitors, DNA
interstrand-crosslinking agents, DNA synthesis inhibitors, alkylating agents, and
UV (Berti et al., 2013; Ray Chaudhuri et al., 2012; Zellweger et al., 2015).
Additionally, EM analysis suggests that cells undergoing rapid proliferation utilize
replication fork slowing and fork reversal as a means to protect against genomic
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instability produced by endogenous replication stress (Ahuja et al., 2016). There is
evidence to support fork reversal as a mechanism to protect against genomic
instability as it may guard against extensive ssDNA generation, provide DNA repair
machinery access to the damaged template, or promote lesion bypass (Betous et
al., 2012; Cortez, 2015; Couch et al., 2013; Ray Chaudhuri et al., 2012; Zellweger
et al., 2015). However, reversed replication forks are also a substrate liable to
nuclease processing and DSB formation (Couch et al., 2013; Neelsen et al., 2013;
Schlacher et al., 2011; Schlacher et al., 2012; Ying et al., 2012).

EM analysis of replication fork intermediates from BRCA2 depleted cells
shows a decrease in reversed replication fork intermediates. The levels of reversed
replication fork species are rescued by MRE11 inhibition (Lemacon et al., 2017;
Mijic et al., 2017). Interestingly, in BRCA2 deficient cells, reversed replication fork
intermediates are detected at normal levels at early time points after replication
stress but then decrease due to MRE11 dependent nucleolytic processing
(Lemacon et al., 2017). These data along with observations from DNA fiber
analysis suggest that BRCA2 protects reversed replication fork structures from
nucleases.

Analysis of replication fork species by EM in RAD51 depleted cells also
shows a decrease in reversed replication forks (Kolinjivadi et al., 2017; Mijic et al.,
2017; Zellweger et al., 2015). Unlike BRCA2 depleted cells, the reversed
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replication fork levels in RAD51 depleted cells are not rescued by MRE11 inhibition
(Mijic et al., 2017). Levels of reversed replication forks in BRCA2 deficient cells are
not rescued by RAD51 depletion or with concomitant MRE11 inhibition despite
rescue of nascent strand degradation at stalled replication forks (Mijic et al., 2017).
Conclusions from this work are that BRCA2 and RAD51 are both important for
protecting reversed replication forks by stabilization of RAD51 nucleofilaments,
while RAD51 may perform an additional independent function in promoting
replication fork reversal. These data suggest a model by which depleting RAD51
prevents replication fork reversal and averts the formation of a substrate for
MRE11 degradation in the absence of BRCA2/RAD51 nucleofilament formation.

A RAD51 dominant negative separation of function mutant, T131P,
identified in an individual with Fanconi anemia-like syndrome is proficient for HDR
but deficient for replication fork protection (Mijic et al., 2017; Wang et al., 2015).
The RAD51-T131P mutant does not form stable nucleofilaments due to
hyperactive ATPase activity (Wang et al., 2015). The RAD51-T131P mutant cells
undergo MRE11 dependent nascent strand degradation at stalled replication forks
(Mijic et al., 2017). Reversed replication fork species are also decreased in
RAD51-T131P cells but are rescued by MRE11 inhibition (Mijic et al., 2017). The
RAD51-T131P cells are heterozygous and express RAD51 mutant protein at a
ratio of 1:5 to WT (Wang et al., 2015). The RAD51 activity presumably is enough
to support replication fork reversal, but not the formation of stable RAD51
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nucleofilaments that can protect the reversed replication fork from MRE11
degradation.

The differences in the reporting of the requirement of RAD51 for protecting
against nascent strand degradation may be due to the extent that RAD51 is
depleted or inhibited. The use of the BRC4 peptide or B02 inhibitor, like RAD51T131P, may prohibit stable RAD51 nucleofilament formation leaving DNA
vulnerable to nuclease degradation but still leave enough RAD51 activity for
replication fork reversal (Schlacher et al., 2012; Taglialatela et al., 2017). The
formation of stable RAD51 nucleofilaments may not be required for replication fork
reversal activity, but is required for protection of the regressed fork from nucleolytic
activity (Kolinjivadi et al., 2017; Mijic et al., 2017).

EM analysis of replication fork structures has largely focused on reversed
replication forks, but other intermediates have also been identified. RAD51 and
BRCA2 depletion in Xenopus egg extracts results in replication fork intermediates
with increased ssDNA at the fork and behind the fork (Hashimoto et al., 2010;
Kolinjivadi et al., 2017). MRE11 inhibition rescues ssDNA gaps behind the fork but
not the increased ssDNA at the fork junction (Hashimoto et al., 2010; Kolinjivadi et
al., 2017). Replication forks with ssDNA at the junction may be intermediates that
proceed replication fork reversal; however, levels in BRCA2 and RAD51 depleted
extracts appear to be similar despite the perceived independent role of RAD51 in
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fork reversal (Kolinjivadi et al., 2017). Cells treated with genotoxic agents also
show increased regions of ssDNA behind the fork and at the fork (Zellweger et al.,
2015). While unprotected reversed replication forks are targeted by MRE11,
internal ssDNA gaps behind the fork are also MRE11 substrates, and further
understanding of the role of BRCA2/RAD51 fork protection in preventing their
generation is needed.

1.5.3 Nuclease processing at stalled replication forks in BRCA2 deficient
cells
Restoring replication fork protection in BRCA2 deficient cells has been an
intense area of research that has largely focused on prohibiting processing by
MRE11. MRE11 travels with the replisome and its recruitment to chromatin is
enhanced by exogenous replication stress (Dungrawala et al., 2015; Mirzoeva and
Petrini, 2003; Robison et al., 2004). The presence of MRE11 at the replisome
following replication stress is PARP1 dependent, important for Chk1 signaling, and
replication fork restart (Bryant et al., 2009; Lee and Dunphy, 2013; Olson et al.,
2007; Trenz et al., 2006). While MRE11 is required for the processing of stalled
replication forks, aberrant activity at unprotected stalled replication forks in BRCA1
and BRCA2 deficient cells contributes to increased genomic instability (Ray
Chaudhuri et al., 2016; Schlacher et al., 2011; Schlacher et al., 2012; Ying et al.,
2012). In BRCA2 deficient cells treated with genotoxic agents, MRE11 inhibition
reduces genomic instability providing evidence that replication fork protection may
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be an important mechanism for resistance to DNA damage (Ray Chaudhuri et al.,
2016; Schlacher et al., 2011).

Despite the hypersensitivity of BRCA1 and BRCA2 deficient cells to PARPi,
deficiency of PARP1 protects against nascent strand degradation of stalled
replication forks by preventing MRE11 recruitment (Bryant et al., 2009; Ding et al.,
2016; Ray Chaudhuri et al., 2016; Ray Chaudhuri et al., 2012). Recent work has
demonstrated that MRE11 recruitment to sites of replication stress is also
dependent on PTIP and the associated methyltransferases MLL3/MLL4, the
chromatin remodeler CHD4, and RAD52 (Mijic et al., 2017; Ray Chaudhuri et al.,
2016). Depletion of these factors rescues nascent strand degradation in BRCA
deficient cells similar to MRE11 inhibition. Similarly, the decrease in reversed
replication fork intermediates in BRCA2 deficient cells treated with genotoxic
agents are rescued by RAD52 inhibition or depletion of PTIP (Lemacon et al.,
2017; Mijic et al., 2017). These data suggest that deficiency of PARP1, MLL4,
PTIP, CHD4, or RAD52, in BRCA1 or BRCA2 deficient cells rescues nascent
strand degradation by prohibiting MRE11 fork processing (Mijic et al., 2017; Ray
Chaudhuri et al., 2016).

Recent studies extend the resection of unprotected nascent DNA at stalled
forks to EXO1 and CtIP. Depletion of EXO1 or CtIP rescues nascent strand
degradation in BRCA2 deficient cells (Lemacon et al., 2017). Similarly, knockdown
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of EXO1 rescues reversed fork levels that are decreased in BRCA1/2 deficient
cells treated with replication stress inducing drugs (Lemacon et al., 2017). A clear
role for DNA2 in the processing of stalled replication forks in BRCA deficient cells
has not been determined. Lemacon et al found that DNA2 depletion does not
rescue nascent strand degradation in BRCA2 deficient cells. On the contrary,
Chaudhuri et al show that in BRCA2 deficient B-cells DNA2 inhibition is epistatic
with MRE11 in the rescue of nascent strand degradation. It is unclear what
accounts for the difference in the requirement of DNA2 for nascent strand
degradation in BRCA2 deficient cells, but the studies use different cell types and
assess the role of DNA2 using two different methods, by siRNA depletion and
small molecule inhibitor (Lemacon et al., 2017; Ray Chaudhuri et al., 2016).
Further investigation will be required to determine the dependency of DNA2 in
nascent strand degradation of BRCA2 deficient cells. The implication of EXO1 and
CtIP leaves us to contemplate a model of resection similar to DSB end resection
at unprotected regressed forks. In the absence of BRCA2, resection may be
initiated by CtIP and MRE11 followed by more extensive processing by EXO1.
Although it is also possible that the nucleases have different substrates at stalled
replication forks.
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Figure 1.5 BRCA2 and RAD51 mediated replication fork protection
Replication fork reversal is proposed to be a global response to replication stress
that requires RAD51-mediated fork reversal. When a replication fork encounters
replication stress the generation of ssDNA may serve to promote replication fork
reversal that entails the annealing of the nascent strand DNA and reannealing of
the parental DNA strands. This process requires RAD51 in a BRCA2 independent
process. To prevent nuclease degradation, RAD51 must be loaded and stabilized
on the nascent DNA by BRCA2.
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1.5.4 DNA translocases in replication fork protection and processing
Similar to RAD51 depletion in BRCA2 deficient cells, depletion of any of the
three ATPase dependent DNA translocases of the SNF2 family of chromatin
remodelers, SMARCAL1, ZRANB3, or HLTF, rescue resection of nascent strand
DNA by loss of replication fork reversal. These related proteins have been shown
to have similar fork remodeling activity in vitro. SMARCAL1 demonstrates affinity
for DNA fork structures and catalyzes activity promoting strand annealing, fork
regression, and branch migration (Betous et al., 2012; Ciccia et al., 2012; Yusufzai
and Kadonaga, 2008). ZRANB3 and HLTF also catalyze replication fork reversal
in vitro (Ciccia et al., 2012; Yuan et al., 2012; Yusufzai and Kadonaga, 2010).

These translocases have been found to associate with the replication fork;
however, how they each associate with the fork is different (Figure 1.6).
SMARCAL1 travels with the replication fork and becomes further enriched
following replication stress through interaction with RPA. (Bansbach et al., 2009;
Betous et al., 2012; Ciccia et al., 2009; Dungrawala et al., 2015; Kolinjivadi et al.,
2017; Postow et al., 2009; Yuan et al., 2009). SMARCAL1 interaction with RPA is
important for providing substrate specificity to promote replication fork reversal and
prevent activity during normal DNA replication (Betous et al., 2013). ATR
phosphorylation of S652 of RPA bound SMARCAL1 has been shown to be
important for regulating its activity at the replication fork (Couch et al., 2013).
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HLTF and ZRANB3 have been shown to interact with PCNA. HLTF contains
a RING finger domain and a N-terminal HIRAN domain (Poole and Cortez, 2017).
HLTF acts as ubiquitin ligase to polyubiquitinate PCNA in a MMS2-Ubc13
dependent manner (Motegi et al., 2008; Unk et al., 2008). In vitro studies indicate
the HIRAN domain of HLTF recognizes the 3’ end of the leading strand to promote
replication fork reversal (Kile et al., 2015). Upon replication stress, ZRANB3 is
recruited to DNA through a PCNA-interacting protein (PIP) box and an AlkB
homolog 2 PCNA-interaction motif (APIM) to PCNA (Ciccia et al., 2012; Weston et
al., 2012; Yuan et al., 2012). ZRANB3 contains a NPL4 zinc finger (NZF) motif that
preferentially binds K-63 poly-ubiquitinated PCNA and is required for its
localization to sites of replication stress (Ciccia et al., 2012; Vujanovic et al., 2017).

In the absence of any of the three translocases, SMARCAL1, ZRANB3, or
HLTF, cells become hypersensitive to replication stress inducing agents and have
increased genomic instability (Bansbach et al., 2009; Ciccia et al., 2009;
Taglialatela et al., 2017). Likewise, translocase activity must be carefully regulated
to prevent inappropriate fork reversal and breakage. Overexpression of
SMARCAL1 increases ssDNA and DNA damage (Bansbach et al., 2009).
Similarly, in ATR inhibited cells, excessive ssDNA is generated in part due to
aberrant SMARCAL1 activity (Couch et al., 2013). Inappropriate SMARCAL1
activity generates intermediates that have been shown to be acted on by SLX4
coupled nucleases and CtIP (Couch et al., 2013).
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Despite similar biochemical activity, SMARCAL1 and ZRANB3, do not act
redundantly as increased DNA damage accrues upon depletion of both proteins
(Ciccia et al., 2012). This may be attributed to synergistic functions at replication
forks, different roles and replication fork substrates, or roles outside of more global
replication fork remodeling. SMARCAL1 activity is also important for replication
through difficult to replicate telomeric sequences, a function not attributed to
ZRANB3 or HLTF (Poole et al., 2015).

Recent work has further expanded the role of SMARCAL1, ZRANB3, and
HLTF to replication fork reversal in vivo. Depletion of SMARCAL1, ZRANB3, and
HLTF results in decreased detection of reversed replication fork intermediates by
EM (Vujanovic et al., 2017). Depletion of any of any of these three translocases
rescues nascent strand degradation at forks defective for BRCA2 replication fork
protection. This is thought to occur by preventing replication fork reversal, a
substrate for MRE11 (Kolinjivadi et al., 2017; Taglialatela et al., 2017; Vujanovic
et al., 2017). SMARCAL1 depletion in BRCA1, BRCA2, or FANCD2 deficient cells
rescues degradation of nascent DNA at stalled replication forks (Kolinjivadi et al.,
2017; Taglialatela et al., 2017). Similarly, depletion of ZRNAB3 or HLTF in BRCA1
or BRCA2 deficient cells rescues nascent strand degradation (Mijic et al., 2017;
Taglialatela et al., 2017).
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The overall impact of rescuing nascent strand degradation in replication fork
protection deficient cells by depletion of these translocases is unclear, as depletion
on their own increases DNA damage and current findings are contradictory. In one
study, DNA damage is reduced by ZRANB3 depletion in BRCA deficient cells, with
no further rescue observed with co-depletion of SMARCAL1 (Taglialatela et al.,
2017). While another study observes rescue of nascent strand degradation by
ZRANB3 depletion, but increased genomic instability (Mijic et al., 2017). These two
studies analyzed different cell types under different conditions of damage,
hydroxyurea (HU) versus camptothecin (CPT), likely in part contributing to the
observed differences. Replication fork reversal is a response to many types of DNA
damage, so moving forward it is of interest to clarify how each of these
translocases respond to specific types of damage and if they work cooperatively
or have distinct roles at different replication fork substrates (Zellweger et al., 2015).

1.5.5 Deficiency of RADX, a RAD51 effector protein, rescues nascent strand
degradation in BRCA2 deficient cells
RADX is a single stranded DNA binding protein recently identified as being
enriched at replication forks following replication stress (Figure 1.7) (Dungrawala
et al., 2017). RADX has sequence similarity to RPA and binds through three RPAlike OB folds. RADX is recruited to replication forks where it modulates the RAD51
recombinase (Dungrawala et al., 2017). In the absence of RADX, increased levels
of RAD51 accumulate at stalled replication forks while BRCA2 levels are
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Figure 1.6 Replication fork reversal mediated by the SNF2 family
translocases SMARCAL1, ZRANB3, and HLTF.
Replication fork reversal is mediated by the SNF2 family chromatin remodelers
SMARCAL1, ZRANB3, and HLTF. HLTF is important for the polyubiquitination of
PCNA that serves as a platform for recruitment of ZRANB3. SMARCAL1 is
recruited to the replication fork through interaction with RPA. How these
translocases remodel the replication fork and whether they work synergistically to
reverse replication forks is unclear and needs further investigation.

40

unaffected. Conversely RADX overexpression results in a decrease in RAD51
recruitment to stalled replication forks (Dungrawala et al., 2017).

Depletion of RADX results in increased DNA damage and DSB formation
and slowed replication fork progression (Dungrawala et al., 2017; Schubert et al.,
2017). These defects are rescued by co-depletion of RAD51. Similarly, depletion
of replication fork remodelers, SMARCAL1 and ZRNAB3, or the MUS81 nuclease
rescue DSBs in RADX depleted cells. These data suggest that in the absence of
RADX, hyperactivity of RAD51 interferes with normal replication and promotes
inappropriate replication fork remodeling that results in DSBs mediated by MUS81
(Dungrawala et al., 2017).

RADX levels must be carefully controlled as overexpression also increases
DNA damage. RADX overexpression increases nascent strand degradation at
stalled replication forks, which likely is the result of antagonizing the protective
RAD51 nucleofilament. Conversely, depletion of RADX rescues nascent strand
degradation but not HDR defects in BRCA2 deficient cells. In BRCA2 depleted
cells, some RAD51 nucleofilament formation may occur in the absence of RADX
antagonism, which may be significant enough to protect the nascent DNA from
degradation (Dungrawala et al., 2017). RADX depletion also increases BRCA2
deficient cells resistance to PARPi (Dungrawala et al., 2017). This presents the
tradeoff of RADX inhibition to promote replication fork protection in BRCA2

41

deficient cells versus the possibility of inappropriate fork reversal promoted during
replication that may result in DSBs. Increased viability of BRCA2 deficient and
RAD51 depleted U2OS cells to genotoxic agents by RADX inhibition suggest
restoration of replication fork protection is more important.

Another effector protein of RAD51 is FBH1, a 3’-5’ DNA helicase of the UvrD
family that contains an F-Box domain, a PIP box, and APIM (Bacquin et al., 2013;
Kim et al., 2002). FBH1 negatively modulates RAD51 through its E3 ubiquitin
ligase activity that preferentially targets K58/64 of RAD51 (Chu et al., 2015; Kim et
al., 2002). Unlike RADX, FBH1 depletion in BRCA2 deficient cells does not rescue
replication fork protection (Higgs et al., 2015; Leuzzi et al., 2016). However, FBH1
depletion in cells deficient for either BOD1L or WRNIP1, two other replication fork
protection factors, does rescue nascent strand degradation at stalled replication
forks (Higgs et al., 2015; Leuzzi et al., 2016). Further investigation is required to
understand the differences in fork protection and antagonism by all of these
factors.
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Figure 1.7 RADX modulates RAD51 activity at replication forks
(A) The proposed model of RADX activity is to regulate RAD51 activity at the
replication fork to prevent unnecessary RAD51 association and fork reversal
during normal DNA replication progression. Upon RADX depletion there is
increased genomic instability and DSBs that may be the result of inappropriate fork
remodeling leading to increased fork cleavage and collapse. (B) The depletion of
RADX in BRCA2 deficient cells rescues nascent strand degradation at HU stalled
replication forks. Removal of RADX antagonism of RAD51 may permit rescue of
RAD51 fork protection and prevent degradation by nucleases.
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1.5.6. MUS81 cleavage of stalled replication forks in BRCA2 deficient cells
MUS81 has previously been described as the nuclease responsible for the
DSBs formed during replication stress that results in replication fork collapse.
However, MUS81 is also important for replication fork restart and depletion of
MUS81 increases chromosomal aberrations in cells challenged by replication
stress (Franchitto et al., 2008; Hanada et al., 2007; Pepe and West, 2014;
Regairaz et al., 2011). MUS81 activity is responsible for breakage at late
replicating regions in the genome also known as common fragile sites (CFS).
However, without MUS81 processing CFSs can cause greater genomic instability
during mitosis (Naim et al., 2013; Ying et al., 2013). Controlled DNA breakage by
MUS81 is a necessary compromise to promote genome stability and resume
replication at stalled forks. However, in the case of oncogene-induced DNA
replication stress, when the cell cycle is deregulated, there is increased MUS81
dependent DSB formation that contributes to increased genome instability (Murfuni
et al., 2013; Neelsen et al., 2013).

MUS81 depletion prevents DSB formation in BRCA2 deficient cells, but
does not rescue nascent strand degradation. Prevention of nascent strand
degradation by MRE11 or EXO1 deficiency also decreases DSB formation in
BRCA2 deficient cells (Lemacon et al., 2017). This places MUS81 activity and
breakage downstream of MRE11 and EXO1 processing. (Lemacon et al., 2017).
Reversed replication fork intermediates, visualized by EM, are rescued by
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depletion of MUS81 in BRCA2 deficient cells, but these replication fork
intermediates appear to have a ssDNA flap (Lemacon et al., 2017). The ssDNA
flap intermediate may be the product of MRE11 or EXO1 processing and the
substrate for MUS81 cleavage (Lemacon et al., 2017).

Another study identified EZH2, a histone methyl transferase, as important
for promoting MUS81 processing of stalled replication forks in BRCA2 deficient but
not BRCA1 deficient cells (Rondinelli et al., 2017). The same study found that
MUS81 depletion rescued replication fork degradation in BRCA2 deficient cells
which is in contrast to Lemacon et al’s findings. EZH2 co-depletion with MRE11
further augmented fork protection, suggesting a separate mechanism from MRE11
recruitment by MLL3/MLL4/PTIP (Rondinelli et al., 2017).

Replication fork restart in BRCA2 deficient cells is defective in the absence
of MUS81 (Lemacon et al., 2017). Similarly, EZH2 inhibition results in reduced
replication fork restart in BRCA2 deficient cells (Rondinelli et al., 2017). DSBs
generated in BRCA2 deficient cells, following replication fork stress, are transient
and return to control levels (Lemacon et al., 2017). Inhibition of nucleases in
BRCA2 deficient cells rescues nascent strand degradation and breakage, but also
result in defects in replication fork restart. It is possible that processing of reversed
replication forks by nucleases is required for replication fork restart and that DNA
breakage is a transient repair intermediate of this process.
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1.6 Objectives
The objective of this thesis was to investigate novel genes mutated in FA
families that have not been assigned to one of the known FA complementation
groups. To achieve this objective, families that fit this criterion were identified from
the International Fanconi Anemia Registry (IFAR) and were evaluated by Whole
Exome Sequencing (WES) and cell-based assays. Examination of patient-derived
cells for hypersensitivity to drugs that generate ICLs and other DNA damaging
agents demonstrated that despite the overlap in clinical features they behaved
differently suggesting the patients do not harbor mutations in the same gene. I will
present three cases identified from the IFAR that were the focus of study in this
thesis.

The first case, the subject of Chapter 2, is the identification of biallelic
UBE2T mutations as causing a new subtype of FA in an individual with typical FA
features. Pathogenic mutations were not identified by WES, but a large duplication
and a large deletion were detected by sequencing of the UBE2T locus upon
discovery of a significant decrease in UBE2T transcripts by RNA sequencing
(RNAseq). Analysis of cells deficient for UBE2T demonstrated it is the primary E2
of the FA pathway and is required for monubiquitination of the ID2 complex.
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The second case, the subject of Chapter 3, is the unexpected identification
of compound heterozygous biallelic FANCD1/BRCA2 mutations in a sibling pair
that does not display the typical clinical findings of this complementation group.
Their atypical presentation had previously precluded their screening for the
FANCD1 complementation group. The objective of this study was to determine the
function of the DBD of BRCA2 that is mutated in this family in order to better
understand the functions of BRCA2 and the consequences its disruption has on
human diseases such as FA and HBOC. The work herein determined that the
BRCA2 DBD is required for replication fork protection and to a lesser extent HR.

The third and final case, the subject of Chapter 4, describes an individual
enrolled in the IFAR that cellular characterization revealed to not have defects in
ICL repair. Due to the heterogeneous nature of FA, defects of other pathways
important for DNA repair or replication can have overlapping clinical features
leading to misdiagnosis. Cellular analysis revealed no classic hallmarks of FA, but
defects in the cellular response to DNA replication stress. The genetic basis of
disease in this individual is still under investigation.

The identification of novel inherited DNA repair disorders increases our
understanding of the cellular networks working to maintain genome integrity,
preserve normal cellular function, and protect against tumorigenesis. These are

47

networks that work in all human cells to assure normal function, so the implications
of these studies go beyond the rare diseases studied.
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Chapter 2: Deficiency of UBE2T causes a new
subtype of Fanconi anemia and is the primary
E2 ubiquitin-conjugating enzyme necessary for
FANCD2 and FANCI ubiquitination
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2.1 Introduction
A key step in the repair of ICLs is the monoubiquitination of FANCD2 and
FANCI at residues K561 and K523 respectively. Site specific mutagenesis of either
of these lysine residues results in failure of FANCD2 and FANCI to be ubiquitinated
and recruited to ICLs (Garcia-Higuera et al., 2001; Smogorzewska et al., 2007b).
FANCD2 and FANCI monoubiquitination requires an intact FA core complex that
acts as an E3 ubiquitin ligase with FANCL as the catalytic subunit (Hodson et al.,
2014; Meetei et al., 2003a). The E2 ubiquitin-conjugating enzyme UBE2T was
identified as an interactor of FANCL by a yeast two-hybrid screen (Machida et al.,
2006). Depletion of UBE2T results in defective ubiquitination of FANCD2, loss of
FANCD2 recruitment to foci after DNA damage, and cellular sensitivity to ICLs (Alpi
et al., 2008; Machida et al., 2006). Here we describe a new FA complementation
group identified in a patient enrolled in the International Fanconi Anemia Registry
(IFAR) presenting with typical FA features and deficiency of the ubiquitinconjugating enzyme (E2), UBE2T.

2.2 Results
2.2.1 Presentation of Fanconi anemia patient of unknown complementation
group
The subject of study was identified as a participant enrolled in the
International Fanconi Anemia Registry (IFAR) diagnosed with FA of unknown
complementation group. The patient was born premature at 36 weeks gestation
weighing 3lbs 7oz and measuring 16.5 inches long in the 3rd percentile. At birth the
subject presented with bilateral radial aplasia and absent thumbs, microcephaly,
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micrognathia, café au lait spots, ventricular septal defect (VSD), patent ductus
arteriosus (PDA), and absent left kidney. At birth the patient had thrombocytopenia
that resolved in subsequent days. There was family history of Thalassemia, but no
history of early onset cancer or bone marrow failure.

The patient was clinically diagnosed with Fanconi anemia at birth.
Cytogenetic studies were performed at the Laboratory of Human Genetics and
Hematology at The Rockefeller University Hospital and showed elevated
chromosomal breakage in peripheral blood (PB) samples treated with the DNA
crosslinking agent diexpoxybutane (DEB). Initially, breakage levels of PB collected
at 2 days old displayed significantly elevated chromosomal breakage levels at 5.8
breaks per cell in 85% of the cell population. Decreasing breakage levels over time
demonstrated the development of somatic mosaicism in the hematopoietic
compartment, a phenomenon seen in a small subset of FA patients (Table 2.1)
(Gregory et al., 2001; Lo Ten Foe et al., 1997; Soulier et al., 2005; Waisfisz et al.,
1999).

The patient is seen at Cincinnati Chidlren’s hospital for bone marrow testing
annually. Our most recent blood counts for age 16 years old report a hemoglobin
of 13.9, platelet count of 202,000, and white blood cell count of 6.6 (absolute
neutrophil count mildly decreased at 0.79 and an elevated absolute lymphocyte
count of 5.6). Peripheral blood smear shows moderate neutropenia and microcytic

51

Table 2.1 Chromosome breakage analysis of subject's peripheral
blood samples treated with DEB
Age, Report Date
2 days, 11/30/98
10 days, 11/30/98
1 years, 11/06/98
6 years, 05/22/05
6 years, 10/05/05
6 years, 10/10/05
16 years, 4/18/15

# DEB treated
cells analyzed
20
10
10
15
50
40
50

52

Mean chromosome breaks per
cell/ percent of cells with breaks
5.8, 85%
7.1, 80%
7.5, 80%
4.1, 47%
0.08, 8%
0.28, 17.5%
0.32,18%

red blood cells consistent with thalassemia trait. Bone marrow biopsy
demonstrates mild hypocellularity for age in the 35-45% range with trilineage
hematopoiesis. Chromosome studies show a normal 46, XY karyotype. To date
there is no evidence of abnormal clonal cells, MDS, or leukemia in this patient.

The patient has a history of normal Adrenocorticotropic hormone (ACTH)
and Growth Hormone (GH) stimulation. The patient takes thyroid replacement
therapy for hypothyroidism. Cardiac evaluation by ECG was normal and
echocardiogram reveals a normal heart with normal valve anatomy and function.
The patient has a solitary kidney and normal renal function with a creatinine value
of 0.57. The patient at 16 years of age, performed well in school with no known
learning disabilities, and is generally active. The patient has bilateral conductive
hearing loss and uses hearing aids. The patient’s height remains below the 5th
percentile and most recent bone age was slightly greater than chronological age.

2.2.2 Cellular phenotype of Fanconi anemia cell line of unknown
complementation group
To support the elevated chromosomal breakage levels identified in early PB
tests and diagnosis of FA, we analyzed patient derived fibroblasts (RA2627).
RA2627 fibroblast are hypersensitive to crosslinking agents MMC and DEB in
survival assays (Figure 2.1A-B). Chromosomal breakage levels are elevated in
RA2627 fibroblasts treated with DEB as compared to BJ wild type fibroblast,
although slightly lower than FA-A patient cells (RA3087) (Figure 2.1C-D). RA2627
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cells are deficient for FANCD2 monoubiquitination (Figure 2.1E) while the
lymphoblastoid cell line (LCLs) (RA2946), derived from blood that showed
mosaicism, displayed normal FANCD2 monoubiquitination, consistent with genetic
reversion (Figure 2.1F). By immunofluorescence, FANCD2 foci were not observed
in RA2627 cells following 24-hour treatment with MMC (Figure 2.1G). These data
demonstrate that the subject’s fibroblasts display deficiency of FA pathway
activation, consistent with either the deficiency of the FA core complex, one of the
associated proteins, or the ID2 complex, whereas the subject’s LCLs are
phenotypically reverted consistent with mosaicism observed in the subject’s blood.

2.2.3 Whole exome sequencing and high-resolution array comparative
genomic hybridization
High-resolution array comparative genomic hybridization (aCGH) of
genomic DNA from the subject’s fibroblasts and peripheral blood samples did not
detect deletions or duplications in the known FA genes. Whole exome sequencing
(WES) of DNA derived from proband LCLs and parental peripheral blood samples
was performed. Analysis of WES data revealed a single FANCA mutation,
c.2574C>G/p.Ser858Arg, previously described in FA (Tamary et al., 2000; Wijker
et al., 1999). A second mutation in FANCA was not identified, but detection may
not be possible in DNA derived from a revertant cell line. Normal levels of FANCA
were detected by western blot in RA2627 cells (Figure 2.2A) and overexpression
of wild type FANCA in RA2627 failed to rescue the monoubiquitination defect of
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Figure 2.1 Characterization of cell lines from an individual with FA under
study.
(A-B) MMC and DEB cell survival assays of the subject’s RA2627 fibroblasts in
comparison to FANCA-mutant (RA3087) and BJ wildtype fibroblasts. Cells were
treated in triplicate with increasing concentration of MMC or DEB. Cell numbers
were determined after 7 days and normalized to untreated control to give percent
survival. Error bars indicate s.d. (C) Example of metaphase spread of RA2627
following 0.1 ug/ml DEB treatment. Inset images highlight radial chromosomes.
(D) Quantification of chromosome breaks of DEB treated BJ, FANCA-mutant, and
RA2627 fibroblasts. Mean breaks per cell were 0.19, 7.5, and 3.3 respectively (EF) Western blot with FANCD2 antibody of BJ, RA2627 proband fibroblasts, and
FANCA-mutant fibroblasts or non-FA control RA2987 lymphoblasts, RA2946
proband lymphoblasts, and FANCA-mutant lymphoblasts. Cells were cultured with
or without 1 µM MMC for 24h. (G) FANCD2 foci formation following treatment
with or without 1 µM MMC for 24h.
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FANCD2 and FANCI excluding FANCA as a causative gene in this cell line (Figure
2.2C). WES analysis identified no other mutations in reported FA genes.

2.2.4 Identification of biallelic UBE2T mutations in the subject
RNA sequencing (RNA-seq) was performed on RA2627 fibroblasts to
assess altered transcript levels that might indicate functionally significant gene
mutations not captured by WES. Compared to a non-FA patient cell line (RA3380),
a marked reduction in UBE2T was detected, but not in any of the known FA genes
(Figure 2.3A). Decreased UBE2T transcript levels were confirmed by RT-qPCR
(Figure 2.3B) and UBE2T protein was undetectable in RA2627 fibroblast lysates
by western blot analysis (Figure 2.3C). Interestingly, UBE2T transcript and protein
were present at near normal levels in proband LCLs (RA2946) (Figure 2.3D)
supporting the presence of a genetic reversion in the hematopoietic compartment.

Sanger sequencing of genomic DNA and cDNA from proband primary
fibroblasts (RA2627), parental peripheral blood, and LCLs revealed compound
heterozygous mutations in UBE2T, a large paternally derived deletion and
maternally derived duplication (Figure 2.4).

The paternally derived deletion, g.202332626_202341295del, appears to
have resulted from recombination of two AluYa5 repeats within the UBE2T gene
(Figure 2.5). The paternally derived deletion was uncovered by genomic
sequencing of the proband and parental DNA. Genomic deletion was suspected
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Figure 2.2 FANCA cDNA fails to complement RA2627 FANCD2 and FANCI
monoubiquitination defect.
A) Western blot with FANCA antibody of RA2627, BJ, and FANCA-mutant
fibroblasts. (B) Expression of wild type HA-FLAG tagged FANCA cDNA or empty
vector control (EV) in RA2627 and FANCA-mutant fibroblasts. (C) Western blot
with FANCD2 and FANCI antibody of FANCA complemented cells.
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based on the inheritance of an informative polymorphic marker rs14451 (exon2)
detected in WES of the proband and parental DNA. Somatic mosaicism of the
proband LCLs complicated interpretation of WES data; however, the homozygous
presence of rs14451 in the paternal data and absence in proband data suggested
hemizygosisty for the proband in this region even in the revertant LCLs. PCR and
Sanger sequencing of the UBE2T locus confirmed this finding and revealed
additional informative markers rs10753914 (IVS1) and rs788801 (IVS6). The
proband is hemizygous for the rs10753914 (IVS1) SNP, but heterozygous for the
downstream rs788801 (IVS6) SNP suggesting break boundaries for the indel. A
long range genomic PCR using primers flanking these markers failed to amplify
the predicted 10,120bp product, but a smaller amplicon of ~1500 bp was present
in the proband and the father but not the mother or non-FA control (Figure 2.5A).
Sanger sequencing of this smaller PCR product confirmed a large genomic
deletion, g.202332626_202341295del, in the proband and father likely resulting
from Alu-Alu mediated non-allelic homologous recombination (NAHR) between
two AluYa5 repeats within the UBE2T gene. The sequence intervening IVS1
AluYa5 and IVS6 AluYa5 and one Alu is lost in the paternally derived allele
resulting in an 8670bp deletion (Figure 2.5B). The resulting single AluYa5
sequence is bordered by IVS1 on the 5’ side and IVS6 on the 3’ (Figure 2.5C). This
deletion is expected to be a null allele, as it results in the loss of a majority of the
gene including the start codon.
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Figure 2.3 UBE2T is deficient in RA2627 cells.
(A) Comparison of normalized RNA-seq expression, Fragments Per Kilobase of
transcripts per Million reads (FPKM), of known FA genes and UBE2T for RA2627
and non-FA control RA3380 primary cells. (B) RT-quantitative PCR of UBE2T
expression levels in RA2627 fibroblasts (left) and RA2946 lymphoblasts (right) in
comparison to wild type control and FANCA-mutant cells. Error bars indicate
standard error of three replicates. (C-D) Western blot with UBE2T antibody.
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The maternal duplication, g.202332626_202341295dup, also appears to be
mediated by Alu recombination. The maternally derived mutation consists of a
large duplication of the genomic region between the two AluYa5 repeats (Figure
2.4 and Figure 2.6). Analysis of UBE2T cDNA revealed a unique Exon6-Exon2
junction suggesting a genomic duplication of a region of UBE2T (Figure 2.6A). This
unique junction, was also identified in the genomic DNA from proband fibroblasts
and mother’s LCLs using PCR and Sanger sequencing (Figure 2.6B). The region
following exon 6 was found to contain IVS6 sequence flanking the 5’ of the AluYa5
repeat and IVS1 sequence flanking the 3’ of the repeat, and was confirmed by
cloning. This is likely a duplication event mediated by Alu recombination (Figure
2.6C).

Cloning of cDNA from proband fibroblasts revealed a transcript containing
the hypothesized duplication c.-64_468dup (dupEx2_6) (Figure 2.6A and C). In
this transcript, exon 6 is spliced to the duplicated exon 2. Inclusion of the noncoding
region from exon 2 results in a frameshift and a premature stop codon. The c.64_468dup transcript can be detected at very low frequency in RA2627 cells and
is likely degraded by nonsense-mediated decay due to the premature stop codon.
If any transcript is translated, it may produce a residual amount of the predicted
protein p.A157Cfs*7. PCR analysis of gDNA demonstrates that the maternally
derived mutation is absent in the RA2946 LCLs (Figure 2.6D). This indicates that
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Figure 2.4 UBE2T deficiency is the result of AluYa5 mediated non-allelic
homologous recombination.
Schematic of the paternally derived deletion and maternally derived duplication
resulting from Alu-Alu mediated non-allelic homologous recombination (NAHR) of
AluYa5 repeats present in IVS1 and IVS6 of the UBE2T gene. For the paternal
allele, recombination resulted in the loss of the intervening sequence and one
AluYa5 repeat (8,670bp). For the maternal allele, recombination resulted in the
insertion of another AluYa5 repeat and duplication of the sequence between the
Alu repeats.
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Figure 2.5 Identification of paternally-derived deletion resulting from AluYa5
mediated non-allelic homologous recombination.
A) PCR to identify mutations in UBE2T in the indicated cell lines and parental
peripheral blood (PB) samples. RA2627 are proband-derived fibroblasts and
RA2946 are proband LCLs. The expected PCR product amplifying with primers
474Fwd and 479Rev is 10,120bp. The large amplicon PCR failed, but a smaller
amplicon of ~1,500bp was identified in the proband and father but not the mother
and non-FA control. Asterisk denotes non-specific bands. (B) Schematic of
UBE2T indicating the location of PCR primers 474Fwd and 479Rev and the span
of PCR amplicons. Recombination between the AluYa5 sites results in an 8,670bp
deletion that yields the smaller 1,450bp PCR products. (C) Chromatograms
displaying sequencing results of the 1,450bp PCR product. UBE2T IVS1 borders
the 5’ AluYa5 sequence and the 3’ AluYa5 sequence is bordered by IVS6. The
sequence intervening the Alu repeats and one AluYa5 repeat has been deleted.
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Figure 2.6 Identification of maternally-derived duplication mutation resulting
from AluYa5 mediated non-allelic homologous recombination.
(A) Examination of RT-PCR products amplified with primers 474Fwd and 479Rev
yielded the maternal duplication transcript that is 1,250bp in length.
Chromatograms depict the Exon6-Exon2 and Exon6-Exon7 junctions present in
this mRNA transcript. (B) Analysis of genomic DNA for Alu mediated duplication.
PCR using 509Fwd and 538Rev primers results in a 1,128bp PCR product in
proband fibroblasts and maternal LCLs. Chromatograms display PCR sequencing
demonstrating that UBE2T IVS6 borders the 5’ AluYa5 sequence and the 3’
AluYa5 sequence is bordered by IVS1. The sequence between the Alu repeats
and one AluYa5 repeat has been duplicated. (C) Schematic of UBE2T indicating
location of PCR primers and span of amplicons for genomic and cDNA assays.
(D) 1,128bp PCR product that is specific to the maternal duplication (509Fwd and
538Rev primers). Analysis of gDNA from fibroblasts, LCLs, and PB from the
proband compared to maternal and paternal gDNA.
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the expression of wild type UBE2T in the proband blood may be due to
recombination of the maternally derived allele to restore the WT sequence.

2.2.5 Complementation of RA2627 cellular defects by wild type UBE2T
expression
To prove that UBE2T deficiency is the cause of the subject’s FA, we
introduced wild type UBE2T into RA2627 fibroblasts and assayed for rescue of FA
phenotypes. Overexpression of UBE2T rescued cellular hypersensitivity to
crosslinking agents MMC, DEB and cisplatin (Figure 2.7A-C). UBE2T expression
restored monoubiquitination of FANCD2 and FANCI (Figure 2.7D) and FANCD2
foci following treatment with MMC (Figure 2.7G). Analysis of cell cycle distribution
following treatment with MMC revealed an accumulation of RA2627 cells in G2 that
was rescued by UBE2T overexpression to the levels observed in wild type BJ cells
(Figure 2.7E). These results confirm that deficiency of UBE2T results in Fanconi
anemia-T complementation group.

2.2.6 The primary role of UBE2T is in ICL repair
To determine if UBE2T is important for resistance to other types of damage,
RA2627 cells were tested for sensitivity to other genotoxic agents. RA2627 cells
were not found to be sensitive to UV, IR, CPT, HU, or the PARP inhibitor olaparib
(PARPi) (Figure 2.8A-F). These results are in contrast to previously reported UV
and HU sensitivity of UBE2T deficient DT40 cells (Kelsall et al., 2012). These data
suggest that UBE2T does not have a major role in responding to DNA lesions or
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Figure 2.7 UBE2T cDNA complements RA2627 hypersensitivity
crosslinking agents and monoubiquitination of FANCD2 and FANCI.

to

(A-C) Complementation of MMC, DEB, and cisplatin sensitivity of proband
fibroblasts (RA2627). Error bars indicate s.d. (D) Western blot analysis with
FANCD2 and FANCI antibody of UBE2T complemented cells with 1 µM MMC
treatment for 24h. (E) Complementation of cell cycle defect after 45 nM MMC
treatment. Cells were treated with drug and cultured for 48 h before analysis. (F)
Expression of wild type HA-FLAG tagged UBE2T cDNA or empty vector control
(EV) in RA2627 fibroblasts. (G) FANCD2 foci formation of complemented cells
following treatment with or without 1µM MMC for 24h.
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replication stress produced by these agents and its primary function is in ICL
repair.

2.2.7 A potential a mechanism of FA pathway regulation through UBE2T
While our manuscript was in press, Hira et al., published the identification
of two individuals with compound heterozygous UBE2T mutations. Both individuals
harbored different LOF mutations in trans to a N-terminal aa substitution p.Q2E
(Hira et al., 2015). The Q2E substitution replaces a polar aa with an acidic residue
and results in decreased FANCL binding and reduction in ID2 ubiquitination (Hira
et al., 2015).

Analysis of the S. pombe E1-E2 structure of Uba1-Ubc15 shows that acidic
residues of the N-terminus may reduce E1-E2 binding and that introduction of
negative charge at the N-terminus also reduces E1-E2 interaction. Similarly,
phosphorylation of the N-terminal of Ub E2s may also serve to regulate the E1-E2
interaction and a number of Ub E2s have serine/threonine phosphorylation sites in
the N-terminal region (Lv et al., 2017). The UBE2T N-terminus contains a protein
kinase C (PKC) consensus sequence and can be targeted by basophilic kinases
on Ser5 in vitro (Lv et al., 2017). The structure of UBE2T and the FANCL RING
domain demonstrates that the RING domain is also in proximity to UBE2T Ser5
suggesting that phosphorylation would disrupt the E1 as well as the E3 interaction
(Hodson et al., 2014; Lv et al., 2017).

70

Compared to unmodified wild type UBE2T protein, phosphorylated Ser5
(pSer5) and the phosphomimetic mutant S5D have severely diminished
monoubiquitination activity in vitro. Similarly, the Q2E substitution disrupts E1-E2
thioester transfer and monoubiquitination of FANCD2 (Lv et al., 2017). To
determine the consequences phosphorylation may have in vivo, we overexpressed
the UBE2T S5D phosphomimetic mutant in UBE2T deficient RA2627 fibroblasts
(Figure 2.9A). The Q2E substitution was also overexpressed for comparison. Both
S5D and Q2E showed significant defects in monoubiquitination of FANCI and
FANCD2 by western blot and foci formation following treatment with mitomycin C
(MMC) (Figure 2.9B-D). The S5D and Q2E mutants did not fully rescue sensitivity
to MMC by cell survival assay (Figure 2.9E). In contrast, the S5A phosphomutant
rescues monoubiquitination of FANCD2/I, FANCD2 foci formation, and
hypersensitivity to MMC (Figure 2.9G-H). The pSer5 was undetectable in cell
lysates using a phospho specific antibody and by mass spectrometry. However,
the S5A phosphomutant is able to fully rescue the defects of the UBE2T deficient
cells suggesting the S5D phosphomimetic is not a non-specific disruption of the
E1-E2 or E2-E3 interaction. These data demonstrate that phosphorylation of the
N-terminus in UBE2T may serve to regulate E1-E2 and E2-E3 interactions, but
more investigation and identification of a responsible kinase would be required to
determine if this is an important mechanism of regulation of the FA pathway.
Additionally, in light of these findings, we predict that the patient Q2E mutation
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Figure 2.8 UBE2T does not have a major role in repair of other types of DNA
damage.
(A) UV treated cell survival assay of the UBE2T complemented pair of RA2627
fibroblasts compared to BJ wild type fibroblasts depleted of XPF. (B) Western blot
of XPF levels for cells used in A. (C) IR cell survival assay of RA2627 fibroblasts
in comparison to RAD50 patient fibroblasts (RAD50mut). (D-E) Camptothecin
(CPT) and PARP inhibitor olaparib (PARPi) cell sensitivity assays comparing
RA2627 fibrobalsts to a patient SLX4 fibroblast cell line (SLX4mut). Patient SLX4
complemented pair are transduced with wild type SLX4 cDNA or empty vector
(EV). (F) Cell survival assay to hydroxyurea (HU) of RA2627 cells compared to
BRCA2 patient fibroblast cell line (BRCA2mut). Error bars indicate s.d.
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Figure 2.9 UBE2T/FANCT deficient RA2627 cells expressing UBE2T S5D
phosphomimetic are defective for FANCD2 and FANCI monoubiquitination.
(A) Western blot of HA-FLAG-tagged UBE2T expression. RA2627 UBE2T/FANCT
deficient fibroblasts expressing wild type (WT) UBE2T, empty vector control (EV),
and UBE2T mutants Q2E and S5D. (B) Western blot analysis of FANCD2 and
FANCI monoubiquitination in UBE2T complemented cells following 24h treatment
with 1 µM MMC. (C) FANCD2 foci formation in RA2627 cells expressing wild type
and mutant UBE2T after 24h treatment with 1 µM MMC. (D) Quantification of
FANCD2 foci formation visualized in C. (E) MMC cell survival assay of RA2627
hTERT cells expressing WT and mutant UBE2T. (F) Western blot of HA-FLAGtagged S5A UBE2T expression in RA2627 cells used in G-H. (G) Quantification
of FANCD2 foci formation of UBE2T S5A mutant compared to EV and WT
expressing RA2627 fibroblasts. (H) MMC cell survival assay of UBE2T S5A
mutant compared to WT and EV expressing RA2627 fibroblast.
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described by Hira et al. likely disrupts both E1 and E2 interaction by substitution
of an acidic residue leading to suboptimal activation of the FA pathway.

2.3 Summary and Conclusion
In this study, we have identified a Fanconi anemia subtype resulting from
deficiency of UBE2T. Analysis of RNA-seq data was critical in identifying UBE2T
deficiency stressing that multipronged diagnostic approaches are often necessary
in a genetically heterogeneous disease like FA.

We have identified compound heterozygous mutations in UBE2T, a large
genomic deletion in the paternally derived allele and a large duplication in the
maternally derived allele. Both of the mutations appear to be driven by Alumediated non-allelic homologous recombination (NAHR). NAHR is a prevalent
mechanism in genetic disorders arising from copy number defects due to recurrent
intrachromosomal recombination events (Deininger, 2011). Recently, sequencing
of FANCA deletion variants identified that breakpoints preferentially lie within Alu
elements and has revealed NAHR as a major mechanism of deletion in FANCA
(Flynn et al., 2014).

The subject presented at birth with classic FA features including
developmental defects and increased chromosomal breakage. The subject has not
yet developed bone marrow failure at the age of 16. Blood counts are likely
preserved due to the somatic mosaicism of the hematopoietic compartment.
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Restoration of UBE2T expression is detected in the individual’s lymphoblast cells
and we have observed increasing rescue of chromosomal breakage in peripheral
blood since birth. The subject’s bone marrow remains stable but hypocellular for
age (30-40%) and it is unclear whether mosaicism will continue to improve the
bone marrow cellularity.

The paternally derived deletion mutation is expected to not produce protein
due to deletion of the majority of the coding region and start codon, while the
maternally derived duplication results in very low levels of the c.-64_468dup
UBE2T transcript. This transcript may theoretically produce a UBE2T p.A157Cfs*7
protein, but it is clearly insufficient to fully support FA pathway function as evident
by the phenotype of the subject and the cellular defects. The subject’s fibroblasts
are as sensitive as FA-A patient cells by cell survival assay and no
monoubiquitination of FANCD2 or FANCI is detected. However, breakage levels
are not as elevated as the FA-A fibroblasts leaving the possibility that residual
truncated UBE2T may be present and active at a very low level, affecting the
breakage phenotype. An alternative explanation could be that another E2 with low
levels of activity may partially substitute in the pathway.

UBE2T has been demonstrated to be the major E2 ubiquitin-conjugating
enzyme required for the monoubiquitination of FANCD2 and FANCI (Alpi et al.,
2008; Hodson et al., 2014; Longerich et al., 2014; Longerich et al., 2009; Machida
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et al., 2006; Sato et al., 2012). Efficient and specific FANCD2 monoubiquitination
in vitro by UBE2T/FANCL requires the presence of FANCI and DNA (Longerich et
al., 2014; Sato et al., 2012). In vitro studies have demonstrated that a second E2,
UBE2W, can also ubiquitinate FANCD2 (Alpi et al., 2008; Zhang et al., 2011). In
recent work, the in vitro monoubiquitination of FAND2 by UBE2W is demonstrated
to be nonspecific, does not require interaction of ID2 complex, and is not stimulated
by DNA (Longerich et al., 2014). Additionally, ΔUBE2W chicken DT40 cells do not
display sensitivity to MMC and display normal levels of MMC induced
monoubiquitination of FANCD2 (Longerich et al., 2014).

The RA2627 patient cells do not have any detectable UBE2T by western
blot and transcript levels are extremely low making them ideal for studying cellular
defects of UBE2T deficiency. Previously, it was reported that UBE2T deficient
DT40 cells are sensitivity to UV and HU (Kelsall et al., 2012). In RA2627 cells,
UBE2T deficiency does not result in cellular sensitivity to UV and the patient does
not report sensitivity to sun exposure. We also demonstrate that UBE2T is not
required for cellular resistance to other types of DNA damage produced by IR,
CPT, PARP inhibitor, or HU. These results demonstrate the primary role of UBE2T
is in ICL repair and not in response to other types of DNA damage by these agents.

The Olsen laboratory determined the S. pombe Uba1-Ubc15 E1-E2
complex structure and observed that negative charge or phosphorylation of N-
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terminus residues of Ub E2s inhibits their function in vitro by interrupting the E1E2 interaction (Lv et al., 2017). The UBE2T and FANCL RING domain structure
also indicates that disruption in this region of UBE2T may also impact the E2-E3
interaction (Hodson et al., 2014; Lv et al., 2017). Expression of phosphomimetic
S5D and Q2E UBE2T in RA2627 cells mildly ameliorates UBE2T deficiency but
still results in reduced FA pathway activation and ICL sensitivity. UBE2T Ser5 may
be a regulatory site that disrupts both E1-E2 and E2-E3 interaction; however,
pSer5 was not detected in vivo. Nonetheless, the deleteriousness of the patient
Q2E substitution, that is the outcome of a point mutation, likely results from the
disruption of both the E1-E2 and E2-E3 interactions resulting in inadequate FA
pathway activation.

Our identification of biallelic UBE2T mutations and UBE2T deficiency in an
individual with FA corroborates that UBE2T is the primary E2 of the FA pathway
required for the activation of ID2 complex by monoubiquitination of FANCD2 and
FANCI and repair of DNA interstrand crosslinks. Deficiency of UBE2T causes
complementation group Fanconi anemia-T disease and future evaluation of FA
patients with unknown gene mutations should include complementation studies of
UBE2T.
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Chapter 3: Differential roles of the BRCA2 DNA
binding domain in replication fork protection in
response to hydroxyurea and DNA interstrand
crosslink damage
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3.1 Introduction
FANCD1/BRCA2 is an essential gene required for organismal development
and cellular survival. Single allele mutations in BRCA2 predispose to breast and
ovarian cancer and biallelic mutations results in a subtype of Fanconi anemia, FAD1 (Howlett et al., 2002). FA is a heterogeneous disease, but even within the
disease spectrum, FANCD1 patients are phenotypically distinct. A higher
proportion of FA-D1 patients have developmental abnormalities and the probability
of presenting with malignancy is 97% by the age of 5 (Alter et al., 2007). FA-D1
patients are rare, making up only 2% of Fanconi anemia cases (Wang and
Smogorzewska, 2015). Here we identify individuals with atypical FA-D1
presentation with mutations that lie within the BRCA2 DNA biding domain (DBD).
The identification of these FA-D1 individuals suggests that certain mutations of
BRCA2/FANCD1 may present differently than those previously described (Alter et
al., 2007; Myers et al., 2012; Wagner et al., 2004). It provides a unique opportunity
to uncover the BRCA2 function that is specific to this domain.

Functional analysis of BRCA2 has historically focused on canonical
homologous recombination (HR) and the requirement for BRCA2 in ICL repair has
been attributed to the importance of HR repair of DSBs generated during ICL
processing. As described in the main introduction of this thesis, the role of BRCA2
has been expanded to the protection of stalled replication forks (Quinet et al.,
2017). Analysis of replication fork intermediates by EM corroborates that reversed
replication forks are a structure that requires BRCA2-RAD51 protection to prevent
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Figure 3.1 BRCA2 mutations identified in a sibling pair with atypical Fanconi
anemia
Family pedigree showing a sibling pair with Fanconi anemia (red circles) who are
compound heterozygous for BRCA2 c.2330dupA (maternal inheritance) and
c.8524C>T (paternal inheritance) mutations. Family history of breast cancer
(purple), skin cancer (grey), and colon cancer (green). (B) Chromatograms of
Sanger sequencing confirming BRCA2 c.2330dupA and c.8524C>T mutations
identified by whole exome sequencing (WES).
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nucleolytic degradation (Lemacon et al., 2017; Mijic et al., 2017). Mitomycin C
(MMC) treatment is reported to increase reversed replication fork intermediates
but the physiological relevance of fork reversal in ICL repair has not been
investigated (Zellweger et al., 2015). RAD51 is recruited to replication forks stalled
at ICLs prior to DSB production and has been shown to have a role in protecting
ICLs against extensive resection by DNA2 and WRN (Long et al., 2011; Wang et
al., 2015). Here, the requirement for BRCA2 to protect against hyper-resection of
ICLs, separate from its role in HR, is investigated. These studies reveal that
replication fork protection at hydroxyurea-stalled forks and ICLs both require
BRCA2 but that they are distinct processes.

3.2 Results
3.2.1 Atypical presentation of Fanconi anemia in individuals with biallelic
FANCD1/BRCA2 mutations
Two female siblings with unknown causative gene mutations displaying a
multitude of congenital abnormalities and mildly elevated levels of chromosomal
breakage were entered into the International Fanconi Anemia Registry (IFAR). The
first sibling, at three years of age, was diagnosed with probable FA based on
congenital abnormalities. A DEB test showing elevated levels of chromosomal
breakage above normal but lower than typically seen in FA suggested the
possibility of somatic mosaicism. The second sibling was diagnosed at birth with
similar findings. There is no reported family history of FA, but there are some cases
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Figure 3.2 Schematic of BRCA2 structure showing location of patient DNA
binding domain mutations.
(A) Schematic of BRCA2 domain structure and key interacting proteins. (B)
BRCA2 structure of the DBD illustrating the location of the patient p.del2830-33
and p.R2842C mutations at the base of the Tower domain and OB2. Structure
adapted from Yang et al., 2005. (C) Alignment of the DBD peptide sequence in
the region of the patient BRCA2 mutations. The alignment shows that this
sequence is evolutionary conserved across many species. In green are the aa
residues modified by the patient mutations, p.del2830-33 and p.R2842C are
highlighted. Purple arrows indicate aa residues that contact DNA (Yang et al.,
2005).
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of breast cancer that were all diagnosed later in life (above 60 years of age) (Figure
3.1A).

Analysis of whole exome sequencing (WES) of patient LCLs was performed
and the data was filtered for variants that were shared between the siblings with
an allele frequency less than 1% in the 1000 genomes database (Genomes Project
et al., 2010). Biallelic FANCD1/BRCA2 mutations, in the now young adult sibling
pair, were identified and no other FA gene mutations were observed. These results
were surprising since neither sibling displayed the typical clinical findings of the
FANCD1/BRCA2 complementation group with no history of malignancy or bone
marrow failure at the ages of 20 and 23. An updated family history was notable for
early onset colorectal cancer of the father at the age of 40 and some skin cancer
diagnosis in the family (Figure 3.1A). The role of BRCA2 in colorectal cancer
(CRC) susceptibility is controversial, but there is some evidence that mutations in
BRCA2 may account for some familial CRCs (Degrolard-Courcet et al., 2014a;
Garre et al., 2015; Phelan et al., 2014).

Sanger sequencing confirmed compound heterozygous BRCA2 mutations.
A frameshift c.2330dupA mutation of exon 11 (maternal origin) results in premature
truncation of BRCA2 (p.Asp777Glu Fs*11) and has previously been described in
HBOC (Figure 3.1B). A second mutation, c.8524C>T, a missense variant of exon
20 (paternal origin) results in an p.Arg2842Cys residue change in the highly
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conserved DNA binding domain (DBD) of BRCA2 and has previously been
identified as a variant of unknown significance (VUS) in HBOC (Figure 3.1B and
Figure 3.2). At the protein level, the missense mutation results in the p.Arg2842Cys
change at a highly conserved residue at the base of the BRCA2 Tower domain of
the DBD (Figure 3.2.B-C). Sequencing of peripheral blood and lymphocytes
demonstrates the presence of both mutations and no evidence of somatic
mosaicism. With the recent release of the Genome Aggregation Database
(gnomAD) allele frequencies for c.2330dupA and c.8524C>T are available at
4.068e-6 and 1.084e-5 respectively. A combined annotation dependent depletion
(CADD) score of 35 is reported for this variant (Kircher et al., 2014). Given the
conservation of the affected amino acid (aa) residue, rare allele frequency, and
predicted deleteriousness by prediction tools, we hypothesized that the BRCA2
VUS c.8524C>T is pathogenic and contributing to diseases in this family.

One other adult individual with biallelic BRCA2 mutations is cited in the
literature (Howlett et al., 2002). This individual is homozygous for c.IVS19-1G>A
mutation that impacts the splice acceptor site for exon 20. cDNA analysis
demonstrated the use of an alternate spice acceptor that results in the loss of 12
bp of exon 20 and translates into p.del2830-2833 (Howlett et al., 2002). Amino
acid residues 2830-2833 are located at the transition of OB2 and the base of the
Tower domain (Figure 3.2.B-C). This individual at the age of 30 had history of
thumb malformation, but no history of bone marrow failure or malignancy. The
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patient is deceased due to cause unrelated to disease. Similar to the sibling pair
identified in the IFAR, the reported chromosomal breakage was modest (Howlett
et al., 2002).

We pursued characterization of patient-derived cells to determine how
these DBD mutations affect the function of BRCA2. We hypothesized that the
defects conferred by these BRCA2 DBD mutations leads to characteristic FA
developmental defects, but not early childhood bone marrow failure and
malignancies typically seen in other FANCD1 cases. The region of the BRCA2
DBD mutated here has been proposed to bind at ssDNA-dsDNA junctions, but its
role and the consequences of mutations here are unknown. In light of the HR
independent role of the BRCA2 binding partner RAD51/FANCR in replication fork
protection at ICLs, we hypothesized that these mutations may also disrupt
replication fork protection where recognition of ssDNA-dsDNA junctions may be
important.

3.2.2 Phenotype of FANCD1/BRCA2 DNA binding domain patient cell lines
Lymphoblastoid cell lines (LCLs) (RA3105 and RA3106) were derived from
the sibling pair with compound heterozygous BRCA2 mutations, c.2330dupA and
c.8524C>T. FA pathway activation, monitored by FANCI ubiquitination, was
normal in patient-derived LCLs (Figure 3.3A). Analysis of BRCA2 expression by
western blot demonstrated a full length (~390 kDa) band, the presumed product of
the c.8524C>T allele, for both patient cell lines (Figure3.3B). DEB breakage
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Figure 3.3 Characterization of BRCA2 patient lymphoblast cell lines from a
sibling pair with atypical Fanconi anemia.
(A) Immunoblot analysis for FANCI ubiqutination following treatment with 1µM
MMC for 24h of RA2985 (WT), RA2939 (FANCA), and patient RA3105 and
RA3106 LCLs. (B) Immunoblot showing BRCA2 levels in RA2985 (WT) control,
RA2525 (FANCD1) and patient RA3105 and RA3106 LCLs. (C) Quantification of
chromosome breaks following DEB treatment of RA2985 (WT), RA2939 (FANCA),
and patient RA3105 and RA3106 LCLs. (D) Metaphase for RA2985 and RA3105
following DEB treatment. (E-F) Cell survival assays of patient derived lymphoblast
cell line (LCLs) RA3105, RA2939 (FANCA), RA2985 (WT), and RA2525
(FANCD1) after mitomycin C (MMC), diepoxybutane (DEB), PARP inhibitor
olaparib (PARPi), and camptothecin (CPT) treatment. Survival assays were
performed in triplicate. Cells were treated with increasing concentrations of
genotoxic agents and counted after 7-10 days in culture. Relative cell survival was
normalized to untreated controls to give percent survival. Error bars indicate s.d.
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analysis confirmed previous clinical data that breakage is elevated, but not to
levels of typical FANCA LCLs (RA2939) (Figure 3.3C-D). RA3105 LCLs displayed
hypersensitivity to crosslinking agents MMC and DEB, but to a lesser degree than
RA2939 FANCA LCLs (Figure 3.3E-F). RA3105 cells were also hypersensitive to
the replication stress inducing agents including olaparib, a PARP inhibitor (PARPi),
and topoisomerase I inhibitor camptothecin (CPT) (Figure 3.3G-H).

Patient derived fibroblasts (HSC62) from the individual with homozygous
c.IVS19-1G>A mutations were available (Howlett et al., 2002). Analysis of HSC62
cells revealed more moderate chromosomal breakage to DEB and MMC and
cellular hypersensitivity to crosslinking agents, DEB, MMC, and cisplatin (Figure
3.4A-E). Interestingly, the cells were not hypersensitive to ionizing radiation (IR),
but were sensitive to replication stress induced by CPT and PARPi (Figure 3.4FH). In contrast, the cells were not sensitive to replication stress produced by the
agents aphidicolin and hydroxyurea (HU).

To determine the impact of DBD disruption on the ability of c.IVS19-1G>A
BRCA2 to load RAD51 onto ssDNA following DNA damage, we analyzed RAD51
foci formation after IR and MMC in HSC62 cells. Levels of RAD51 foci were
reduced after IR and MMC treatment (Figure 3.5B-C). The RAD51 foci were
quantitatively fewer and qualitatively smaller (Figure 3.5A). Given the normal
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Figure 3.4 Cellular sensitivity of HSC62 BRCA2 c.IVS19-1G>A patient
fibroblast cell line.
(A-B) Quantification of chromosome breaks following DEB and MMC treatment of
BJ wild type fibroblasts, FANCA patient fibroblasts (FA-Amut), and HSC62
fibroblasts. (C-J) Cell survival of HSC62 fibroblasts compared to BJ WT fibroblast,
FANCA patient fibroblast (FA-Amut), FANCA complemented patient cells
expressing wild type FANCA (FA-A+A) or empty vector (FA-A+EV), or FA BRCA2
patient fibroblast (BRCA2mut). Cell survival assays were performed in triplicate.
Cells were treated with increasing concentrations of indicated agent. Cell survival
was determined by counting cells after 7-9 days in culture. Relative cell survival
was normalized to untreated controls to give the percent survival. Error bars
indicate s.d.
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Figure 3.5 Characterization of HSC62 BRCA2 c.IVS19-1G>A fibroblast cell
line from an adult patient with atypical Fanconi anemia.
(A) Immunofluorescence images of RAD51 foci, 8h following 12 Gy ionizing
radiation (IR) of BJ WT fibroblast and patient derived HSC62 fibroblast, detected
with anti-RAD51 antibody. Third row images are individual cells enlarged to better
reveal differences in RAD51 foci size. (B) Quantification of RAD51 foci 1h, 8h, and
24h following 12 Gy ionizing radiation (IR) of BJ WT fibroblast and HSC62
fibroblast. Error bars indicate s.d. of two independent experiments (³200 cells per
experiment). (C) Quantification of RAD51 foci 8h, 24h, and 48h following 1h
treatment with 3 μM MMC of BJ WT fibroblast and HSC62 fibroblast. (D) Sister
chromatid exchange (SCE) assay in BJ WT fibroblast and HSC62 fibroblast
following treatment with MMC (0.1 μg/ml or 0.2 μg/ml). (E) SCE assay in BJ WT
fibroblast and HSC62 fibroblast following depletion of BLM. (F) Representative
images of SCEs in BJ WT fibroblast and HSC62 fibroblast metaphases. (G) qRTPCR of BLM expression levels in cells described in E. Error bars indicate s.d.

95

96

resistance to IR, sister chromatid exchange (SCEs) levels were analyzed as a
readout of HR (Sonoda et al., 1999). SCEs were induced by increasing
concentrations of MMC or depletion of the Bloom helicase (BLM) and no significant
difference in SCE levels was observed between BJ wild type fibroblast and HSC62
cells (Figure 3.5D-F). These observations suggest that the DNA binding domain
defect in HSC62 cells, while moderately decreasing RAD51 foci formation, does
not result in defective HR as observed by normal resistance to IR and SCE levels
in these cells. Interestingly, there is a greater impact on replication fork stress
induced by ICL generating agents as determined by cellular sensitivity.

3.2.3 CRISPR/Cas9 mediated correction of the BRCA2 c.IVS19-1G>A
mutation rescues cellular defects of patient HSC62 fibroblasts
We complemented the patient cell line to demonstrate that the c.IVS191G>A mutations cause the defects we observe in the HSC62 cell line, and so that
future analysis could be performed in isogenic cell lines. The size of BRCA2 cDNA
hinders efficient complementation by overexpression, so the homozygous
c.IVS19-1G>A mutations were corrected to wild type at the endogenous locus
using CRISPR/Cas9 gene targeting. Both heterozygous and homozygous clones
were recovered (HSC62WT/MUT or HSC62WT/WT) (Figure 3.6A). cDNA analysis
demonstrated that restoration of the splice acceptor base (A>G) in HSC62WT/MUT
or HSC62WT/WT clones restored the cDNA exon 19 and exon 20 junction (Figure
3.6C). Both HSC62WT/MUT and HSC62WT/WT clones rescued RAD51 foci formation
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Figure 3.6 Complementation of HSC62 BRCA2 c.IVS19-1G>A DNA binding
domain patient fibroblast cell line at the endogenous locus by CRISPR/Cas9
mediated gene targeting.
(A) Chromatograms of PCR amplified gDNA of CRISPR/Cas9 targeted HSC62
fibroblasts. Gene editing reverted the c.IVS19-1G>A mutation either to
homozygous WT (HSC62WT) or heterozygous WT (HSC62mut/WT) at the
endogenous locus in HSC62 patient cells. The silent mutation that was
incorporated to destroy the CRISPR PAM sequence is indicated. (B) Immunoblot
showing BRCA2 levels in CRISPR/CAS9 corrected patient cell line HSC62WT,
uncorrected HSC62 cells (HSC62mut), and RA2630 (FANCR) patient fibroblasts.
(C) cDNA analysis of HSC62 clones with either homozygous or heterozygous
correction of the c.IVS19-1G>A mutation demonstrating rescue of the 12bp
deletion of exon 20 that results because of alternate splicing.
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defects after IR and MMC, and also rescued hypersensitivity to replication stress
inducing agents MMC, CPT, and PARPi (Figure 3.7A-D and Figure 3.8A-D).

3.2.4 Defective ICL repair in HSC62 cells results in increased RPA activation
that is dependent on DNA2 and WRN
Our lab has previously described a FANCR/RAD51 p.T131P patientderived cell line that is proficient for HR but defective in ICL repair. One
characteristic of this cell lines is hyperactivation of RPA upon MMC treatment
(Wang et al., 2015). Given that BRCA2 and RAD51 interaction is required for their
canonical function in HR and for the non-canonical function in replication fork
protection at HU-stalled forks, we hypothesized that BRCA2 also functions with
RAD51 in preventing increased ssDNA generation at ICLs (Schlacher et al., 2011;
Wang et al., 2015). We observed an increase in RPA foci formation and
phosphorylation in HSC62MUT cells compared to wild type fibroblast upon MMC
treatment (Figure 3.9A-B). Similar to FANCR/RAD51 p.T131P expressing patient
cells, the increased RPA foci formation in HSC62 cells was also dependent on
DNA2 and WRN activity, but not MRE11, EXO1, CtIP, or BLM (Figure 3.9C). These
results support an ICL repair model that requires both BRCA2 and RAD51 activity
to protect against aberrant processing by DNA2 and WRN, but not the other
effectors of DSB end resection such as MRE11, EXO1, or CtIP (Wang et al., 2015).
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Figure 3.7 Defects in RAD51 foci formation in HSC62 BRCA2 patient
fibroblasts are rescued by gene correction.
(A) Quantification of RAD51 foci 8h after 12 Gy ionizing radiation (IR) of BJ WT
fibroblast, wild type HSC62 (HSC62WT) clones 1-3, and HSC62 uncorrected patient
cell line (HSC62mut). (B) Quantification of RAD51 foci 24h following 1h treatment
with 3 uM MMC. Error bars indicate s.d. of three independent experiments (³200
cells per experiment). Representative images of RAD51 foci, 8h post IR (C) and
24h post MMC (D) detected by immunofluorescence with anti-RAD51antibody.
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Figure 3.8 Rescue of cellular sensitivity of HSC62 BRCA2 patient fibroblasts
to genotoxic agents by gene correction.
(A-D) Cell survival of HSC62 uncorrected patient cell line (HSC62mut) compared to
BJ WT fibroblast and wild type HSC62 (HSC62WT) clones 1-3. Cell survival assays
were performed in triplicate. Cells were treated with increasing concentrations of
indicated agent. Cell survival was determined by counting cells after 7-9 days in
culture. Relative cell survival was normalized to untreated controls to give percent
survival. Error bars indicate s.d.
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3.2.5 Generation of isogenic BRCA2 DNA binding domain mutations in
human fibroblasts
The lack of patient derived fibroblasts from the sibling pair with compound
heterozygous BRCA2 mutations, c.2330dupA and c.8524C>T, precluded the
direct comparison of the DNA binding domain mutations in similar cell types. In
order to directly compare the defects conferred by the BRCA2 DBD mutations
c.8524C>T (p.R2842C) and c.IVS19-1G>A (p.del2830-2833), we generated
isogenic cell lines by introducing the mutations into wild type BJ fibroblasts with
CRISPR/Cas9 gene editing (Figure 3.10). To examine the specific impact of the
DBD mutations, cells homozygous for the mutations were selected to be used in
further analysis. Knock in of the BRCA2 c.IVS19-1G>A mutation in BJ fibroblasts
confers the same splicing defect, loss of the first 12bp of exon 20 , observed in
HSC62 cells (Figure 3.10B). Western blot analysis of BRCA2 levels demonstrates
~390 kDa bands for all mutants except for BRCA2 clones harboring frameshift
mutations in exon 20 (Figure 3.10E). The BRCA2 frameshift mutant is homozygous
c.8531dupA with a predicted p.R2845K FS*22 truncation (BRCA2Trun.).

Functional analysis of isogenic DBD mutants demonstrated defects in
RAD51 foci formation following IR and MMC (Figure 3.11 and Figure 3.12). The
c.IVS19-1G>A mutation has a more deleterious impact on RAD51 foci formation,
resulting in reduction of cells with RAD51 foci and reduced foci size. The
c.8524C>T mutants do not show a significant reduction in the number of cells with
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Figure 3.9 Depletion of DNA2 and WRN in HSC62 patient cells suppresses
increased RPA activation and foci formation induced by MMC.
(A) Images of RPA foci, 24h post 1h treatment with 3 μM MMC, detected by
immunofluorescence with anti-RPA32 antibody. (B) Quantification of RPA foci 24h
following 1h treatment with 3 μM MMC of BJ WT fibroblast, wild type HSC62 clones
(HSC62WT), and HSC62 uncorrected patient cell line (HSC62mut). (C) Quantification
of RPA foci 24h following 1h treatment with 3 μM MMC in HSC62mut cells depleted
of DNA2, MRE11, EXO1, CtIP, WRN, or BLM by siRNA compared to luciferase
control (Luc). Error bars indicate s.d. of four independent experiments. (D) qRTPCR of DNA2, EXO1, WRN, and BLM expression levels of cells in C. Error bars
are s.d. (E) Immunoblot analysis of MRE11 and CtIP siRNA depletion for cells
utilized in C.
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RAD51 foci; however, the foci are much smaller in size (Figure 3.11B and Figure
3.12B). By comparison the BRCA2Trun. mutant has complete loss of observable
RAD51 foci formation. Analysis of cellular sensitivity of the DBD mutants revealed
trends that correlated with the RAD51 foci data, demonstrating the c.IVS19-1G>A
mutation to be more deleterious to BRCA2 function than the c.8524C>T mutation.
Both mutations sensitize cells to MMC with some clonal variation for the c.IVS191G>A mutation, but overall the same trends are observed (Figure 3.13A-B). Both
the c.8524C>T and c.IVS19-1G>A mutants are sensitive to replication stress
inducing drugs PARPi and CPT compared to WT cells, but not aphidicolin as seen
in the patient HSC62 fibroblast (Figure 3.4 and Figure 3.13C-E). Increased RPA
foci following MMC was also observed for c.8524C>T and c.IVS19-1G>A mutants,
with a greater increase in RPA foci seen in the c.IVS19-1G>A mutants (Figure
3.14).

The c.IVS19-1G>A mutation confers a splicing defect in which the
consequence is the loss of the first four aa of exon 20 in a very conserved region
of the DBD, at the OB2 and base of the Tower domain (Figure 3.2). How the loss
of these four aa impact protein folding of this region is unknown; however, the
greater defects in RAD51 recruitment, cellular viability to genotoxic agents, and
increased generation of ssDNA at ICL lesions as measured by RPA foci suggest
that this mutation is much more disruptive to BRCA2 activity than the c.8524C>T
mutation. In this region, proximal to both the c.8524C>T and c.IVS19-1G>A
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mutants, are three aa residues that have been identified for their direct interaction
with DNA, K2833, Y2839, and F2841 (Yang et al., 2005). Using CRISPR/Cas9 in
BJ wild type fibroblasts, we generated a DBD mutant (BRCA2DBDx3A) by mutating
these three codons to alanine (Figure 3.15A). We hypothesized that the DBDx3A
mutations would be less disruptive to BRCA2 structure and function than the
c.IVS19-1G>A mutation, but would still interfere with proper DNA binding in this
region. BRCA2DBDx3A cells were hypersensitive to MMC but not to the extent of
BRCA2IVS19-1G>A. RAD51 foci formation levels were nearly equivalent to WT cells
following IR, but foci, similar to BRCA28524C>T clones, were greatly reduced in size
(Figure 3.15C-D). A marked increase in RPA foci following MMC was seen in the
BRCA2DBDx3A cells, but less than BRCA2IVS19-1G>A (Figure 3.15E). These data are
consistent with the defects in BRCA2 c.8524C>T and c.IVS19-1G>A cells being
due to diminution of BRCA2 DNA binding ability; however, the greater defects
conferred by the c.IVS19-1G>A mutation may be an outcome of a more distorting
effect on BRCA2 structure that effects other domains.
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Figure 3.10 Generation of isogenic BRCA2 DNA binding domain mutants by
CRISPR/Cas9 mediated gene targeting in human fibroblasts.
(A) Chromatograms of BRCA2 BJ fibroblast clones generated by CRISPR/Cas9
targeting. BRCA2 exon 20 DNA binding domain mutations c.8524C>T and
c.IVS19-1G>A were generated by targeting CRISPR/Cas9 in the vicinity of the
desired mutation and supplying a 100bp ssDNA donor containing the mutation.
Sanger sequencing of PCR amplified genomic DNA demonstrated homozygous
knock-in for both mutations. (B) cDNA analysis of homozygous c.IVS19-1,G>A BJ
fibroblast clones demonstrated that the splice site mutation, as seen in the patient
HSC62 fibroblasts, results in the usage of an alternative splice site donor resulting
in a 12bp deletion at the start of BRCA2 exon 20. (C) A frameshift exon 20 BRCA2
mutant was generated by a homozygous single base pair insertion (c.8531dupA)
during CRISPR/Cas9 targeting. This presumed truncation mutant is annotated as
BRCA2Trun. (D) cDNA sequencing of c.8524C>T BJ fibroblasts demonstrating the
missense mutation and silent mutation introduced by CRISPR/Cas9 targeting. (E)
Immunoblot showing BRCA2 levels in bulk BJ WT fibroblasts, BRCA2WT fibroblast
clone, c.IVS19-1G>A BJ clones 1-3, c.8524C>T BJ clones 1-2, and BRCA2Trun.
clones 1-2.
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Figure 3.11 RAD51 foci formation in BRCA2 DNA binding domain mutants
following ionizing radiation.
(A) Quantification of RAD51 foci 1h, 8h and 24h following 6 Gy ionizing radiation
(IR) of BJ WT fibroblasts, BJ WT fibroblast clone (BRCA2WT), c.IVS19-1G>A BJ
clones 2-3, c.8524C>T BJ clones 1-2, and a BRCA2 homozygous truncation
mutant, c.8531dupA (BRCA2Trun). Error bars indicate s.d. of three independent
experiments (³200 cells per experiment). (B) Representative images of RAD51
foci, 8h post 6 Gy IR, detected by immunofluorescence with anti-RAD51 antibody.
Third row images are individual cells enlarged to better reveal differences in
RAD51 foci size.
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Figure 3.12 RAD51 foci formation in BRCA2 DNA binding domain mutants
following mitomycin C.
(A) Quantification of RAD51 foci 8h, 24h and 48h following 1h treatment with 3 μM
MMC of BJ WT fibroblasts, BJ WT fibroblast clone (BRCA2WT), c.IVS19-1G>A BJ
clones 2-3, c.8524C>T BJ clones 1-2, and a BRCA2 truncation mutant,
c.8531dupA (BRCA2Trun). Error bars indicate s.d. of three independent
experiments (³200 cells per experiment). (B) Representative images of RAD51
foci, 24h post 1h treatment with 3 μM MMC, detected by immunofluorescence with
anti-RAD51antibody. Third row images are individual cells enlarged to better reveal
differences in RAD51 foci size.
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Figure 3.13 Cellular sensitivity of isogenic BRCA2 DNA binding domain
mutants.
(A-E) Cell survival of BJ WT fibroblasts, BJ WT fibroblast clone (BRCA2WT),
c.IVS19-1G>A BJ clones, c.8524C>T BJ clones, and exon 20 BRCA2 frameshift
mutant (BRCA2Trun.). Cell survival assays were performed in triplicate. Cells were
treated with increasing concentrations of indicated agent. Cell survival was
determined by counting cells after 7-9 days in culture. Relative cell survival was
normalized to untreated controls to give the percent survival. Error bars indicate
s.d.
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Figure 3.14 BRCA2 DNA binding domain mutants have increased RPA foci
formation following mitomycin C.
(A) Quantification of RPA foci 8h, 24h and 48h following 1h treatment with 3 μM
MMC of BJ WT fibroblasts, BJ WT fibroblast (BRCA2WT), c.IVS19-1G>A BJ
clones 2-3, c.8524C>T BJ clones 1-2, and a BJ BRCA2 truncation mutant
(BRCA2Trun.). Error bars indicate s.d. of three independent experiments (³200
cells per experiment). (B) Representative images of RPA foci, 24h post 1h
treatment with 3 uM MMC, detected by immunofluorescence with anti-RPA32
antibody. Third row images are individual cells enlarged to better reveal RPA foci.
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Figure 3.15 CRISPR/Cas9 mediated gene targeting to mutagenize key DNA
interacting residues of the BRCA2 DNA binding domain.
(A) Chromatogram of BRCA2 CRISPR/Cas9 generated DNA binding domain triple
mutant (DBDx3A). Three codons of exon 20, previously identified to interact with
DNA (2833K, 2839Y, and 2841F), were mutagenized to produce alanine when
translated. BRCA2DBDx3A was generated by targeting CRISPR/Cas9 in the vicinity
of the desired mutations and supplying a 100bp ssDNA donor containing the three
codon mutations. Sanger sequencing of PCR amplified genomic DNA
demonstrates homozygous knock-in of the three alternate codons. (B) Cell
survival of BRCA2WT, BRCA2IVS19-1G>A, and BRCA2DBDx3A BJ fibroblast cell lines.
Survival assay was performed in triplicate and treated with increasing
concentrations of MMC. Cell survival was determined by counting cells after 8
days in culture. Relative cell survival was normalized to untreated controls for the
percent survival. Error bars indicate s.d. (C) Quantification of RAD51 foci 8h after
6 Gy ionizing radiation (IR) of BRCA2WT, BRCA2IVS19-1G>A, and BRCA2DBDx3A BJ
fibroblast cell lines. Error bars indicate s.d of three independent experiments. (D)
Representative images of RAD51 foci, 8h post 6 Gy IR, detected by
immunofluorescence with anti-RAD51antibody. Third row images are individual
cells enlarged to better reveal differences in RAD51 foci size. (E) Quantification of
RPA foci, 24h post 1h treatment with 3 μM MMC, of BRCA2WT, BRCA2IVS19-1G>A,
and BRCA2DBDx3A BJ fibroblast cell lines. Error bars indicate s.d of three
independent experiments.
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3.2.6 Determination of homologous recombination efficiency in DNA binding
domain mutants
The patients harboring the c.8524C>T and c.IVS19-1G>A mutations have
an unusually mild clinical presentation for patients in the FANCD1/BRCA2
complementation group. The embryonal tumors of this complementation group are
not a prominent feature in the majority of other FA subtypes, suggesting these
tumors may be the result of HR deficiency outside of the FA pathway during
development. HR mediated double strand break repair is necessary for resolution
of ICLs, but there is debate about the role of the BRCA2 DBD and its importance
for HR (Saeki et al., 2006; Schlacher et al., 2011; Siaud et al., 2011). To analyze
HR activity, DBD mutations as well as an exon 27 p.S3291A mutation, previously
reported to have no effect on HR, were generated in HEK293T cells (Figure 3.16).
Western blot analysis of BRCA2 indicated full length BRCA2 with the exception of
a BRCA2Trun. (c.8531dupA) used as a control (Figure 3.16B). Cellular sensitivity to
MMC was assessed in the BRCA2 HEK293T clones demonstrating increasing
levels of sensitivity (p.S3291A < c.8524C>T < c.IVS19-1G>A) (Figure 3.16C).

To determine the HR proficiency of BRCA2IVS19-1G>A and BRCA28524C>T
cells, we utilized an assay that takes advantage of the targeted DSBs generated
by CRISPR/Cas9. A CRISPR/Cas9 vector expressing a sgRNA targeting the
LMNA locus was transfected along with a LMNA homology donor template
containing a N-terminus mClover fluorescent protein tag (Figure 3.17A) (Arnoult et
al., 2017; Pinder et al., 2015). Cells that undergo HR can utilize the HR donor
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template which results in expression of fluorescently tagged LMNA that can be
assessed by flow cytometry analysis. Compared to wild type, HR in all BRCA2
clones was moderately decreased by their mutations (Figure 3.17D). The
previously described separation of function mutation, p.S3291A, moderately
impacts HR efficiency. This demonstrates that Ser3291 is important for BRCA2 Cterminal domain activity during HR and not just exclusively at stalled replication
forks (Kim et al., 2014; Schlacher et al., 2011). The DBD BRCA2IVS19-1G>A and
BRCA28524C>T cells showed similar decreases in HR levels to approximately half
that of wild type cells, but they retained more HR activity than cells depleted of
RAD51 and BRCA2 or BRCA2Trun cells. Two of the c.IVS19-1G>A mutants appear
to express lower BRCA2 levels (Figure 3.16B), suggesting these may be
hemizygous clones, but this did not further impair HR levels as compared to similar
levels in a third homozygous clone.

3.2.7 The BRCA2 DNA binding domain is required for replication fork
protection at HU-stalled forks and ICLs to prevent resection by DNA2
We previously demonstrated, in the patient HSC62 cell line (c.IVS191G>A), that increased RPA foci formation observed following MMC treatment is
the result of DNA2 and WRN activity. In BJ fibroblast BRCA2 DBD mutants, we
also observed increased RPA foci after MMC treatment (Figure 3.14 and Figure
3.18). The increased RPA foci formation and phosphorylation of RPA in
BRCA28524C>T, BRCA2IVS19-1G>A, and BRCA2DBD3xA cells were all reduced by DNA2
and WRN depletion (Figure 3.18). The rescue of RPA activation was less striking
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Figure 3.16 HEK293T BRCA2 DNA binding domain and Exon 27 p.S3291A
clones generated by CRISPR/Cas9 gene editing.
(A) Chromatograms of BRCA2 CRISPR/Cas9 generated HEK293T clones aligned
to WT. A frameshift Exon 20 BRCA2 mutant (BRCA2Trun.) was generated by
homozygous single base pair insertion as a result of CRISPR/Cas9 targeting.
BRCA2 exon 20 mutations, c.8524C>T and c.IVS19-1G>A, and Exon 27
p.S3291A clones were generated by targeting the respective BRCA2 exon with
CRISPR/Cas9 and a 100bp ssDNA template donor. Where applicable, silent
mutations are indicated. (B) Immunoblot showing BRCA2 levels in WT HEK293T
cells and BRCA2 mutant HEK293T clones: c.8531dupA (BRCA2Trun), c.8524C>T
(clones 1-2), c.IVS19-1G>A (clones 1-3), and p.S3291A (clones 1-3). (C) Cell
survival of WT cells and BRCA2 clones performed in triplicate and treated with
increasing concentrations of MMC. Cell survival was determined by counting cells
after 6 days in culture. Relative cell survival was normalized to untreated controls
for the percent survival. Error bars indicate s.d.
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Figure 3.17 Homologous recombination efficiency of BRCA2 DNA binding
domain mutants.
(A) Schematic of mClover LMNA homologous recombination CRISPR/Cas9
reporter assay. A plasmid expressing Cas9 and a sgRNA targeting the LMNA 5’
UTR was co-transfected with a donor template plasmid containing mClover
flanked by LMNA homology. Repair at the LMNA locus by HR using the donor
template results in mClover tagging of the N-terminus of LMNA. mClover green
cells were quantified by flow cytometry analysis. (B) Immunoblot of RAD51
knockdown for HEK293T cells used in D. (C) qRT-PCR of BRCA2 expression
levels of cells utilized in D. Error bars are s.d. (D) Levels of mClover positive cells
were normalized to WT HEK293T (siLuc). Error bars indicate s.d. of three
independent experiments performed in triplicate.
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in the BRCA2IVS19-1G>A cells, suggesting that for this more deleterious mutation
there may be other sources of ssDNA besides DNA2 and WRN at ICLs. These
data are consistent with the requirement for BRCA2 function at replication forks
encountering ICLs to prevent over resection by DNA2 and WRN.

To determine the requirement for the BRCA2 DBD in replication fork
protection after HU, BRCA28524C>T and BRCA2IVS19-1G>A cells were examined using
DNA fiber analysis. Replication fork protection by BRCA2 has largely been
attributed to the C-terminal RAD51 interacting domain by analysis of the p.S3291A
BRCA2 mutation. S3291 is a CDK phosphorylation site that when phosphorylated
prohibits RAD51 binding. The C-terminal RAD51 interacting domain is thought to
stabilize RAD51 nucleofilaments in a cell cycle controlled manner (Ayoub et al.,
2009; Schlacher et al., 2011). Our data, and another recently published study
suggests that this mutant moderately impacts HR proficiency; nonetheless, it does
abrogate replication fork protection at HU-stalled replication forks (Feng and Jasin,
2017).

Analysis

of

BRCA2Trun.,

BRCA28524C>T,

and

BRCA2IVS19-1G>A cells

demonstrated defects in replication fork protection of HU-stalled forks as measured
by the degradation of nascent DNA tracks labeled with nucleotide analogs, IdU
and CldU (Figure 3.19). As previously reported, nascent strand degradation in the
absence of BRCA2 was rescued by the MRE11 inhibitor mirin and MRE11
depletion (Figure 3.19 and Figure 3.20A). These data demonstrate that the
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Figure 3.18 Depletion of DNA2 and WRN suppresses increased RPA
activation and foci formation induced by MMC in BRCA2 DNA binding
domain mutants.
(A-B) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3
μM MMC. BRCA2WT, BRCA2c.8524C>T, BRCA2c.IVS19-1G>A, and BRCA2DBDx3A BJ
fibroblast cells were transfected with siRNA control luciferase (Luc) or siRNAs
targeting DNA2 or WRN. (C-D) Quantification of RPA foci 24h following 1h
treatment with 3 μM MMC in cells depleted of DNA2 or WRN by siRNA. Error bars
indicate s.d of two independent experiments. (E-G) qRT-PCR of DNA2 and WRN
expression levels of cells utilized in A-D. Error bars indicate s.d.
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BRCA2Trun., BRCA28524C>T, and BRCA2IVS19-1G>A cells are all similarly defective for
replication fork protection and that the DBD is required for protection of replication
forks from MRE11 processing in contrast to a previous report (Schlacher et al.,
2011).

At ICLs, DNA2 is involved in aberrant processing in the absence of
replication fork protection by RAD51 and BRCA2, as shown here (Wang et al.,
2015). To determine if processing of replication forks by DNA2 is distinct to ICLs,
DNA2 was depleted in BRCA2 mutants, and cells were analyzed for nascent
strand degradation following HU (Figure 3.20A). Depletion of DNA2 rescues
resection in all of the BRCA2 mutants including BRCA2Trun., BRCA28524C>T,
BRCA2IVS19-1G>A, and BRCA2S3291A. These data demonstrate that both the DBD
and C-terminal domain of BRCA2 are required for proper replication fork protection
at HU-stalled forks, and that both domains are required to protect against
degradation by MRE11 and DNA2.

All of the BRCA2 mutants showed similar levels of nascent strand resection
as measured by DNA fibers, but levels of chromosomal breakage differed (Figure
3.20B). In parallel to our DNA fiber experiments, metaphases were analyzed after
5 hours of 6 mM HU and release into colcemid. BRCA2Trun. cells showed a large
increase in genomic instability upon stalling with HU in comparison to WT and the
other BRCA2 mutants. BRCA28524C>T and BRCA2S3291A cells did not show an
elevation
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Figure 3.19 BRCA2 DNA binding domain mutants are defective in replication
fork protection at hydroxyurea-stalled forks.
Isogenic BJ fibroblast BRCA2 mutants, BRCA2Trun., BRCA28524C>T and
BRCA2IVS19-1,G>A, were analyzed for replication fork resection. Cells were labeled
with DNA analogs, IdU for 20 minutes and then CldU for 20 minutes. Cells were
then incubated in 6 mM hydroxyurea (HU) with and without MRE11 inhibitor mirin
(50 uM) for 4h before being harvested. DNA fibers were prepared and visualized
by immunofluorescence detection of IdU and CldU and measured. Error bars
indicate s.d.
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Figure 3.20 DNA2 promotes nascent strand degradation at hydroxyureastalled replication forks.
(A) Isogenic BJ fibroblast BRCA2 mutants, BRCA2Trun., BRCA28524C>T,
BRCA2IVS19-1G>A, and BRCA2S3291A, were transfected with siRNA control luciferase
(Luc) or siRNAs targeting DNA2 or MRE11. Cells were labeled with DNA analogs,
IdU for 20 minutes and then CldU for 20 minutes. Cells were then incubated in 6
mM hydroxyurea (HU) for 4h before being harvested. Error bars indicate s.d. (B)
Quantification of chromosome breaks following 5h of 6 mM HU and released into
colcemid. (C) Immunoblot analysis of MRE11 depletion for cells utilized in A. (D)
qRT-PCR of DNA2 expression levels of cells utilized in C. Error bars indicate s.d.
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elevation in breakage and BRCA2IVS19-1G>A cells had a mild increase. The elevated
chromosomal breakage in BRCA2Trun. cells was reduced by MRE11 depletion, but
was exacerbated by DNA2 depletion. DNA2 depletion results in a mild increase in
breakage for all mutants but none to the extent of BRCA2Trun. Previous studies
have reported elevated breakage resulting from replication fork degradation in
p.S3291A expressing cells and BRCA2 deficient cells (Mijic et al., 2017; Schlacher
et al., 2011). However, our data demonstrate that different levels of BRCA2
function have different consequences at HU-stalled forks. These data demonstrate
that replication fork resection at HU-stalled forks does not correlate with
chromosomal breakage. Neither BRCA28524C>T or BRCA2S3291A cells have a
significant increase in breakage after HU, despite having levels of fork degradation
similar to BRCA2Trun. How this breakage results in BRCA2 depleted or LOF cells
needs to be investigated further, but like nascent DNA degradation, it is in part
dependent on MRE11.

3.2.8 Depletion of SLX4 or MUS81 does not rescue MMC induced RPA foci in
BRCA2 DBD mutants
SLX4 is a nuclease scaffold protein that complexes with XPF, MUS81, and
SLX1, all nucleases that have been implicated in ICL repair (Dendouga et al.,
2005; McPherson et al., 2004; Niedernhofer et al., 2004). The unhooking of ICLs
is dependent on the SLX4-XPF interaction and deficiency of either protein results
in FANCP or FANCO FA complementation group, respectively (Bogliolo et al.,
2013; Kim et al., 2011). Furthermore, replication fork collapse has been reported
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to be due to MUS81 nuclease activity and depletion of MUS81 has shown to rescue
DSBs produced during replication stress. To determine if preventing ICL
unhooking or nuclease mediated fork collapse would rescue RPA foci formation in
BRCA2 DBD mutants following MMC, SLX4 and MUS81 were depleted. Depletion
of either SLX4 or MUS81 did not rescue RPA hyperactivation in the BRCA28524C>T,
BRCA2IVS19-1G>A, and BRCA2DBDx3A cells (Figure 3.21A-B). SLX4 depletion further
increased RPA activation and foci formation. It was also observed that MMC
treatment of SLX4 patient cells on their own have increased RPA foci formation,
presumably due to inappropriate processing of MMC induced ICLs (Figure 3.28A).
Depletion of SLX4 exacerbates the RPA phenotype in BRCA2 mutant cells,
suggesting that further defects in ICL repair result in the absence of SLX4. This
could be due to loss of activity of any of the SLX4-associated nucleases.

3.2.9 Replication fork remodeling by SNF2 family translocases, SMARCAL1,
ZRANB3, and HLTF, is not required for ICL repair
Replication fork reversal has been observed as a response to replication
stress induced by a number of different classes of genotoxic agents including MMC
(Zellweger et al., 2015). SMARCAL1, ZRANB3, and HLTF are ATPase dependent
DNA translocases of the SNF2 family of chromatin remodelers that have recently
been shown to promote replication fork reversal in vivo. Depletion of any of the
three rescues nascent strand resection at HU stalled forks in BRCA2 deficient cells
(Mijic et al., 2017; Taglialatela et al., 2017).
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Figure 3.21 Depletion of SLX4 or MUS81 does not rescue increased RPA
activation and foci formation in BRCA2 DNA binding domain mutants.
(A) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 μM
MMC. BRCA2WT, BRCA2c.8524C>T, BRCA2DBDx3A, and BRCA2c.IVS19-1G>A. BJ
fibroblast cells were transfected with control siRNA (Luc) or siRNAs targeting SLX4
or MUS81. (B) Quantification of RPA foci 24h following 1h treatment with 3 uM
MMC in cells depleted of SLX4 or MUS81 by siRNA. Error bars indicate s.d of two
independent experiments. (C) Immunoblot analysis of MUS81 depletion for cells
utilized in A-B. (D) qRT-PCR of SLX4 expression levels of cells utilized in A-B. Error
bars indicate s.d.
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To determine if replication fork reversal is important for the repair of ICLs, wild type
cells were depleted of SMARCAL1 or ZRANB3 and tested for sensitization to
MMC. Cells depleted of either translocase are not sensitive to MMC (Figure
3.22A). In BRCA28524C>T and BRCA2IVS19-1G>A cells depleted of SMARCAL1 or
ZRANB3 nascent strand degradation is rescued at HU stalled forks (Figure 3.23A).
Depletion of either translocase did not rescue cellular hypersensitivity to MMC or
CPT in BRCA2IVS19-1G>A cells (Figure 3.23B-C). Depletion of SMARCAL1,
ZRANB3, or HLTF also did not rescue increased RPA activation and foci formation
after MMC (Figure 3.24 and Figure 3.25). These data suggest that replication fork
reversal is not an important intermediate step in ICL repair and that reversed forks
observed in MMC treated cells may be part of a more general cellular response to
replication stress to prevent genomic instability during replication but not
specifically at the ICL.

3.2.10 Depletion of RADX partially rescues defects of ICL repair in BRCA2
DNA binding domain mutants
RADX depletion has been shown to rescue nascent strand degradation at
HU-stalled replication forks in BRCA2 deficient cells. RADX depletion restores fork
protection without restoring HR, placing the RADX modulation of RAD51
specifically at replication forks. (Dungrawala et al., 2017). We hypothesized that if
BRCA2 is involved in the early steps of fork protection at ICLs then RADX depletion
would rescue increased ssDNA and RPA foci resulting from MMC treatment (Wang
et al., 2015). Consistent with previously reported data, depletion of RADX did
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Figure 3.22 SMARCAL1 and ZRANB3 translocases do not have a major role
in cellular resistance to DNA interstrand crosslinks.
(A) MMC cell survival of BJ BRCA2WT fibroblasts depleted of SMARCAL1 or
ZRANB3 by shRNA or transduced with shRNA luciferase control (shLuc). Cell
survival assays were performed in triplicate and treated with increasing
concentrations of the indicated agent. Cell survival was determined by counting
cells after 7-9 days in culture. Relative cell survival was normalized to untreated
controls to give percent survival. Error bars indicate s.d. (B-C) Immunoblot
analysis of shRNA depletion of SMARCAL1 and ZRANB3.
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Figure 3.23 Depletion of SMARCAL1 and ZRANB3 translocases rescues
nascent strand degradation at HU-stalled replication forks but does not
promote cellular resistance to MMC or CPT in BRCA2 DBD mutants.
(A) BJ fibroblast BRCA2 mutants BRCA28524C>T and BRCA2IVS19-1G>A, were
analyzed for replication fork resection when depleted of either SMARCAL1 or
ZRANB3 by shRNA or transduced with control shRNA (shLuc). Cells were labeled
with DNA analogs, IdU for 20 minutes and then CldU for 20 minutes. Cells were
then incubated in 6 mM hydroxyurea (HU) for 4h before being harvested. DNA
fibers were prepared and visualized by immunofluorescence detection of IdU and
CldU and measured. Error bars indicate s.d. (B-C) MMC and CPT cell survival
assay of BJ BRCA2c.IVS19-1G>A depleted of either SMARCAL1 or ZRANB3 by
shRNA or transduced with shRNA luciferase control (shLuc). Cell survival assays
were performed in triplicate. Cells were treated with increasing concentrations of
indicated agent. Cell survival was determined by counting cells after 7-9 days in
culture. Relative cell survival was normalized to untreated controls to give percent
survival. Error bars indicate s.d.
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Figure 3.24 Depletion of SMARCAL1 or ZRANB2 translocases does not
rescue increased RPA activation and foci formation induced by MMC in
BRCA2 DNA binding domain mutants.
(A) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 uM
MMC. BRCA2c.8524C>T and BRCA2c.IVS19-1G>A BJ fibroblast cells were depleted of
either SMARCAL1 or ZRANB3 by shRNA or transduced with shRNA control (Luc)
(B) Quantification of RPA foci 24h following 1h treatment with 3 uM MMC in cells
depleted of SMARCAL1 or ZRANB3. Error bars indicate s.d of two independent
experiments.
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Figure 3.25 Depletion of HLTF translocase does not rescue increased RPA
activation and foci formation in BRCA2 DNA binding domain mutants.
A) Immunoblot analysis of RPA phosphorylation 24h post 1h treatment with 3 uM
MMC. BRCA2WT, BRCA2c.8524C>T, BRCA2DBDx3A, and BRCA2c.IVS19-1G>A BJ
fibroblast cells were transfected with siRNA control (Luc) or siRNAs targeting
HLTF. (B) Quantification of RPA foci 24h following 1h treatment with 3 uM MMC
in cells depleted of HLTF. Error bars indicate s.d of two independent experiments.
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not rescue HR levels in BRCA2 mutant cell lines (Figure 3.26C-D) (Dungrawala et
al., 2017). However, as expected, RADX depletion rescued nascent strand
degradation of HU-stalled replication forks in BRCA28524C>T and BRCA2IVS19-1G>A
cells (Figure 3.27A).

RADX depletion in BRCA28524C>T and BRCA2IVS19-1G>A cells partially
ameliorated the increased RPA foci formation following MMC (Figure 3.27B).
RADX depletion also makes BRCA2 mutant cells more resistant to MMC (Figure
3.27C-D). These data taken together support a role for both BRCA2 and RAD51
at the early steps of ICL repair independent of HR (Figure 3.27F). It is possible that
in the absence of RADX antagonism that BRCA2 defective cells have improved
BRCA2-RAD51 protection at ICLs from DNA2-WRN. However, we also observe
that RADX depletion sensitizes WT cells to MMC (Figure 3.27C). RADX activity
may also be required for the response to MMC induced ICLs. Further investigation
is needed to determine how RADX promotes proper ICL repair and if this is
mediated through RAD51 modulation. However, the partial rescue effect of RADX
depletion on MMC sensitivity in BRCA2 mutants also indicates that RADX activity
is deleterious for ICL repair in the setting of defective BRCA2 function.
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Figure 3.26 Deficiency of RADX does not impact homologous recombination
efficiency in BRCA2 DNA binding domain mutants.
(A) Immunoblot analysis of RADX depletion by siRNA for cells utilized in C. (B)
Immunoblot analysis of RADX depletion by two shRNAs for cells utilized in D. (C)
Comparison of levels of mClover positive cells of HEK293T BRCA2 mutants
transfected with siRNAs targeting RADX or control (Luc). (D) Comparison of levels
of mClover positive cells of HEK293T BRCA2 mutants (c.8524C>T, c.IVS191G>A, p.S3291A, BRCA2Trun.) transduced with shRNAs targeting RADX (1 or 2)
or shRNA control (C). Error bars indicate s.d. of experiments performed in
triplicate.
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Figure 3.27 Depletion of RADX partially rescues ICL repair defects in BRCA2
DNA binding domain mutants.
(A) BJ fibroblast with BRCA2 mutations, BRCA28524C>T and BRCA2IVS19-1G>A, were
analyzed for replication fork resection when depleted of RADX by shRNA or
transduced with shRNA control (shCONT.). Cells were labeled with DNA analogs,
IdU for 20 minutes and then CldU for 20 minutes. Cells were then incubated in 6
mM hydroxyurea (HU) for 4h before being harvested. DNA fibers were prepared
and visualized by immunofluorescence detection of IdU and CldU and measured.
Error bars indicate s.d. (B) Quantification of RPA foci 24h following 1h treatment
with 3 μM MMC in cells depleted of RADX by shRNA. Error bars indicate s.d. of
two independent experiments. (C-D) Cell survival of BJ BRCA2WT, BRCA2c.IVS191G>A

, and BRCA2c.8524C>T fibroblasts depleted of RADX by shRNA or transduced

with control shRNA (shCONT.). Cell survival assays were performed in triplicate
and cells were treated with increasing concentrations of MMC. Cell survival was
determined by counting cells after 8 days in culture. Relative cell survival was
normalized to untreated controls to give percent survival. Error bars indicate s.d.
(E) qRT-PCR of RADX expression levels of cells utilized in A-C. Error bars indicate
s.d. (F) Schematic of proposed model of how RADX depletion partially ameliorates
the increased RPA foci formation in BRCA2 deficient cells.
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3.2.11 ICLs are a substrate of nucleolytic processing in the absence of a
functioning FA pathway
Having demonstrated that BRCA2 and RAD51 share a role in protecting
ICLs from over resection by DNA2 and WRN, we investigated whether other FA
proteins are required for protection against DNA hyper-resection at ICLs. Analysis
of a panel of FA patient derived cells FANCA, FANCL, FANCD2, FANCI, FANCJ,
and FANCP/SLX4 demonstrated increased RPA foci formation following MMC
treatment for all complementation groups (Figure 3.28A). To determine if the
source of RPA was the same as in BRCA2 and RAD51 mutant cells, DNA2 and
WRN were depleted in a complemented pair of FANCA patient-derived cells
(Figure 3.28B). Interestingly, the dependence on DNA2 was the same, but the
helicase dependency is different, as WRN did not rescue RPA levels but BLM
depletion did (Figure 3.28B-C). These data demonstrate a dependence on the FA
core complex to prevent resection of ICLs by DNA2 and BLM. However, whether
the source of RPA is the same in each of these FA patient cell lines needs further
investigation because these factors have different roles in the repair of ICLs.
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Figure 3.28 Deficiency of Fanconi anemia proteins results in hyperphosphorylation and foci formation of RPA after MMC.
(A) Quantification of RPA foci 8h, 24h and 48h following 1h treatment with 3 μM
MMC of FA patient derived fibroblasts compared to BJ wild type fibroblasts.
Patient cells lines from FA complementation group FANCR/RAD51 (FA-Rmut),
FANCA (FA-Amut), FANCL (FA-Lmut), FANCD2 (FA-D2mut), FANCI (FA-Imut),
FANCJ/BRIP

(FA-Jmut),

and

FANCP/SLX4

(FA-Pmut).

FANCA

patient

complemented cell lines were generated by transducing WT FANCA cDNA (FAA) or empty vector control (EV). Error bars indicate s.d. of two independent
experiments. (B) FANCA patient cells expressing WT FANCA (FA-A+A) or empty
vector (FA-A+EV) were transfected with siRNA control luciferase (Luc) or siRNAs
targeting DNA2 and WRN. Quantification of RPA foci 24h following 1h treatment
with 3 μM MMC. Error bars indicate s.d. of two independent experiments. (C) qRTPCR of DNA2 and WRN expression levels of FANCA cells utilized in B. Error bars
indicate s.d. (D) FA-A+EV were transfected with siRNA Luc or siRNAs targeting
DNA2 and BLM. Quantification of RPA foci 24h following 1h treatment with 3 μM
MMC. Error bars indicate s.d. of two independent experiments. (E) qRT-PCR of
DNA2 and BLM expression levels of FANCA cells utilized in D. Error bars indicate
s.d. Experiment shown in (A) performed by Athena Huang and Experiment shown
in (D) performed by Anderson Wang.
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Figure 3.29 The role of BRCA2 in homologous recombination and replication
fork protection requires the DNA binding domain.
Schematic representing the different roles of BRCA2 in replication fork protection
and homologous recombination. BRCA2 has a role in two distinct types of
replication fork protection. At HU stalled forks, BRCA2 and RAD51 protect DNA
from degradation by nucleases that include, MRE11, CtIP, EXO1, and DNA2.
Replication fork reversal is dependent on RAD51 and the SNF2 translocases,
SMARCAL1, ZRANB3, and HLTF. At ICLs, BRCA2 and RAD51protect against
resection by DNA2-WRN. This process does not involve replication fork reversal.
During homologous recombination repair of DSBs, BRCA2 assembles RAD51
nucleofilaments onto ssDNA overhangs, which is important for the RAD51
mediated homology search of the sister chromatid for use as a repair template.
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3.3 Summary and Conclusions
We have identified a family with an unusual clinical presentation of biallelic
BRCA2 mutations. Unlike other FANCD1/BRCA2 patients, the sibling pair displays
a relatively mild phenotype, even as adults, which is characterized by marked
developmental abnormalities, but no bone marrow failure or cancer. The BRCA2
mutations consist of a LOF frameshift mutation of exon 11 in trans to a missense
mutation

c.8524C>T/p.R2842C

of

the

BRCA2

DBD.

An

additional

FANCD1/BRCA2 adult presenting with mild disease was identified in the literature
and is homozygous for the splice site mutation, c.IVS19-1G>A, that translates into
the loss of the first four aa of exon 20 of the BRCA2 DBD (Howlett et al., 2002).

Analysis of LCLs from the sibling pair (RA3105/RA3106) show cellular
sensitivity to ICL generating agents and a mild elevation in chromosomal breakage
to DEB. Comprehensive analysis of HSC62 fibroblasts (c.IVS19-1G>A) reveals
sensitivity to ICL generating agents, but not IR. Lack of IR sensitivity and normal
SCEs levels suggest that HR is largely intact in these fibroblasts. Using
CRISPR/Cas9 gene editing, the c.IVS19-1G>A splice site mutation was corrected
to WT in HSC62 fibroblasts, and the observed cellular defects were rescued
demonstrating that the c.IVS19-1G>A base substitution is responsible for the
cellular defects.

To compare the phenotypes of both DBD mutations in isogenic cell lines,
c.8524C>T and c.IVS19-1G>A, were generated in human fibroblasts using

147

CRISPR/Cas9 targeting of the endogenous BRCA2 locus. Side-by-side
comparison of the mutations demonstrated that the BRCA2 c.IVS19-1G>A
mutation has a more pronounced phenotype than c.8524C>T. BRCA2IVS19-1G>A and
BRCA28524C>T cells both have defects in RAD51 foci formation, cellular sensitivity
to MMC, and elicit increased RPA activation and foci formation after MMC.
Furthermore, to evaluate these mutations for HR proficiency, BRCA2 DBD mutants
were generated in HEK293T cells and analyzed using a mClover LMNA
homologous recombination CRISPR/Cas9 reporter assay (Arnoult et al., 2017;
Pinder et al., 2015). Interestingly, the DBD mutants showed a similar moderate
reduction in HR despite the greater defect in MMC sensitivity in the c.IVS19-1G>A
clones than the c.8524C>T clones. The previously described separation of function
mutant, p.S3291A, showed a moderate reduction in HR, which demonstrated that
p.S3291A, like our BRCA2 mutations, decreases HR function in contrast to a
previous report (Schlacher et al., 2011). These results demonstrate that the
c.8524C>T mutation, identified previously as a VUS, is pathogenic and deleterious
to BRCA2 function.

HSC62 cells show markedly increased RPA foci formation that is dependent
on DNA2 and WRN after MMC treatment. Previously, DNA2-WRN dependent
resection at ICLs was reported in the RAD51/FANCR p.T131P patient cell line. In
the RAD51/FANCR p.T131P patient cell line, the mutant protein makes up 20% of
cellular RAD51 and has a dominant negative effect on RAD51 function. The minor
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amount of mutant protein does not impact HR, but disrupts RAD51 function at ICLs
revealing an HR-independent role for RAD51 in ICL repair (Wang et al., 2015).
These results suggest that like the well described interdependence of BRCA2 and
RAD51 in HR and the protection of HU-stalled forks, BRCA2 and RAD51 function
together to prevent resection at ICLs.

Like HSC62 fibroblasts, isogenic BRCA2 DBD mutants have elevated RPA
activation and foci formation after MMC that is DNA2-WRN dependent. The greater
increase in RPA activation and foci formation resulting from the c.IVS19-1G>A
mutation is not fully rescued. However, there is a marked reduction in pRPA and
RPA foci in c.8524C>T cells and in another DBD mutant, DBDx3A. The DBDx3A
mutant has 3 aa substitutions at residues that interact with DNA (K2833A, Y2839A,
and F2841A) (Yang et al., 2005). We hypothesize that the alanine substitutions of
these residues disrupt DNA binding, but are minimally disruptive to the BRCA2
structure. The DBDx3A mutant cells have a slightly milder phenotype than
c.IVS19-1G>A cells by MMC cellular sensitivity and RPA activation and RPA foci
formation. The c.IVS19-1G>A splice site mutation results in the deletion of four aa,
which may distort the BRCA2 structure and further impair BRCA2 function. This
likely results in more ssDNA from sources other than DNA2-WRN activity.

Our analysis of BRCA2 DBD mutants demonstrates that the function of the
DBD is required for replication fork protection of HU-stalled forks from MRE11 and
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DNA2. While the role of MRE11 in nascent strand degradation of BRCA2 deficient
cells has been widely shown, there is conflicting data about resection mediated by
DNA2 (Lemacon et al., 2017; Ray Chaudhuri et al., 2016). However, a role for
DNA2 with WRN has been described in a mechanism of replication fork restart,
and it has also been reported that DNA2 degrades nascent DNA at stalled forks in
the setting of RECQ1, BOD1L, or Abro1 deficiency (Higgs et al., 2015; Thangavel
et al., 2015; Xu et al., 2017).

Previously, it was reported in Brca2 deficient hamster V-C8 cells,
complemented with a BRCA2 bacterial artificial chromosome (BAC) construct
missing the entire DBD (p.D2451-3210), that the DBD was dispensable for
replication fork protection at HU-stalled forks (Schlacher et al., 2011). Our analysis
of BRCA2 DBD mutants demonstrate that the replication fork protection role of
BRCA2 at HU-stalled replication forks is not distinct to the C-terminal domain and
that fork protection likely requires the DBD to bind DNA at the replication fork.
Biochemical analysis of BRCA2 mutants will need to be carried out to determine
how these mutations impact binding at replication fork structures. The location of
the mutations at the transition of the OB2 and base of the Tower domain suggests
that they may interfere with ssDNA-dsDNA binding. The Tower domain contains a
3HB domain at the apex that binds dsDNA, so interruption of this region may
preclude binding at replication fork ssDNA-dsDNA junctions where BRCA2 binding
may be especially important for replication fork protection (Yang et al., 2002).
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Genomic instability resulting from the absence of proper replication fork
protection has largely been studied by depletion of BRCA2 by RNAi (Lemacon et
al., 2017; Mijic et al., 2017; Taglialatela et al., 2017). Here we show that a
significant increase in chromosomal breakage after HU does not correlate with
replication fork resection. For some of the BRCA2 mutants (c.8524C>T and
p.S3291A) described in this study replication fork protection at HU-stalled forks is
defective, but there is no significant increase in chromosomal breakage after HU.
Our results showing increased breakage in cells expressing a BRCA2 LOF
truncation, are consistent with many previous reports that BRCA2 knockdown
results in increased chromosomal breakage that is rescued by MRE11
depletion/inhibition (Lemacon et al., 2017; Mijic et al., 2017; Schlacher et al., 2011;
Taglialatela et al., 2017). All of the BRCA2 mutants in our analysis that undergo
MRE11 dependent fork resection at HU-stalled replication forks do not have
elevated breakage. The consequences of nascent strand degradation requires
further investigation in the background of hypomorphic fork protection mutants
such as, c.8524C>T and p.S3291A, instead of BRCA2 knockdown by RNAi. These
results demonstrate the importance of using BRCA2 mutants that permit
distinguishing between different BRCA2 functions as opposed to RNAi depletion
that removes all function.

We show that DNA2 depletion in BRCA2 mutant cells also rescues
resection at HU-stalled replication forks. Interestingly, at the same time we observe
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that DNA2 depletion exacerbates chromosomal breakage to HU. This observation
suggests that in the setting of BRCA2 deficiency DNA2 depletion is deleterious,
which may be due to its role in replication-coupled repair or modulation of reversed
forks (Hu et al., 2012; Karanja et al., 2012; Thangavel et al., 2015). Recent reports
have also implicated EXO1 and CtIP as degrading HU-stalled forks in the absence
of BRCA2 (Lemacon et al., 2017). It would be interesting to know what the
consequences of EXO1 and CtIP depletion are on chromosomal breakage to HU
given the different effects of MRE11 and DNA2 depletion on the breakage levels.
Taken together, resection of the regressed fork in the absence of BRCA2 is now
reported to involve all of the DSB end-resection nucleases. MRE11 and DNA2 are
already reported to be required for replication fork restart (Bryant et al., 2009;
Thangavel et al., 2015). However, further investigation is required to determine if
all of these factors have a normal function in processing stalled forks or restoring
reversed forks under normal genetic conditions. These results are also interesting
in that all of the nucleases may be acting at HU-stalled forks in BRCA2 deficient
cells, but only DNA2 has activity at the ICL.

Depletion of the replication fork remodelers SMARCAL1, ZRANB3, and
HLTF rescues nascent strand degradation at HU-stalled forks in BRCA2 DBD
mutants, but does not mitigate cellular sensitivity or increased RPA after MMC.
Despite the observation that MMC increases replication fork reversal in cells
(Zellweger et al., 2015), our study demonstrates that replication fork reversal is not
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a major step in the repair of ICLs and that the processing at HU-stalled forks is
different from ICLs. However, RADX depletion does ameliorate the increased RPA
foci and cellular sensitivity to MMC independent of HR. RADX specifically
modulates RAD51 at replication forks indicating that this rescue is related to
BRCA2-RAD51 replication fork protection at the ICL and not downstream
processing of DSBs. This is also consistent with the previous identification of
RAD51 localization to ICLs prior to DSBs (Long et al., 2011).

FA proteins have previously been shown to be important for protection at
HU-stalled replication forks (Schlacher et al., 2012). Analysis of FA patient cell
lines of various complementation groups also demonstrates increased ssDNA and
RPA foci formation after MMC. In FANCA cells, the increase in RPA foci is due to
DNA2 and BLM, but not WRN. This suggest that the fork protection of BRCA2RAD51 is not redundant with the FA core complex, but further investigation would
be needed to determine the source of increased ssDNA in the absence of the other
FA proteins. DNA2 has previously been reported to interact with FANCD2 and be
recruited to ICLs where it is required for repair but is deleterious in the absence of
FANCD2 (Karanja et al., 2012; Karanja et al., 2014). BLM has been reported to
interact with a number of FA proteins and co-localize with FANCD2 at ICLs (Meetei
et al., 2003b; Pichierri et al., 2004; Suhasini and Brosh, 2012). Consistent with
BLM depletion rescuing increased ssDNA at the fork in the absence of FANCA,
BLM knockout was also recently reported to rescue ICL sensitivity and reduce DNA
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damage in FA deficient cells (Moder et al., 2017). It is possible that DNA2, WRN,
and BLM are recruited to ICLs to perform normal functions, but in the absence of
key FA/BRCA pathway components are left unregulated.

The mutations reported in this study may have more differential impact on
BRCA2 function depending on the nature of the DNA lesion. It is clear that the
BRCA2 DBD is important for HR and replication fork protection (Figure 3.29). Both
BRCA2 mutations, c.8524C>T and c.IVS19-1G>A, have a similar and moderate
impact on HR efficiency. However, the impact on BRCA2 function in ICL repair
demonstrates the c.IVS19-1G>A mutation to be more deleterious than either the
c.8524C>T substitution or DBDx3A mutant. For HR, DSBs generated by targeted
nuclease are likely different than DNA substrates encountered by the replication
fork due to stalling by HU or ICLs. It is possible that DSB repair by HR may not be
as sensitive to defects in BRCA2 ssDNA-dsDNA binding which could be of greater
importance at a replication fork.

The identification of BRCA2 DBD mutations in conjunction with atypical
disease presentation gives the opportunity to investigate how defects in the DBD
impact BRCA2 function and gives insight into how these defects may give rise to
the developmental defects characteristic of FA but not the early childhood
malignancies seen in other patients with biallelic FANCD1/BRCA2 mutations.
There is not a clear correlation of disease severity and deleteriousness of the
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mutation for the sibling pair with the c.8524 C>T variant and the individual with
homozygous c.IVS19-1G>A mutation. Analysis of the mutations in isogenic cell
lines in the homozygous state demonstrates the c.IVS19-1G>A to be more
deleterious to BRCA2 function than c.8524C>T. However, the sibling pair presents
with much more severe congenital abnormalities. It is possible that there are other
modifying factors, environmental and/or genetic, that impact the phenotypes of
these patients. The dose of hypomorphic BRCA2 during development may also
play a role. In the sibling pair the c.8524C>T mutation is in trans to a LOF allele
instead of two hypomorphic alleles in the case of the individual with c.IVS19-1G>A.
Regardless, the disease presentation of these individuals is very atypical for
FANCD1/BRCA2 complementation group and resembles the phenotype of FA-like
patients described for FANCR/RAD51 and FANCO/RAD51C complementation
groups (Vaz et al., 2010; Wang et al., 2015). The patients have congenital
abnormalities typical of FA but no bone marrow failure or malignancy even into
adulthood. Due to the moderate impact that these DBD mutations have on HR, we
hypothesize that the retention of ~50% of HR function that we observe is sufficient
enough for cellular function and to safeguarded against early embryonal tumors in
these individuals. However, the sibling pair will have to be monitored for
hematopoietic abnormalities, FA related cancers, and HBOC cancers as adults. In
the future, diagnosis and classification as FANCD1/BRCA2 complementation
group should also be considered for patients appearing with FA-like syndrome.
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Chapter 4: Novel bone marrow failure and DNA
repair deficiency syndrome
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4.1 Introduction
Bone marrow failure (BMF) occurring during childhood is frequently genetic
while BMF arising later in life is more often acquired. The most common inherited
causes of aplastic anemia are Fanconi anemia (FA), Dyskeratosis congenita
(DKC), Diamond Blackfan anemia (DBA), and Shwachman-Diamond syndrome
(SDS) (Alter, 2017). DKC is the result of defects in telomere homeostasis and DBA
and SDS are a result of defects in ribosome biogenesis. All three disorders are
also associated with an increase in hematopoietic malignancies and solid tumors
(Alter, 2002; Khincha and Savage, 2013). Diagnostically FA can be distinguished
from other BMF syndromes by chromosomal breakage analysis. However, somatic
mosaicism can skew breakage results and false positive results can occur in cases
of other chromosomal instability syndromes (Oostra et al., 2012). FA is a very
heterogeneous disorder and as a consequence of overlapping clinical features with
BMF and chromosomal instability syndromes, patients may be misdiagnosed. Our
studies have identified an individual enrolled in the IFAR misdiagnosed with FA.
The characterization of patient derived cells indicated proficient ICL repair, but a
deficiency in response to replication stress, not previously described in a genetic
syndrome.

4.2 Results
4.2.1 A patient enrolled in the International Fanconi Anemia Registry
identified as non-FA
An individual enrolled in the IFAR without known disease-causing mutations
presented at 5 years of age with recurrent pneumonia and was discovered to be
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Figure 4.1 Bone marrow failure in a non-Fanconi anemia family enrolled in
the IFAR.
Family pedigree showing a child with bone marrow failure diagnosed at 5 years
old. The patient had two failed bone marrow transplants and died after
complications of the second transplant. Family history is significant for a first cousin
that was diagnosed with acute lymphoblastic leukemia (ALL) at 4 years old who
was treated, and is currently alive and well. Maternal grandmother had history of
skin cancer and paternal grandfather had history of bladder cancer. There was no
history of FA.
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pancytopenic. On exam, the patient was described as having short stature, small
midface, microopathalmia, and café-au-lait spots. Birth history reported a normal
full-term pregnancy without complication and a birth weight of 6lbs 4oz (25th
percentile). The patient had no history of myelodysplasia or leukemia and bone
marrow studies only reported hypocellularity.

Two subsequent DEB-induced chromosomal breakage tests on peripheral
blood showed mildly elevated breakage, 0.54 and 0.61 breaks per cell. These
values are higher than normal but much lower than expected for a typical FA
patient. The patient was presumed to have FA with somatic mosaicism to account
for the low chromosomal breakage levels. There was no family history of FA, but
a first cousin was diagnosed with leukemia (ALL) at 4 years of age (Figure 4.1).
The maternal grandmother had a history of skin cancer and paternal grandfather
had history of bladder cancer. The family denied consanguinity.

The patient underwent bone marrow transplant (BMT) at 8 years old with a
FA conditioning regimen of fludarabine and cyclophosphamide which ultimately
failed. A second transplant with the same donor was performed with the addition
of total body irradiation (TBI) to the regimen. The second transplant failed and the
patient developed graft versus host disease (GVHD). The patient developed
encephalopathy, Parkinsonian features, congestive heart failure, respiratory
failure, and died at 10 years of age.
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4.2.2 Characterization of patient derived cells reveals no defects in ICL repair
Bone marrow failure can have many etiologies so to better characterize the
presumed defect in ICL repair in this family, patient derived fibroblasts were
analyzed. Unlike typical FA cells, the patient derived fibroblasts (RA2177) were not
sensitive to the crosslinking agents MMC or cisplatin and did not show increased
chromosomal aberrations upon treatment with DEB (Figure 4.2A-C). Clinical
breakage analysis showed a mild increase in breakage to DEB, but our analysis
of chromosomal breakage in LCLs from the proband (RA2143) and family (father,
mother, and healthy sibling) does not show an increase above normal cells (Figure
4.2D-E). The patient cells do not show the hallmark LCL sensitivity and
chromosomal breakage of FA. The lack of ICL repair deficits in the patient derived
fibroblasts indicates that the patient does not have FA.

To investigate whether the patient’s disease may be due to defects in DNA
repair of other pathways, the cells were tested for hypersensitivity to other DNA
damaging agents. Patient cells did not show increased sensitivity to IR (Figure
4.3A) suggesting no defect in the NHEJ pathway of DSB repair. Additionally, the
patient cells did not show a significant increase or decrease in SCEs compared to
BJ wild type fibroblasts suggesting no defect in HR or deficiency of BLM helicase
(Figure 4.3B). The patient RA2177 fibroblasts were sensitive to a number of
replication stress inducing agents including CPT, olaparib (PARPi), HU, and
aphidicolin (Figure 4.4C-F). These data demonstrate that the patient’s disease
may result from defects in the cellular response to replication stress. Defects in HR
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Figure 4.2 RA2177 fibroblasts do not display features of ICL repair defects.
(A-B) MMC and DEB treated cell survival assays of RA2177 patient fibroblasts,
WT BJ fibroblasts, and SLX4 patient fibroblasts (SLX4mut). (C) Quantification of
chromosomal breaks in metaphases of DEB treated RA2177, parental (RA3572,
RA3573), and FANCA deficient (FA-A) fibroblasts. (D-E) Quantification of
chromosomal breaks in metaphases of DEB treated LCLs from the proband
(RA2143), parents (RA3534, RA3535), and FANCA deficient (FA-A) cells. Error
bars indicate s.d.
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Figure 4.3 RA2177 fibroblasts are hypersensitive to replication stress
inducing agents
(A) Cell survival of RA2177 cells after IR compared to RAD50 patient fibroblasts
(RAD50mut). (B) SCE assay in BJ WT fibroblasts and RA2177 fibroblasts following
treatment with MMC (0.1 μg/ml or 0.2 μg/ml). (C-F) Cell survival of RA2177 cells
after CPT, olaparib (PARPi), HU, and aphidicolin treatment. SLX4mut and
BRCA2mut are FA patient control cell lines. Error bars indicate s.d.
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can also result in sensitivity to these agents, but HR is also required in the later
steps of ICL repair and similar cellular sensitivity would then be expected for ICL
generating agents which was not observed (Figure 4.2A-B).

Fibroblasts derived from the proband’s parents were obtained to evaluate
for similar defects. The parental fibroblasts (RA3572 and RA3573) behaved as wild
type and were not sensitive to replication stress inducing agents (Figure 4.4A-D).
The fibroblasts were tested for chromosomal breakage following treatment with
HU and aphidicolin. The patient RA2177 cells displayed a significant increase in
chromosomal breakage compared to BJ wild type fibroblasts and parental
fibroblasts (Figure 4.4E-F). Analysis of LCLs derived from the proband also
demonstrated sensitivity to HU and CPT suggesting no somatic mosaicism of the
blood (Figure 4.5A-B).

4.2.3 Analysis of DNA replication in RA2177 cells reveals abnormalities only
under conditions of replication stress
Given the hypersensitivity of RA2177 cells to replication stress inducing
agents, we wanted to investigate the replication dynamics in these cell on the
single molecule level. To visualize in situ replication dynamics, DNA combing of
patient and parental cells grown in the presence of replication stress inducing
agents (hydroxyurea or aphidicolin) was performed (Figure 4.6). For DNA combing
analysis, DNA was labeled in replicating cells with the nucleotide analogs IdU and
CldU and then immunostained for visualization. RA2177 cells have replication
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speeds that are similar to those of parental cell lines, RA3572 and RA3573, under
unperturbed conditions (Figure 4.6B). RA2177 cells have slowed replication
compared to parental cell lines under conditions of replication stress induced by
low dose HU or aphidicolin (Figure 4.6C-D). To test the ability of RA2177 cells to
resume replication following replication fork stalling, cells were treated with high
dose HU (2 uM) to stall progressing forks. HU was then washed out and
resumption of replication was monitored by incorporation of CldU. RA2177 cells
did not have increased levels of fork stalling as measured by analysis of IdU and
CldU labeled DNA fibers (Figure 4.7A-C). However, in RA2177 cells, CldU:IdU
ratios were lower, indicating that CldU tracks after HU were shorter. It is possible
that in RA2177 cells the replication forks are able to recover from replication
stalling but the recovery or the ensuing replication may be slower (Figure 4.7D).
These data demonstrate that unperturbed replication is normal in RA2177 cells but
under conditions of replication stress it is defective

4.2.4 Genetic analysis and evaluation of candidate disease-causing genes
The analysis of the patient-derived cell lines links a defect in cellular
response to replication stress to the patient’s disease. Previously described
diseases, including Fanconi anemia and Dyskeratosis congenita, link genome
instability and bone marrow failure like in this patient. Both fibroblasts and LCLs
were equally susceptible to replication stress demonstrating the genetic cause to
likely be germline and not somatic. WES was analyzed for gene candidates from
the family trio. WES data revealed no mutations in known FA genes or genes
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Figure 4.4 Parental fibroblasts behave as wild type.
(A-D) Cell survival of RA2177 fibroblasts and parental fibroblasts, RA3572 and
RA3573, after HU, aphidicolin, olaparib (PARPi), and CPT treatment. (E-F)
Quantification of chromosomal breaks in metaphases of HU and aphidicolin
treated BJ, RA2177 (proband), RA3572 (paternal), and RA3573 (maternal)
fibroblasts. Error bars indicate s.d.
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Figure 4.5 RA2143 patient LCLs display hypersensitivity to replication
stress.
(A-B) Cell survival of RA2143 patient derived LCLs and parental LCLs (RA3535
and RA3536) after HU and CPT treatment. Error bars indicate s.d. Assays
performed by Sonia Singh.
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Figure 4.6 Assessment of replication fork progression in RA2177 cells under
conditions of replication stress.
(A) Schematic of experimental conditions. Cells were labeled with nucleotide
analogs Idu and CldU and DNA fibers were immunostained and visualized. (B)
Average DNA fiber lengths in RA2177 patient cells and wild type parental cell lines
RA3572 and RA3573. Total DNA track length was measured after 30min of IdU
and 1h of CldU treatment. (C-D) Ratio of CldU:IdU DNA track lengths. Cells were
labeled with IdU for 30 mins and subsequently with CldU for 2h with HU or
aphidicolin. Error bars indicate s.d.
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Figure 4.7 Assessment of replication fork dynamics in RA2177 patient cells.
(A) Cells were labeled with IdU for 30 mins and subsequently treated with 2 mM
HU to stall replication forks for 2 hours. Cells were washed and released into CldU
for 2 hours. Quantification of ongoing replication forks, characterized as having
both IdU and CldU label, as a percent of all DNA species. (B) Quantification of
newly fired replication forks, characterized as CldU only. (C) Quantification of
stalled or terminated replication forks, characterized as IdU only. (D) Ratio of
CldU:IdU DNA track lengths. Error bars indicate s.d.
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mutated in known DNA repair disorders. Variants were filtered for an allele
frequency of 0.01 or less in the 1000 Genome database. Possible modes of
inheritance that were prioritized were autosomal recessive and de novo. The family
reported non-consanguinity.
No LOF de novo mutations were identified. One coding de novo missense
mutation of sedoheptulokinase (SHPK) was identified; however, a second
mutation was not identified and homozygous LOF has previously been described
in isolated Sedoheptulokinase deficiency and infantile nephropathic cyctinosis that
includes a 53kb deletion encompassing SHPK (Wamelink et al., 2015). No LOF or
missense homozygous coding variants of rare allele frequency in genes that could
be linked to the phenotype were identified. Compound heterozygous mutations,
p.R206H and p.A466T, in PFAS were identified having an allele frequency less
than or equal to 0.01 in 1000 Genome database (0.01 and 0.002, respectively) and
CADD scores of 25.4 and 31. Each parent is a carrier of one allele and the healthy
sibling only carries one variant (Figure 4.8A). We decided to pursue this as a
candidate gene as PFAS is important for the 4th step of de novo purine synthesis.
Purines are necessary for cellular processes such as DNA replication,
transcription, and energy metabolism. Disorders of nucleotide metabolism have
previously been described and have a heterogeneous clinical spectrum that
includes immunodeficiency and anemia (Ng et al., 2015; Ng et al., 2010; Rainger
et al., 2012; Roach et al., 2010; Stone et al., 1992).
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Depletion of PFAS in BJ WT fibroblasts results in cellular sensitivity to HU
and CPT similar to RA2177 fibroblasts (Figure 4.8C-E). Complementation of
patient RA2177 fibroblasts by expression of wild type PFAS was complicated by
toxicity and increased hypersensitivity resulting from overexpression of the protein
(Figure 4.8B). To test PFAS variants for pathogenicity, CRISPR/Cas9 gene editing
was used to knock in the p.A466T mutation at the endogenous locus in the
maternal cell line RA3573, so that the protein is expressed at levels regulated by
the cell (Figure 4.8E). Homozygous p.A466T RA3573 cells were tested for
hypersensitivity to HU and the homozygous mutation did not produce the cellular
hypersensitivity seen in the proband’s RA2177 cell line (Figure 4.8F). These data
demonstrate that the PFAS variants are not responsible for the defect in this
patient’s cells and are unlikely to have caused her disease.

Whole genome sequencing (WGS) on DNA derived from primary fibroblasts
obtained from the mother, father, and proband was performed. Thus far, no
additional gene candidates were identified using a 0.001 allele frequency cut off
for coding variants in the Exome Aggregation Consortium (ExAC) with CADD
scores greater than the mutational significance cutoff (MSC) (Itan et al., 2016).
Further analysis of WGS will permit a more comprehensive investigation of copy
number and non-coding variants that may be disease-causing.
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Figure 4.8 PFAS variants do not cause the cellular defects to replication
stress in RA2177 patient cells
(A) Chromatograms of Sanger sequencing of PFAS variants identified in this
family, exon 6 p.R206H and exon 12 p.A466T. (B) CPT treated cell survival
assays of patient RA2177 cells expressing empty vector (EV) control and HA
tagged WT PFAS compared to WT BJ fibroblasts. (C-D) HU and CPT treated cell
survival assays of WT BJ fibroblasts with PFAS targeting shRNAs (1 and 2) and
shRNA control (shCONT.) compared to RA2177 cells. (E) Validation of shRNA
knockdown of PFAS in BJ WT cells by RTqPCR. (F) Chromatograms of Sanger
sequencing of CRISPR/Cas9 edited RA3573 fibroblasts (maternal cell line)
containing the exon 12 p.A466T mutation. (G) Cell survival assay of RA3573 clone
homozygous for exon 12 p.A466T mutation compared to RA2177 cells. Error bars
indicate s.d.
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4.3 Summary and Conclusions
Here we describe an individual with proficient ICL repair but defects in
cellular response to replication stress. The patient’s clinical picture had many
overlapping features of FA including developmental abnormalities and BMF in
childhood. DEB chromosomal breakage testing is the gold standard for FA
diagnosis, but in some instances a mild increase in breakage can be observed due
to another chromosomal instability syndrome (Oostra et al., 2012). Another
explanation for lower breakage levels in the blood in FA is somatic mosaicism,
which was the conclusion for this individual at the time of diagnosis. Examination
of patient derived cells, LCLs and fibroblasts, demonstrates no defects in ICL
repair. Fibroblasts from FA patients with somatic mosaicism display the typical
hallmarks of ICL deficiency, so this individual does not have FA. The failure of bone
marrow transplant in this individual may have been in part due to modified
conditioning protocol typically used for FA patients.

Patient-derived fibroblasts, RA2177, are hypersensitive to PARP inhibitor,
CPT, aphidicolin, and HU and display elevated chromosomal breaks following HU
or aphidicolin, suggesting a defect in resolving replication stress. Replication
stress, if not resolved, can cause replication fork collapse and DNA double strand
breaks that are repaired by homologous recombination (HR) mediated double
strand break repair (Lundin et al., 2002). RA2177 cells do not display
hypersensitivity to double strand breaks induced by ionizing radiation (IR) and
have normal levels of homologous recombination as measured by sister chromatid
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exchange levels (SCE) suggesting proficient HR and double strand break repair
(Sonoda et al., 1999). This is also consistent with proficient ICL repair that requires
HR mediated DSB repair. Single molecule analysis of replication forks
demonstrates that the RA2177 cells replicate at normal speeds when not
perturbed, but are significantly slower during conditions of replication stress and
recover from replication fork stalling more slowly than parental control cell lines.

These studies help us to better understand what cellular processes may be
defective in this individual and suggest that defects in the cellular response to
replication stress may underlie disease in this individual. In cases where breakage
analysis of peripheral blood is inconclusive and disease-causing mutations are not
known, analysis of fibroblasts should be performed to support a FA diagnosis. In
this case, a diagnosis of FA had implications for treatment and impacted the choice
of the bone marrow transplant regimen. Fludarabine is a purine analog, that like
HU, inhibits DNA synthesis by causing a shortage of nucleotides (Montillo et al.,
2006). Whether RA2177 cells are hypersensitive to fludarabine still needs to be
investigated, but given the similar mechanism of action to HU it seems likely. The
patient cells are sensitive to replication stress so the use of this drug as a
conditioning regimen may have contributed to the patients decline and multi organ
failure.

The investigation into the genetic cause of disease in this individual is
ongoing. Analysis of WES yielded candidate disease-causing variants, compound
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heterozygous missense mutations in PFAS, but after thorough investigation we
conclude that the variants identified are not disease causing. WGS was performed
on the family trio using fibroblast DNA to compare to our WES results, done on
LCLs, in the event of somatic mosaicism and for better mutation detection (Belkadi
et al., 2015). The more recently published Exome Aggregation Consortium (ExAC)
and Genome Aggregation Database (gnomAD) are much larger gene variant
databases that permit filtering patient sequencing data at a lower allele frequency
without possibly removing rare variants (Lek et al., 2016). The WGS was analyzed
using a MAF cutoff of 0.001 in ExAC to be consistent with rare disease incidence
of pediatric bone marrow failure and FA (Young et al., 2008). No new gene
candidates with biallelic coding variants were identified. Analysis of WGS will have
to be expanded to copy number variants and non-coding regions of the genome.
Identification of disease-causing variants in a single patient can be challenging,
but here we have an ideal system in which a cellular phenotype has been identified
and complementation can be used to rescue defects conferred by the defective
gene. In this individual, the characterization of patient cells gives insight into
potential gene candidates that can be explored further. In similar cases,
concomitant cellular characterization, even in the absence of knowing the genetic
origin of the disease, may improve disease management.
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Chapter 5: Discussion
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5.1 Investigating the genetic cause of disease in individuals not assigned to
a Fanconi anemia complementation group
The International Fanconi Anemia Registry (IFAR) at the Rockefeller
University has been enrolling patients since 1982 when it was established by Dr.
Arleen Auerbach. The IFAR has numerous FA patient-derived cell lines and DNA
samples archived, which presents the opportunity to investigate those patients
enrolled in the registry without a designated FA complementation group. The
studies described in this thesis evolved from the hypothesis that the patients
without gene classifications may represent undiscovered FA complementation
groups and thus, provide the opportunity to study new genes important for DNA
interstrand crosslink (ICL) repair.

A key advantage of our study was the ability to search for the genetic cause
of disease in several unclassified patients while simultaneously characterizing their
patient-derived cell lines. The characterization of patient-derived cells from the
families of interest, allowed for the patients to be classified into different subgroups.
We were able to exclude some patients from further study, because, although they
appeared to have FA, no DNA repair deficits were identified in their cell lines. Our
understanding of the FA pathway was applied to further delineate the patients. A
key step in the FA pathway is the activation of FANCI and FANCD2 by
monoubiquitination, which requires an intact FA core complex, composed of 8 FA
proteins and associated factors. Some of the cell lines we studied were defective
for monoubiquitination of FANCI and FANCD2, so our genetic analysis could be
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focused to core complex proteins and associated factors. With regards to this
group, we identified the subject of the new FANCT complementation group as well
as an individual of the already established FANCE complementation group.

Other individuals had normal activation of the FA pathway, but defective ICL
repair. From this subgroup, the sibling pair with atypical presentation of biallelic
FANCD1/BRCA2 mutations was identified. We also followed a bone marrow failure
(BMF) patient, whose analysis revealed no defects in ICL repair, but rather
demonstrated defects in another DNA damage pathway that could underlie their
disease. Collectively, in these studies we discovered a surprisingly wide spectrum
of cellular phenotypes that provided insight for our genetic analysis. These studies
resulted in the identification of a new FA complementation group, surprising
separation of function mutations in an already known FA gene, and exclusion of
some patients from FA.

Whole exome sequencing (WES) was performed on patient and parental
DNA where available. We found that for some cases, the identification of candidate
disease-causing mutations was more straightforward as rare coding mutations
were identified in genes that could be linked to the phenotype and further validated.
However, there are still significant challenges in identifying patient diseasecausing mutations by Next-generation sequencing (NGS) because of the
limitations in detecting structural and copy number variants (Boycott and Ardigo,
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2018). For instance, WES analysis was not sufficient alone to ascertain the UBE2T
patient mutations because the large paternal indel was not detected and the LCLs
were mosaic for the maternal indel. We identified low UBE2T transcript levels in
patient fibroblasts by RNAseq, which was supported by the absence of UBE2T
protein by immunoblot. We utilized Sanger sequencing of the UBE2T locus to
identify the mutations, which was aided by SNPs detected in the UBE2T locus by
WES. Therefore, even though NGS has increased the pace at which rare genetic
diseases can be identified and enables single patient studies, our study highlights
some of the limitations of its application (Boycott et al., 2017; Casanova et al.,
2014). We have demonstrated here that a multifaceted approach may be required
to identify disease-causing mutations that are structural or copy number variants
(CNV), or reside outside coding regions (Boycott et al., 2017; Casanova et al.,
2014). Although WGS offers broader coverage of the genome and better SNP
detection in coding regions, CNV and structural variant identification still remains
unreliable (Boycott and Ardigo, 2018; Casanova et al., 2014). Non-coding variants
identified in WGS are more problematic to interpret given their vast numbers and
the difficulty in predicting their functional consequences. Moreover, current variant
databases have much lower genome coverage than exome for precisely
determining non-coding variant allele frequency (Lek et al., 2016).

In the case of the individual described in Chapter 4, with BMF of unknown
genetic origin and cellular defects in responding to DNA replication stress, we will
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have to expand our analysis of the WGS and employ other strategies to determine
the genetic basis of their disease. With the development of new informatics tools,
more information and annotations of non-coding genetic variants may be available
to streamline WGS analysis. In the meantime, the clinical knowledge and cellular
observations in this case can be applied to analyze the non-coding variants of
potential candidate genes. We can consider various possibilities including the
likelihood that the disease presentation and cellular phenotypes described may be
the result of a novel disorder or alternatively, an atypical clinical presentation of a
known disease. Our investigation going forward should include screening intronic
regions of genes implicated in disorders with overlapping features.

Our knowledge of proteins at the replication fork during normal replication
and conditions of stress are expanding. We can apply this data to identifying
additional gene candidates. cDNA screening is another possible technique that we
can employ to identify deficient genes. Patient cells can be transduced with a
cDNA library and their pronounced cellular sensitivity to replication stress can be
exploited in a competition screen to enrich for and identify the complementing
cDNA (Buck et al., 2006). While the genetic cause of disease remains elusive in
this individual, the cellular characterization provides information about potential
pathways and genes that may be of interest for future investigation.
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Identifying the genetic etiology of rare diseases is important for improving
the understanding of the mechanism of DNA repair and how lack of repair results
in abnormal function. It also aids in the classification of other affected individuals
and leads to improved patient care. For example, our identification of the FANCT
complementation group will permit the classification of FA patients to this
complementation group in the future. Our analysis also demonstrates that complex
copy number variants may occur at this locus and that besides sequencing,
UBE2T/FANCT complementation may be necessary for classification. The clinical
presentation of the FANCT patient identified in our study differed from two patients
published in another parallel study (Hira et al., 2015; Rickman et al., 2015). Due to
somatic mosaicism of the blood our patient was likely protected from bone marrow
failure, but Hira et al. reported a case of bone marrow failure and AML in two
FANCT individuals. Taken together, these cases give a clinical picture for the
FANCT complementation group, and suggest that FANCT patients will likely
present with typical FA and are susceptible to bone marrow failure.

The

identification

and

analysis

of

the

individuals

with

biallelic

FANCD1/BRCA2 mutations and their atypical presentation expands the
phenotypic spectrum for this complementation group. These FANCD1/BRCA2
patients have phenotypes that are akin to the FA-like complementation groups
FANCR/RAD51 and FANCO/RAD51C (Jacquinet et al., 2018; Vaz et al., 2010;
Wang et al., 2015). Our findings highlight that in the future, patients with FA-like
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disease features should also be screened for BRCA2 mutations. The FANCD1
complementation group also has implications for HBOC in carriers, so earlier
molecular designation for these individuals is advantageous for preventative
screening in the family.

5.2 BRCA2 DNA binding domain mutations and implications for cancer
The analysis of individuals with atypical disease presentation of the
FANCD1/BRCA2 complementation group determined that their disease is due to
mutations in the highly conserved BRCA2 DBD. Interestingly, these patients
presented with developmental defects seen in FA, but have no history of BMF or
malignancy into adulthood (Alter, 2014; Howlett et al., 2002). We functionally
analyzed their BRCA2 DBD mutations, c.8524C>T, and c.IVS19-1G>A, to
determine if the atypical patient phenotypes were a consequence of disturbing a
specific function of BRCA2. In our studies, we observed that both mutations
reduced HR efficiency by about half and that replication fork protection was
defective at HU-stalled forks and ICLs.

Previously reported analysis of cDNA from HSC62 patient-derived cells,
homozygous for the c.IVS19-1G>A mutation, revealed the mutation to cause
aberrant splicing that results in a 4 aa deletion of exon 20 (Howlett et al., 2002).
HSC62 cells were also reported to have moderately elevated chromosomal
breakage, and taken together c.IVS19-1G>A was presumed pathogenic (Alter et
al., 2007; Howlett et al., 2002). Our analysis, also confirmed these findings. By
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complementing

the

homozygous

c.IVS19-1G>A

patient

fibroblasts

by

CRISPR/Cas9 mediated genome editing, we have demonstrated that this mutation
is indeed the cause of cellular defects and disease in this individual, proving this
variant to be pathogenic. Recently c.IVS19-1G>A has also been reported to
segregate with familial breast cancer (Santos et al., 2014).

The c.8524C>T mutation has previously been described as a variant of
unknown significance (VUS) in HBOC. Many pathogenic LOF mutations of BRCA2
have previously been described that result in early termination of the protein.
However, in BRCA HBOC genetic testing, approximately 1,600 unique VUS have
been discovered and they account for 2-10% of all variants identified during testing
(Guidugli et al., 2014). The clinical significance of these rare missense mutations
is unclear and often, familial information is limited, so variant segregation cannot
be determined. Evaluation of many BRCA2 VUS relies on multifactorial probability
models to estimate if a variant is pathogenic (Guidugli et al., 2014). In vitro analysis
of BRCA2 VUS function is an alternative approach to determine potential
pathogenicity. Functional assays have traditionally assessed HR through reporter
assays by measuring HR mediated repair of DSBs in reporter constructs
(Moynahan et al., 2001). Several studies have utilized the V-C8 Brca2 deficient
hamster cell line or mouse embryonic stem cells to assess HR of BRCA2 VUS by
the DR-GFP assay (Farrugia et al., 2008; Guidugli et al., 2014; Guidugli et al.,
2013; Wu et al., 2005). Additional studies have used other functional readouts of
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BRCA2 VUS including ssDNA binding assays, nuclear localization, centrosome
amplification, and MMC or PARP inhibitor cell survival (Guidugli et al., 2014).

A large number of BRCA2 DBD mutants, including c.8524C>T, were
analyzed for HR proficiency in V-C8 cells using the DR-GFP assay. The
pathogenicity of the VUS were predicted by comparing their HR efficiency to that
of known pathogenic and benign variants in this study (Guidugli et al., 2013). Some
VUS can be easily classified if HR is dramatically reduced; however, a number of
VUS including c.8524C>T showed intermediate phenotypes in this evaluation,
making it difficult to interpret their role in HBOC (Guidugli et al., 2013; Shimelis et
al., 2017).

One caveat of these studies is that they only consider the HR function of
BRCA2 for pathogenic classification. The contribution of other BRCA2 functions,
including replication fork protection, to cellular function and tumorigenesis requires
further investigation. In our system, the c.8524C>T mutant did have a moderate
impact on HR, but we also demonstrate additional deficiency in replication fork
protection. The consequences of loss of replication fork protection in c.8524C>T
cells is still unclear given the observation that this mutant does not show a
significant increase in chromosomal breakage after replication fork stalling by HU.
Predicting VUS pathogenicity only in the context of HR efficiency does not give a
complete picture for all of the functions of BRCA2. It is important to further
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understand the full spectrum of BRCA2 functions and how each might contribute
to genomic instability and tumorigenesis. This determination is essential to gain a
better understanding of how HBOC cancers arise and to make more confident
predictions about the outcome of patient mutations.

The individual with homozygous c.IVS19-1G>A mutations is deceased due
to causes unrelated to FA, but they were not reported to have acquired malignancy
to the age of 30. We note that the FANCD1/BRCA2 sibling pair will have to be
screened for FA related cancers and HBOC. These patients seem to have been
protected from early embryonal cancers, which we hypothesize to be due to
sufficient HR activity of the hypomorphic BRCA2 alleles expressed in their cells.
However, it is unclear whether these patients will be predisposed to squamous cell
carcinoma (SCC) because the majority of FANCD1 patients develop early
childhood malignancy long before SCCs are diagnosed in FA. SCCs in FA are
generally diagnosed in adulthood with a median age of 30, therefore the patients
should be screened regularly for these malignancies because of their cellular
defects in ICL repair (Kutler et al., 2016). HBOC cancer risk may be especially high
for these individuals in adulthood because they have biallelic BRCA2 mutations,
one of which (c.2330dupA) is already reported to predispose to HBOC. There is
insufficient evidence for whether the c.8524C>T variant predisposes to HBOC in
this family, but it is deleterious in terms of BRCA2 function, and causes FA in the
context of biallelic mutations. The father is a carrier of the c.8524C>T mutation and
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developed early onset colorectal cancer, which may have been related to his
carrier status (Degrolard-Courcet et al., 2014b; Garre et al., 2015; Phelan et al.,
2014). However, the father’s tumor was not assessed to determine BRCA2 status.

5.3 Defective replication fork protection at ICLs and HU-stalled forks
We have examined the requirement of the BRCA2 DBD for replication fork
protection in the context of HU- and ICL-stalled replication forks. By studying the
BRCA2 DBD mutant cell lines, we determined some differences in how cells
respond to replication forks stalled by HU versus at ICLs. In this analysis, it was
determined that replication fork protection of HU stalled forks is as much
dependent on the BRCA2 DBD as the C-terminal RAD51 interacting domain.
Similar to previously published studies, the nascent strand degradation at HU
stalled replication forks in our BRCA2 DBD mutant cells is rescued by inhibition of
nucleases or by inhibiting replication fork reversal by the depletion of fork
remodelers, SMARCAL1, ZRANB3, or HLTF (Lemacon et al., 2017; Mijic et al.,
2017; Schlacher et al., 2011; Taglialatela et al., 2017). We found that by
comparison, depletion of these fork remodelers does not rescue the increased
ssDNA generated at ICLs and their deficiency does not sensitize wild type cells to
MMC. These observations, suggest that fork reversal is not an important
intermediate in the repair at ICLs.

We note that when interpreting results, we have to keep in mind that cells
respond differently to treatment with HU and MMC making some direct
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comparisons of DNA fiber analysis after HU and MMC difficult. Here we looked at
single molecule DNA fiber analysis of HU stalled replication forks to measure
nuclease resection. At the dose of HU used for these investigations, all of the
replication forks are prohibited from replicating due to nucleotide depletion in both
WT and BRCA2 mutant cells. Using DNA fibers to study replication fork resection
in MMC treated cells has been confounding because MMC does not globally stall
all forks even at high concentrations (Kehrli and Sidorova, 2014)and data not
shown). This would be consistent with replication forks stalling as a result of
collision with an ICL; while other replication forks that do not encounter a DNA
lesion, continue replicating. It is also possible, that in a FANCM dependent
manner, some replication forks bypass the ICL, and are also able to keep
replicating (Huang et al., 2013).

The next steps to investigate processing of ICLs specifically, would be to
utilize the ICL generating agent trimethylpsoralen, tagged with digoxigenin (DigTMP), that can be detected by immunolabeling of DNA fibers (Huang et al., 2013).
We hypothesize that by using this method our analysis could be limited to those
replication forks that have encountered ICLs. A similar strategy could also be
applied to EM studies if TMP was detected with an appropriate probe. By EM
analysis ssDNA can be detected and measured at replication forks based on the
differences in the width of the DNA molecules (Vindigni and Lopes, 2017). We
predict that with these experimental approaches, the replication fork structures and
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genetic requirements of nucleases and helicases for resection at ICLs can be
examined in FA/BRCA pathway defective cells.

5.4 Implications of defective replication fork protection
As discussed in detail in the introduction, rescue of replication fork
protection in BRCA2 deficient cells has been observed by depleting factors that
either promote MRE11 association with the fork or prevent replication fork reversal.
As an essential gene, the HR function of BRCA2 has traditionally been viewed as
its critical activity for cell viability. Deficiency of PARP1 is reported to prevent
degradation of stalled replication forks and genomic instability by preventing
MRE11 recruitment (Bryant et al., 2009; Ding et al., 2016; Ray Chaudhuri et al.,
2016; Ray Chaudhuri et al., 2012). A recent study reported that PARP1 or PTIP
deficiency rescues lethality of BRCA2 knockout mouse embryonic stem cells
(mESC), which was attributed to restoration of fork protection (Ding et al., 2016;
Ray Chaudhuri et al., 2016). However, in another system, MCF10 epithelial cells,
PARP1 knockout does protect against nascent strand degradation, but it does not
rescue viability of BRCA2 null cells (Feng and Jasin, 2017). Moreover, cells
expressing the BRCA2 S3291E/A fork protection mutant show defects in fork
protection similar to losses incurred by BRCA2 LOF or depletion, but do not have
the marked hypersensitivity or breakage phenotype to DNA damaging agents
(Schlacher et al, 2011; Feng and Jasin, 2017). These reported findings, along with
our data, converge on the central question of what are the specific consequences
of the loss of replication fork protection on viability, cellular function, and genomic
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instability. There needs to be further investigation to determine how this function
specifically contributes to the process of tumorigenesis and later chemoresistance.

In our analysis, we observed that increased chromosomal breakage after
HU-mediated replication fork stalling, does not underlie replication fork resection.
Stalled replication forks in BRCA2 c.8524C>T and p.S3291A cells undergo
resection by MRE11, but do not have elevated levels of chromosomal breakage
as a result. BRCA2 c.IVS19-1G>A mutant cells however, have a mild increase in
breakage and cells expressing truncated BRCA2 show a large increase in
breakage that is MRE11 dependent. We speculate that it is possible that
c.8524C>T and p.S3291A BRCA2 are functionally able to prevent breaks at the
stalled replication forks or alternatively, these mutants retain enough HR function
to repair breaks that do arise. The majority of BRCA2 replication fork protection
studies have been done in the context of BRCA2 knockdown using siRNAs, so the
reported chromosomal breakage cannot be attributed to only deficiency of
replication fork protection, because the cells would also be deficient for HR. It is
already known that DSBs can arise from replication fork collapse as a result of HU
treatment. In the context of BRCA2 deficiency or LOF, the absence of replication
fork protection may further precipitate fork collapse that cannot be properly
repaired due to the concomitant loss of HR function.
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Further investigation is needed to fully determine the consequences of the
loss of BRCA2 replication fork protection function. It is possible that there is
another mutagenic process occurring at replication forks in the context of defective
replication fork protection other than chromosomal breakage. The recent study of
replication through the Escherichia coli Tus/Ter replication fork barrier complex in
mouse cells demonstrates that BRCA2 suppresses long tract gene conversions at
stalled forks (Willis et al., 2014). How exactly the different functions of BRCA2
converge to prevent gene conversion at replication forks needs further
investigation. The BRCA2 mutants that we have identified may be helpful in
parsing out whether this function relies on replication fork protection, HR, or both.
It will be interesting to investigate whether fork protection mutants have an
increase in mutations or gene conversion events at the sites of stalled forks. This
would give insight into the outcome of these resection events and would help clarify
how different defects in BRCA2 may contribute to genomic instability.

In the context of cancer cells, replication fork protection might play a more
significant role for chemoresistance. Alterations in a number of proteins already
discussed, restore fork protection (without restoring HR activity) by precluding
nuclease recruitment or access to DNA. Analysis of BRCA2 ovarian cancers, with
low PTIP or CHD4 expression had poorer prognosis, which hints at a potential
mechanism of restoration of fork protection in these tumors (Guillemette et al.,
2015; Ray Chaudhuri et al., 2016). Similarly, low levels of SMARCAL1 also
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correlated with poor prognosis in BRCA1 breast cancer (Taglialatela et al., 2017).
In BRCA2 ovarian cancers, low EZH2 levels were associated with worse prognosis
(Rondinelli et al., 2017). Taken together these studies link restorations of
replication fork protection with the development of chemoresistance in BRCA1/2
deficient

cancers;

however,

validation

of

the

mechanism

conferring

chemoresistance in these cancers warrants further investigation. It would be
interesting to know if specific loss of replication fork protection results in increased
breakage in cancer cell lines or if this occurs only with BRCA2 LOF. It is possible
that BRCA2 replication fork protection might play a more important role in the
context of cancers where replication fork reversal may be deregulated and
oncogenic stress or chemotherapy agents might be driving increased fork reversal
activity (Neelsen et al., 2013)

5.5 Concluding Remarks
This work was pursued under the hypothesis that by studying a subset of
patients with unclassified FA we would likely discover novel genes not previously
identified in FA. We found that some of the subjects had deficiencies in the FA
pathway which resulted in the identification of a new complementation group and
interesting separation of function mutations. While other patients had defects in
different DNA repair pathways that are imperative to genome maintenance. In
studying these individuals’ mutations, we have increased our understanding of how
these factors operate to maintain genome integrity. Even in the case of an already
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discovered FA complementation groups, the study of specific patient mutations
provides a unique tool to learn about a protein’s functions.
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Chapter 6: Materials and Methods
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6.1 Experimental Procedures
6.1.1 Study subjects
DNA samples and cell lines were derived from subjects enrolled in the
International Fanconi Anemia Registry (IFAR) after obtaining informed written
consent. The Institutional Review Board of The Rockefeller University, New York,
NY, USA, approved these studies.

6.1.2 Cell lines
Patient-derived fibroblast cell lines (Table 6.1) and BJ foreskin normal
control fibroblasts (ATCC) were transformed by expression of HPV16 E6E7 and
immortalized with the catalytic subunit of human telomerase (hTERT). Fibroblasts
were cultured in Dulbecco Modified Eagle medium (DMEM) supplemented with
15% FBS, 100 units of penicillin per mL, 0.1 mg of streptomycin per mL, nonessential amino acids, and glutamax (Invitrogen). Fibroblasts cell lines were
incubated at 37°C, 5% CO2, and 3% O2. Lymphoblast cell lines (Table 6.1) were
established from patient peripheral blood mononuclear cells by Epstein-Barr Virus
(EBV) transformation and grown in Roswell Park Memorial Institute medium
(RPMI) with 20% FBS and further supplemented as above. HEK293T (ATCC) cells
were cultured in DMEM supplemented with 10% FBS and penicillin/streptomycin
and glutamax as indicated above. Lymphoblast and HEK293T cell lines were
incubated at 37°C, 5% CO2, and ambient O2.
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6.1.3 Plasmids and mutagenesis
UBE2T cDNA (Human ORFeome V8.1 Library, GE Healthcare) was
recombined into pDONR223 using Gateway system BP reaction (Invitrogen). A
Gateway system LR reaction (Invitrogen) was used to recombine the pDONR223
with a pMSCV retroviral vector resulting in a C-terminally HA-FLAG tagged
UBE2T. A PFAS expressing pMSCV vector was made by cloning PFAS from WT
cDNA with attB primers for recombination by BP reaction into the pDONR223.
pDONR223-PFAS was recombined with pMSCV by LR reaction. Mutagenesis was
performed using QuickChange Multi Site-Directed Mutagenesis Kit (Agilent) see
Table 6.2 for primers.

6.1.4 Viral transfection/transduction
cDNAs were delivered by retroviral or lentiviral transduction after packaging
in HEK293T cells (TransIT-293 transfection reagent, Mirus). HEK293T cells were
plated at 4.5*106 the evening before transfection of DNA and viral packaging
vectors. Transfection was performed according to the manufacturer’s instructions.
The next day after transfection cell media was replaced and two days after
transfection viral supernatants were harvested and used to infect target cells in the
presence of 4 mg/ml polybrene. Stably expressing cells were selected with the
appropriate agent ((puromycin (2 µg/ml), hygromycin (100-200 µg/ml), blasticidin
(500 µg/ml), neomycin (600 µg/ml).
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6.1.5 RNAi
Cells were transfected with pools of 3 siRNAs against MRE11, DNA2,
EXO1, CtIP, WRN, BLM, BRCA2, RAD51, MUS81, XPF, and SLX4. For RADX
and HLTF depletion a single previously published siRNA was used (Table 6.3)
(Dungrawala et al., 2017; Taglialatela et al., 2017). Cells were transfected using
Lipofectamine RNAiMAX (Invitorgen) according to the manufacturer’s instructions.
For shRNA depletion, virus was packaged in HEK293T cells and used to infect
target cells and cells with stable integration were selected. shRNA constructs for
SMARCAL1 and ZRANB3 were a gift from Alberto Ciccia (Table 6.4). shRNAs to
RADX and PFAS were purchased from Transomics and used in the
pZIP_hCMV_Puro vector or pMSCV-PM-mir30. shRNAs were PCR amplified and
cloned into pMSCV-PM-mir30 by digestion with XhoI and MluI and vector ligation.
See Table 6.2 for PCR primers for amplification of shRNA from UltramiRs of
pZIP_hCMV vector. RNAi knockdown was measured by RT qPCR or western blot.

6.1.6 PCR, reverse transcription, and RT qPCR
PCR reactions were performed using Taq DNA Polymerase (Qiagen),
Phusion High-Fidelity PCR Master Mix with GC buffer (Thermo Scientific), and
PCR SuperMix High Fidelity (Invitrogen) according to manufacturer’s protocols
and primers are listed in Table 6.5. Total messenger RNA was extracted using
RNeasy plus kit (Qiagen). RNA was reverse transcribed to cDNA using the
SuperScript III Reverse Transcriptase (Invitrogen). Platinum SYBR Green
SuperMix-UDG (Invitrogen) was used according to manufacturer’s protocol to
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determine relative transcript levels which were normalized against GAPDH levels.
See Table 6.6 for RT qPCR primers.

6.1.7 Gene targeting
To correct the BRCA2 c.IVS19-1G>A mutation in HSC62 fibroblasts, cells
were transduced with the pCW-Cas9-Puro (addgene #50661) vector which
contains a doxycycline inducible Cas9. Subsequently, HSC62 cells were
transduced with plentiGuide-Hygro (derived from addgene #52963) that expresses
a single guide RNA (sgRNA) (see Table 6.7 for sgRNA sequence) that targets
DNA in proximity to the c.IVS19-1G>A mutation. sgRNAs were designed using the
online CRISPR design tool from the Zhang laboratory (crispr.mit.edu). 1*106 cells
were electroporated with a 100bp template oligonucleotide (see Table 6.8 for
sequence) using Lonza 2b-Nucleofector. Cells were cultured in 500 ng/mL
doxycycline for 48 hours to induce Cas9 expression and then incubated in fresh
doxycycline free media for another 48 hours before being single cell cloned into
96-well plates. Clones were expanded and screened by sequencing of genomic
DNA. For clones HSC62mut/WT-1and HSC62WT/WT-2, cells were selected in low dose
MMC (50 ng/mL) once a week for three weeks before seeding in 96-wells. Clone
3 (HSC62WT/WT) was not selected for.

The rest of the gene targeting was performed by electroporation of
Cas9/gRNA ribonucleoprotein (RNP) complexes with 100bp oligonucleotide donor
templates, with phosphorothioate protected ends. sgRNA was prepared by
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combining crRNA (designed using crispr.mit.edu) and universal tracrRNA as per
manufactures guidelines (IDT). To form RNP complexes gRNA duplex and Cas93NLS (IDT) were combined, incubated at room temperature for 10-15 minutes, and
then placed on ice until used. RNP complexes and 10 ug of 100bp donor template
oligonucleotide were electroporated into 2*105 fibroblasts or 3.5*105 HEK293T
cells using Lonza 4D-Nucleofector. Cells were plated in a 12-well for 48-72 hours
to recover before single-cell plating in 96-wells. Clones were expanded and
screened by sequencing of genomic DNA. No selection was used.

6.1.8 Chromosomal breakage
Cells were treated with 0.1 µg DEB per mL of media for 48-72 hours or 45100 nM of MMC for 24 hours. HU and aphidicolin treatments were as indicated.
LCLs were arrested with colcemid (0.17 µg/mL) for 20 minutes and fibroblasts for
90 minutes. Cells were harvested and incubated in 0.075 M KCL for 10 minutes
before being fixed in methanol and acetic acid (3:1). Cells were dropped onto wet
slides and dried at 40°C for at least one hour before staining with Karyomax
Giemsa (Invitrogen) for three minutes. Dry slides were then imaged on the
Metasystems Metafer slide scanning platform.

6.1.9 Cell survival studies
Fibroblasts were seeded overnight in triplicate and treated the next day with
DNA damaging agents at indicated concentrations. Cells were grown for 4-6 days
and passaged once at appropriate ratios. Once cells reached near confluence (7-
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9 days), cells were counted using Z2 Coulter counter (Beckman Coulter). In the
case of cisplatin treatment, drug was removed after 1 hour and cells were washed
with PBS and given fresh drug-free media. For aphidicolin treatment, after 48 hours
cells were washed with PBS and given fresh drug-free media. For PARPi
treatment, cells were given fresh media with olaparib daily. For ionizing radiation
cells were treated with the indicated IR dose in Falcon tubes prior to being plated.
LCLs were treated at the time of seeding, agitated daily, and counted on the 7th
day. HEK293T cells were seeded overnight, treated with MMC, passaged after 3
days, and counted on the 5th day.

6.1.10 Cell cycle
For cell cycle analysis cells were treated with 45 nM MMC for 48 hours.
Cells were collected and washed in cold PBS. Cells were resuspended in 300 ul
PBS and slowly vortexed while 700 ul of cold 100% ethanol was added dropwise.
Cells were stored at -20°C overnight or longer. Fixed cells were washed two times
in cold PBS and resuspended in propidium iodine solution with RNase in PBS.
Cells were incubated at 37°C for 30 minutes and cell cycle analysis was performed
on BD Accuri C6 and analyzed with FlowJo software.

6.1.11 Western blot
Whole cell extracts were prepared by lysing cell pellets in Laemmli sample
buffer (Bio-Rad or 4% SDS, 20% glycerol, 125 mM Tris-HCl pH 6.8). Samples were
either sonicated or vortexed at highest speed for 30 seconds. Samples were boiled
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for 5 minutes. For pRPA and BRCA2 western blots, samples were instead heated
at 50°C for 10 minutes. Proteins were separated on 4-12% or 3-8% gradient gels
(Invitrogen) by SDS-PAGE. Immunoblotting was performed using the antibodies
indicated in Table 6.9.

6.1.12 Immunofluorescence
Cells were seeded on coverslips the day before. For FAND2 foci, cells were
treated with 1 µM MMC for 24 hours. For RAD51 foci, cells were irradiated for
indicated dose or treated with 3 µM MMC for 1 hour and harvested at indicated
times. For RPA foci cells were treated with 3 µM MMC for 1 hour and harvested at
indicated times. Cells were washed with PBS twice, fixed in 3.7% formaldehyde
for 10 minutes, washed twice with PBS, and permeablized with 0.5% Triton in PBS
for 10 mins. Cells were blocked in 5% [v/v] FBS in PBS, and incubated with primary
antibodies in blocking buffer for two hours at room temperature or overnight at 4°C
(for antibodies see Table 6.9). Cells were washed three times for five minutes with
blocking buffer and then incubated with secondary antibody (1:1000) (Alexa Fluor).
Cells were washed again three times with blocking buffer, rinsed quickly with
water, air dried, and then embedded on glass slides with DAPI Fluoromount-G
(SouthernBiotech).

6.1.13 Sister chromatid exchange
For MMC induced SCEs, fibroblasts were cultured for 24 hours in 10 ug/mL
BrdU and then treated with 0.1 or 0.2 ug/mL MMC for one hour. Cells were washed
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and put into fresh media with 10 ug/mL BrdU for another 24 hours. For cells
depleted of BLM, siRNA transfection was performed twice as described. For the
second siRNA transfection 10 ug/mL BrdU was added to media and cells were
cultured in BrdU for a total of 48 hours before harvest. Cells were collected, fixed,
and dropped on glass slides for metaphases as previously described. Slides were
dried overnight at 42°C and then stained in 20 ug/mL Hoechst 33342 for 30
minutes. Slides were treated with 254 nM UV light for 3 hours. Slides were
incubated at 65°C in 2x SCC for 2 hours, then rinsed in 1x GURR buffer, and
stained in 8% Giemsa Karyomax for 3 minutes. Metaphases were scanned and
imaged on Metasystems Metafer Slide Scanning Platform.

6.1.14 mClover homologous recombination assay
Cells were plated in a 24-well plate the day before and transfected with 0.25
ug pCMV-Cas9-sgLMNA-BFP and 0.4 ug pDONR-LMNA using TransIT-293
Transfection Reagent (Mirus) according to manufactures instructions (plasmids
were a gift from Jan Karlseder)(Arnoult et al., 2017). 24 hours after transfection
cell media was replaced. Cells were incubated for another 48 hours and were then
harvested and analyzed on BD LSRII to determine the proportion of mClover
positive cells and data was analyzed with FlowJo.

6.1.15 DNA molecular combing and DNA fibers
For DNA molecular combing, cells were plated the evening before and
labeled with nucleotide analogs and treated with genotoxic agents as indicated.
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Cells were harvested and pellets were processed using Genomic Vision Extraction
Kit. Briefly, cells were embedded in low melting point agarose. Within the agarose
gel matrix, proteins were digested and cell membranes were solubilized. The
agarose plugs were melted and digested with beta-agarase. Using the Genomic
Vision Molecular Combing System DNA molecules were stretched on coverslips.
Coverslips were dried at 65°C for 2-4 hours. Coverslips were denatured in 0.5M
NaOH and 1M NaCl solution for 8 minutes at room temperature. Coverslips were
then dehydrated 5 minutes each in 70, 90, and 100 percent ethanol and then air
dried at room temperature. For immunostaining coverslips were blocked in 5%
FBS in PBS [v/v] for 30 minutes at 37°C and then incubated with primary antibodies
for one hour at 37°C. Rat anti-BrdU antibody (1:25) was used to detect CldU and
mouse anti-BrdU antibody (1:10) was used to detect IdU. Coverslips were washed
and then incubated with secondary (Alexa Fluor) anti-rat (594) and anti-mouse
(488) at a dilution of 1:100 each for 30 minutes at 37°C. Coverslips were washed
and air dried. Dry coverslips were mounted on glass slides using Fluoromount-G
(SouthernBiotech).

For DNA fibers, cells were plated and treated/labeled as above. Cells were
harvested and cell pellets were washed one time in cold PBS. Cells were
resuspended at a concentration of 1*106 cells/mL in cold PBS. On a clean glass
coverslip 10 ul droplets of spreading buffer (0.5% SDS, 200mM Tris-HCl pH 7.4,
and 50 mM EDTA pH 8) was placed. 2.5 ul of cell suspension was pipetted into
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the spreading buffer, stirred, and pipetted up and down three times. Coverslips
were incubated horizontally for nine minutes at room temperature before gently
being tilted vertically to allow the buffer to run down the slide. Coverslips were dried
at room temperature at an angle and then heated at 65°C for 30 minutes.
Coverslips were fixed in methanol/acetic acid 3:1 overnight at 4°C. The next day
coverslips were washed in PBS three times at room temperature and then
incubated in 2.5M HCl for 1 hour. Coverslips were then washed five times for five
minutes with PBS and after the final wash they were blocked in 5% FBS in PBS
for 30 minutes. For immunostaining, coverslips were incubated with primary
antibodies for 2.5 hours at room temperature. Rat anti-BrdU antibody (1:40) was
used to detect CldU and mouse anti-BrdU antibody (1:20) was used to detect ldU.
Coverslips were washed 5 times with PBS with 0.2% Tween and then blocked for
30 minutes in 5% FBS in PBS. Coverslips were incubated with secondary (Alexa
Fluor) anti-rat (594) and anti-mouse (488) at a dilution of 1:300 for 1 hour at room
temperature. Coverslips were washed 5 times with with PBS with 0.2% Tween and
rinsed with water and air dried. Dry coverslips were mounted on glass slides using
Fluoromount-G. DNA tracks were all imaged on the DeltaVision Image Restoration
microscope and measured using ImageJ.

6.1.16 aCGH
A

custom

CGH

array

was

designed

as

previously

described

(Chandrasekharappa et al., 2013). NimbleGen Service for CGH was used for
manufacturing, hybridization, scanning, and preliminary analysis. DNA from the
203

proband was compared to reference human male DNA (Promega). Data analysis
was performed using NimbleScan and intensity variations were visualized using
SignalMap (NimbleGen software).

6.1.17 Whole Exome Sequencing
The libraries for whole exome sequencing (WES) were constructed and
sequenced on Illumina HiSeq 2000 or Illumina GA-IIX using 76 bp paired-end
reads at the Broad Institute or by using Agilent SureSelect Human All Exon V4
capture kit and 100 bp paired-end sequencing on Illumina HiSeq 2500. Sequence
was aligned to human genome build GRCh37 using BWA (Burrows-Wheeler
Aligner) (Li and Durbin, 2009). Duplicate reads were marked using Picard
[http://picard.sourceforge.net]. Genome Analysis Toolkit (GATK) was used for
base quality score recalibration (BQSR), and local realignment around indels
(DePristo et al., 2011). Variant discovery was performed in part by variant calling
with

GATK

HaplotypeCaller

and

then

joint

genotyping

with

GATK

GenotypeGVCFs. The variant call sets were then refined with Variant Quality
Score Recalibration (VQSR) and VQSR scores helped discriminate low quality
variants. Variant annotation was performed using SnpEff, VCFtools, and in-house
software (NYGC) (Cingolani et al., 2012; Danecek et al., 2011). All WES was
analyzed with the NYGC sequence analysis pipeline.
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6.1.18 RNA sequencing
Indexed RNA sequencing (RNA-seq) libraries were constructed using
TruSeq RNA Sample Prep Kit version 2 (Illumina). Each library was sequenced in
pair-end mode using 1 lane of Illumina HiSeq2000 flowcell to generate 2 x 100 bp
reads. Raw-reads were aligned to the human genome (hg19) using TopHat with
default parameters. Cufflinks with GC and upper quartile normalization was then
used to calculate normalized expression levels, Fragments Per Kilobase of
transcripts per Million reads (FPKM) (Trapnell et al., 2012).
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Table 6.1 List of cell lines
Cell Line

Cell type

BJ

WT

Fibroblast

HA239F

RAD50

Fibroblast

Source
ATCC
(Waltes
2009)

et

al.,

HEK293T WT

Epithelial
kidney

HSC62

BRCA2/FANCD2

Fibroblast

RA3226

FANCD1/BRCA2

Fibroblast

RA2143
RA2177
RA2374

BMF patient, unknown
BMF patient, unknown
BRIP1/FANCJ

Lymphoblast
Fibroblast
Fibroblast

RA2480

FANCI

Fibroblast

RA2525

BRCA2/FANCD1

Lymphoblast

RA2627

UBE2T/FANCT

Fibroblast

RA2630

RAD51/FANCR

Fibroblast

RA2645

FAND2

Fibroblast

RA2939

FANCA

Lymphoblast

RA2985

WT

Lymphoblast

Howlett et al.,
2002
IFAR, (Kim et al.,
2013)
IFAR
IFAR
IFAR
IFAR, (Kim et al.,
2013)
IFAR
IFAR, (Rickman et
al., 2015)
IFAR, (Wang et
al., 2015)
IFAR, (Kalb et al.,
2007)
IFAR, (Zhou et al.,
2012)
IFAR

RA2987

WT

Lymphoblast

IFAR

RA3045

FANCL

Fibroblast

RA3087

FANCA

Fibroblast

RA3105

BRCA2/FANCD1

Lymphoblast

IFAR
IFAR, (Kim et al.,
2013)
IFAR

RA3106

BRCA2/FANCD1

Lymphoblast

RA3331

SLX4/FANCP

Fibroblast

RA3534
RA3535
RA3536
RA3572
RA3573

Unaffected
control
Unaffected
control
Unaffected
control
Unaffected
control
Unaffected
control

sibling
parental
parental
parental
parental

ATCC

IFAR
IFAR, (Kim et al.,
2011)

Lymphoblast

IFAR

Lymphoblast

IFAR

Lymphoblast

IFAR

Fibroblast

IFAR

Fibroblast

IFAR
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Table 6.2 List of cloning primers
Name

Sequence
Mutagenesis primers
GCAGCTCTCTCTTCAGACGATCAGC
UBE2T_mutagen_S5DFwd
TCTCTGCATGCCAACTTT
AAAGTTGGCATGCAGAGAGCTGAT
UBE2T_mutagen_S5DRev
CGTCTGAAGAGAGAGCTGC
CAGACGTGAAGCTCTCTCCATGCC
UBE2T_mutagen_Q2EFwd
AACTTTTTTGT
ACAAAAAAGTTGGCATGGAGAGAG
UBE2T_mutagen_Q2ERev
CTTCACGTCTG
cDNA Cloning Primers
GGGGACAAGTTTGTACAAAAAAGCA
attbUBE2TFwd
GGCTTAATGCAGAGAGCTTCACGT
GGGGACCACTTTGTACAAGAAAGC
attbUBE2T_noSTOP_Rev
TGGGTAACATCAGGATGAAATTTC
GGGGACAAGTTTGTACAAAAAAGCA
GGCTTAATGTCCCCAGTCCTTCACT
attbPFASFwd
T
GGGGACCACTTTGTACAAGAAAGC
TGGGTTCAGCAGCTCCCTTCCAGG
attbPFAS_wSTOP_Rev
G
shRNA cloning primers
TTTTCTCGAGAAGGTATATTGCTGT
5'ultramir_Xholsite
TGACAG
AAAAACGCGTAAAGTGATTTAATTT
3'ultramir_MluIsite
ATACCA
shRNA_5mir30Fwd
GCCTGCACATCTTGGAAACA
shRNA_3mir30Rev
GATAATTGCTCCTAAAGTAGCC
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Table 6.3 List of siRNAs
Name
siLuciferase
siRAD51
siRAD51
siRAD51
siMRE11
siMRE11
siMRE11
siCTIP
siCTIP
siCTIP
siEXO1
siEXO1
siEXO1
siDNA2
siDNA2
siDNA2
siBLM
siBLM
siBLM
siWRN
siWRN
siWRN
siMUS81
siMUS81
siMUS81
siBRCA2
siBRCA2
siBRCA2
siSLX4
siSLX4
siSLX4
siXPF
siXPF
siXPF

siRNAs
Sequence
CGUACGCGGAAUACUUCGA
GGUAGAAUCUAGGUAUGCAtt
CAGUGGUAAUCACUAAUCAtt
CCAGCUCCUUUAUCAAGCAtt
GAUAGACAUUAGUCCGGUUtt
CCCGAAAUGUCACUACUAAtt
CGACUGCGAGUGGACUAUAtt
GUACAAGGUUUACAAGUAAtt
GGAUCUGUCUGAUCGAUUUtt
GGGUCUGAAGUGAACAAGAtt
GCCUGAGAAUAAUAUGUCUtt
CUUUUGAACAGAUCGAUGAtt
GGCUAGGAAUGUGCAGACAtt
CAUCCAAUAUUUUCCCGUAt
CCGUACAGGCAGCAAUUAAtt
GUAACUUGUUUAUUAGACAtt
CCCACUACUUUGCAAGUAA
GGAUGUUCUUAGCACAUCA
GAUAUCUUCCAAAACGAAA
GGAGGGUUUCUAUCUUACUtt
CUGUAGCAAUUGGAGUAAAtt
CGAUGCUAGUGAUUGCUCUtt
UUCUGAAAUACGAAGCGCG
AGAGGGUUUGGAGAGGUCAU
UUAGGAUUCAGGUGCUCCC
UAAUGGAUCAGUAUCAUUUGGUUC
GGAGGACUCCUUAUGUCCAAAUUU
GAGCGCAAAUAUAUCUGAAACUUC
UUUGGAUGAAGAUUUCUGAGAUCUG
UUCCGUGGCUCCUUCUUGCUGGUGG
AAGAGUUCCUGGAAAUUCUCGGCCC
UCGAAAUUCACGCAUAUCC
UGUAUAGCAAGCAUGGUAG
AAGUCAACCACAAGUAUCC

siHLTF

GGAAUAUAAUGUUAACGAUtt

siRADX

CAUAGAGGCCAGCCGUAUA
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Supplier
Sigma
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Ambion
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Thermo
Fisher
Scientific
Dharmacon

Table 6.4 List of shRNAs
shRNAs
Name
pMSCVshSMARCAL1#53711
pMSCV-shZRANB3#D3
shRADX #46
shRADX #49
shPFAS #87
shPFAS #88

Selection
GGAACTCATTGCAGTGTTTAA
CTGGATCAGACATCACACGATT
ACAGCTTGAACTCTCTCGTATA
CCACGCTAATCCAGTTGCTGTA
CCAGCCGACACTGGTTCTTCAA
CCGGGAGTGTCCTGTCAGAAGA

Table 6.5 List of sequencing primers
Sequencing primers
Name
474Fwd
479Rev
509Fwd
510Fwd
538Rev
BRCA2 Exon20_FWD
BRCA2 Exon20_REV
BRCA2 Exon27_FWD
BRCA2 Exon27_REV
BRCA2 cDNA_313
BRCA2 cDNA_311
PFAS_RA2177_Exon6mut_Fwd
PFAS_RA2177_Exon6mut_Rev
PFAS_RA2177_Exon12mut_Fwd
PFAS_RA2177_Exon12mut_Rev

Sequence
GCGTTGCTGCGTTGTGAGG
TTAACTAAGATGAACCAGGACAAG
GTTGTGGGTAAATGGTTGACTCTA
CAGAGAAGCATGCAAGACAGAAAC
AGCCACACTGCACTATTCCTG
GTTCAAGTGATTCTCCTGCCT
CAATAGGTCCTAGTTCCAGGC
GGAGACTGTGTGTAATATTTGCG
GTCGCCTTTGCAAATGCTTAGA
GCTGTTAAGGCCCAGTTAGATCC
CCTAATTTCCAACTGGATCTGAGC
TATACTGGGTGAGGGCCGGCTT
TGGTCTCTCCCAACACCCATG
CTGTGTTCACGCTGCCTTGCT
CCAAAGTCCAGGTCACTGGTGTT
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Table 6.6 List of RT qPCR primers

Name
BLM_Fwd
BLM_Rev
DNA2_Fwd
DNA2_Rev
EXO1_Fwd
EXO1_Rev
WRN_Fwd
WRN_Rev
UBE2T_Fwd
UBE2T_Rev
RADX_FWD
RADX_REV
PFAS_Fwd_2
PFAS_Rev_2
PFAS_Fwd_3
PFAS_Rev_3

RTqPCR primers
Sequence
TTTATCCTGATGCCGACTGG
ACCCCAGGAGAAACACAGG
GCTGTCCTGAGTGAAACTTTTAGG
CCTCATGGAGAACCGTACCA
CTTTCTCAGTGCTCTAGTAAGGACTCT
TGGAGGTCTGGTCACTTTGA
GATGTTGCCAATAAAAAGCTGA
GTTTACCTAAGAGGTGTTTAACCAGAC
GATGACCTGCGAGCTCAAATA
GGATCTGAGGAGGTTCAAATGG
AAGTGCCTCAGCATCAGAAA
TGAGGTACAGCAACTGGATTAG
CATCATGAGCACCCAGGAAT
GGCATACTCCTGTGGGAAAG
CCAGCTGGAGCCATCATTTA
CAGCACTATTCTCCGGTCTC

Table 6.7 List of sgRNAs
sgRNAs
Name
HSC62_g7
HSC62_g6
BRCA2_Ex20g5
BRCA2_Ex27g9
PFAS_Exon12g11

Selection
TGGATGGAGAAGACATCATC
TGTGTAACACATTATTACAG
CATATTTCGCAATGAAAGAG
TGTTTCTCCGGCTGCACAGA
GTCTACAGGATTGGAGTcGG
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Table 6.8 List of oligonucleotide donor templates for
CRISPR/Cas9
Name
IVS19-1_G

IVS19-1_A

8524C>T

DBDx3A

S3291A

PFAS_WT

PFAS_A466T

CRISPR ssDNA templates
Sequence
TTGAATGTTATATATGTGACTTTTTTGGTGT
GTGTAACACATTATTACAgTGGATGGAGAA
GACATCcTCTGGATTATACATATTTCGCAAT
GAAAGAGA
TTGAATGTTATATATGTGACTTTTTTGGTGTG
TGTAACACATTATTACAaTGGATGGAGAAGAA
TCcTCTGGATTATACATATTTCGCAATGAAAGA
GA
CATTATTACAGTGGATGGAGAAGACATCATCT
GGATTATACATATTTtGCAATGAAAGAGAaGAA
GAAAAGGAAGCAGCAAAATATGTGGAGGCCC
AACA
GTGTGTGTAACACATTATTACAGTGGATGGAG
gccACATCATCTGGATTAgccATAgctCGCAATGA
AAGAGAaGAAGAAAAGGAAGCAGCAAAATATGT
GACTGCCTTTACCTCCACCTGTgAGTCCCATT
TGTACATTTGTTgCTCCGGCTGCACAGAAaGC
ATTTCAGCCACCAAGGAGTTGTGGCACCAAA
TACGA
GCATGGAAGTTGTAAAGGTTGGAGGTCCCGTC
TACAGGATTGGAGTcGGAGGTGGAGCTgCTTCA
TCTGTGCAGGTGAGTGGGAATTGCTAAAGGTG
CAG
GCATGGAAGTTGTAAAGGTTGGAGGTCCCGTC
TACAGGATTGGAGTcGGAGGTGGAGCTaCTTCA
TCTGTGCAGGTGAGTGGGAATTGCTAAAGGTGC
AG
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Table 6.9 List of antibodies
Antibody
a-tubulin
Sigma T9026
BRCA2
Millipore Sigma OP95
CtIP
Bethyl A300-488
FANCA
Bethyl A301-980A
FANCD2
Novus NB100-182
antibody raised in-house,
FANCI
#589
HA
Covance MMS-101R
HLTF
Abcam ab17984
MRE11
Gift from John Petrini
MUS81
Abcam MTA30 2G10/3
pRPA S4/S8
Bethyl A300-245A
Clone SWE47, gift from
RAD51
Steve West
RPA32
Bethyl A300-244A
SMARCAL1
Santa Cruz sc-376377
UBE2T
Abcam EPR9446
Vinculin
Sigma hVIN-1
XPF
NeoMarkers MS1381P
ZRANB3
Bethyl A303-033A
DNA combing and fibers
BRDU
BD Biosciences B44
BRDU
EuroBioSciences (BU1/75)
BRDU
Abcam ab6326 (BU1/75)
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IF
NA
NA
NA
NA
1:1000

Western
1:1000
1:250
1:500
1:1000
1:1000

NA

1:1000

1:5000
NA
NA
NA
NA

1:1000
1:1000
1:10000
1:1000

1:1000

1:1000

1:5000
NA
NA
NA
NA
NA
Fibers
1:20
NA
1:40

1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
Combing
1:10
1:20
1:20
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